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ABSTRACT 
Cardiovascular disease is still the main cause of morbidity and mortality in the world. Platelet activation 
is known to play a significant role in its initiation, progression and complications, and for this reason 
direct antiplatelet therapy is a major focus in the management of cardiovascular risk. However, in 
addition to platelet activation, factors such as decreased antioxidant status and increased reactive 
oxygen species, inflammation, dyslipidemia and sedentary lifestyle are also associated with poor 
cardiovascular outcomes.  
Use of antiplatelet therapies, clopidogrel and aspirin in particular, for primary and secondary prevention 
of adverse cardiovascular events is accompanied with high clinical resistance and side effects. There is a 
great need for improvement of treatment particularly when resistance is demonstrated. However the 
complex logistics behind platelet testing and available instrumentation with either high - inter and intra - 
laboratory variation or unsuitable for routine diagnostic laboratory use, prevent formation of set 
guidelines in regards to the assessment of efficacy of antiplatelet therapy and creation of personalized 
treatments. To overcome these limitations of platelet function testing we have developed a novel 
method of collecting, labelling and stabilizing blood collected from a minimally invasive finger-prick 
method for immunophenotyping of platelets and platelet-leukocyte interactions by quantitative flow 
cytometry.  We have demonstrated that this method is sensitive to inhibition of platelet function by 
standard antiplatelet therapy (aspirin), and correlates well with standard laboratory techniques for the 
assessment of platelet function.  The development of this technique allows platelet function testing 
without the need for venipuncture, and once stabilized the sample can be transported from the site of 
collection to the core facility for analysis up to 24 hours later, whereas standard diagnostic methods 
require analysis within 2-3 hours of collection. This new technique may be applied for monitoring of 
antiplatelet therapy, such as for resistance or dosing, for patients and their clinicians who do not have 
ready and immediate access to core scientific infrastructure required for diagnostic platelet function 
testing, such as in regional or rural areas. 
Even though antiplatelet therapies improve morbidity and mortality in cardiovascular disease patients, 
they inhibit both resting and activated platelets and disrupt normal process of haemostasis, and are 
associated with increased bleeding. Antiplatelet therapies are associated with resistance and have 
reported side-effects and contraindications, which prompt for the investigations of natural products as 
alternatives for prevention or treatment of the cardiovascular disease. Natural therapies not only can 
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delay the onset of the disease, but their mechanism of action can serve as a potential therapeutic target 
for production of new generation of safer and more effective agents. Since platelet hyperactivity,  
inflammation and oxidative stress are well identified risk factors for cardiovascular disease development 
and complications and saturated fatty acids accelerate its process, polyunsaturated fatty acids, in 
particular the omega-3, as well as antioxidant supplementation, have potential to decrease 
atherogenesis. 
We have demonstrated, for the first time, that the New Zealand Green Lipped mussel (Perna 
Canaliculus) extract, currently used as an anti-inflammatory agent, also inhibits platelet activation more 
effectively than standard fish oil formulations in a dose dependent manner. We have demonstrated that 
this is achieved, at least in part, by a novel mechanism of cyclo-oxygenase-1 independent inhibition of 
the thromboxane pathway of platelet activation, in addition to thromboxane-dependent inhibition 
common to other marine oils. This potent and novel antiplatelet mechanism may represent therapeutic 
potential for the use of Lyprinol in cardiovascular disease, but also represent a novel therapeutic target 
for next generation antiplatelet therapeutics. 
While there is substantial evidence that exercise improves cardiovascular health over a sedentary 
lifestyle, platelet activation increases in the acute period following intensive exercise, potentially due to 
a reactive oxygen acute phase response to the strenuous exercise bout. This represents a period of 
acute risk for cardiovascular events. In order to prevent the acute platelet activation, we explored an 
antioxidant supplementation strategy aimed at ameliorating the reactive oxygen acute phase response. 
We have demonstrated that six weeks long vitamin E supplementation with high γ and low α  
tocopherol concentration decreases platelet hyperactivity and hypercoagulability due to increased 
oxidative stress caused by strenuous exercise in sedentary individuals better than α tocopherol 
supplementation or placebo. Supplementation with high dose γ tocopherol in combination with exercise 
significantly reduces collagen-induced platelet aggregation below pre-exercise levels. Therefore γ 
tocopherol in the absence of high dose α tocopherol may enhance the beneficial effects of exercise on 
haemostatic and cardiovascular function. We have also demonstrated that γ tocopherol attenuates 
platelet function by inhibiting at least platelet cyclooxygenase-1 and consequently arachidonic acid 
induced platelet activation. 
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1 CHAPTER 1: LITERATURE REVIEW 
1.1 Platelet structure and function 
Platelets are small terminally differentiated anucleate discs 2-5 µm in diameter with a circulating life of 7 
to 10 days [1]. They are produced and released into the circulation by fragmentation of megakaryocytes, 
mainly from the bone marrow, but also  the lungs [2]. Their plasma membrane contains glycocalyx, a 
glycoprotein rich coat that forms the exterior layer, surrounding a phospholipid bilayer [3]. The 
membrane serves as the site of interaction between various platelet agonists and their membrane 
receptors leading to series of chemical events producing platelet activation. It also contains glycoprotein 
(GP) that mediate platelet-extracellular matrix (adhesion) and platelet-platelet (aggregation) interaction. 
The phospholipid bilayer extends through an open canalicular system into the cytoplasm [3]. The 
platelet lipid bilayer is asymmetrically distributed in both resting and shape-changed platelets. The outer 
surface of the phospholipid bilayer is rich in phosphatidylcholine and sphingomyelin, whilst 
phosphatidylserine, phosphatidylethanolamine and phosphinositides are found on the inner side as 
shown on Figure 1.1 [4-6]. This membrane composition is maintained by flippase and floppase,  
adenosine tri-phosphate (ATP) - dependent translocases [5]. Upon weak platelet stimulation, the inner 
lipids participate in platelet signaling [5]. Upon platelet activation with strong agonists, procoagulant 
phosphatidylserine amongst other lipids, is transferred to the outer side of the membrane in a process 
of transbilayer movement (membrane ‘flip-flop’) triggered by increased sodium [7] and calcium [8] 
concentrations and  catalysed by scramblase [4, 5].  Phosphatidylserine binds factors Xa and Va, allowing 
prothrombinase complex formation on the surface of platelets which leads to fibrin formation (Figure 
1.2)[4, 7]. Upon platelet activation, membrane phospholipids also become more susceptible to 
phospholipase A2 (PLA2), releasing arachidonic acid (AA) from glycerophospholipids, a precursor of 
thromboxane A2 (TxA2) formation [4]. Platelet plasma membrane also contains lipid rafts, membrane 
microdomains, with cholesterol and saturated fatty acid-sphingomyelin enriched structures and small 
amounts of phosphatidylcholine, phosphatidylserine and phosphatidylethanolamine [9]. Many platelet 
GPs, CD36, GPIb, GPIIIa and CD9 are found in platelet lipid rafts while some like GPVI can become 
translocated upon stimulation by collagen [9]. Upon platelet activation the rafts aggregate and 
redistribute the lipids and signaling receptors in the platelet membrane which suggests their 
involvement in initiation of platelet signaling pathway (Figure 1.3)[9].  Platelets contain a cytoskeleton 
composed of actin, myosin, actin binding proteins and talin. Its function is to maintain the structural 
integrity of resting platelets but it is highly dynamic during the activation process. Platelet shape change 
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during adherence and spreading at the site of vascular injury, release of soluble agonists during 
degranulation and retraction of filopodia at the end of the process require constant cytoskeletal 
reorganisation [10, 11]. Actin cytoskeleton may be divided into cytoplasmic actin network and 
membrane associated cytoskeleton [12]. Polymerisation of actin monomers into filaments is required 
for platelet shape change. Submembrane actin filaments are linked to GPIb-IX. Upon platelet activation, 
calpain cleaves actin binding proteins disrupting the linkage with GPIb-IX and allowing mobility of the 
platelet membrane. Actin filaments bind to myosin and create the tension which is required for clot 
retraction [10]. 
Platelets contain α and dense storage granules; the dense tubular system, mitochondria, glycogen, 
lysosomes and peroxisomes [3]. Platelets have 50-80 α granules per platelet that contain adhesion 
proteins, coagulation and fibrinolytic factors and serve to enhance heterotypic complex formation by 
expression of P-selectin. [13]. The content of platelet granules is displayed in Table 1.1, and the role of 
various molecules upon release is discussed throughout the review. The content of granules is released 
when the α granule membrane fuses with surface connected membrane of the open canalicular system 
with help of soluble N-ethylmaleimide-sensitive factor attachment protein receptor [13]. The 
phosphorylation of receptors and rapid platelet release reaction depends on platelet activation and 
requires influx of calcium and protein kinase C (PKC) activation [14]. P-selectin is an adhesion molecule 
that is also found with von Willebrand factor (vWF) in Weibel-Palade bodies [15]. It is expressed on 
activated endothelium and the platelet surface upon degranulation [15]. P-selectin mediates the 
recruitment of leukocytes to thrombi, which then promote fibrin formation [16]. 
Platelets have 3 to 8 dense granules that contain nucleotides ATP and adenosine di-phosphate (ADP), 
serotonin, calcium and pyrophosphate [17]. ADP is a potent platelet agonist and ATP can cause 
vasoconstriction of the blood vessels and aids in dense granule exocytosis [17].They both play an 
important role in the amplification of platelet activation. Calcium found in the dense granules accounts 
for 70% of total platelet calcium [17]. Dense granule release depends on the activation of PKC and 
calcium influx and is downregulated by calpain which inhibits PKC [18]. 
Platelets play important roles in haemostasis, thrombosis, atherosclerosis, inflammation and cancer [19] 
but the main physiological function of platelets is to form the haemostatic plug needed for vascular 
integrity and prevention of blood loss [1]. 
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Figure 1-1: Platelet plasma membrane [5]. 
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Figure 1-2: Coagulation cascade and platelets
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Figure 1-3:  Platelet lipid rafts [9]. 
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Table 1-1: Platelet granule content. 
Αlpha Granules Dense Granules Lysosomal Granules 
Albumin ADP Acid phosphatase 
C1 Inhibitor ATP Arylsulphatase 
CD9 Calcium Carboxypeptidase A 
Endothelial cell growth factor Pyrophosphate Carboxypeptidase B 
Epidermal growth factor Serotonin Cathepsin D 
Factor V   Cathepsin E 
Factor VIII   CD63 
Fibrinogen   Proline carboxypeptidase 
Fibroblast growth factor   α-D-galactosidase 
Fibronectin   α-D-mannosidase 
IgG, IgA, IgM    α-L-arabinofuranosidase 
GPIb-IX-V complex   α-L-fucosidase 
Hepatocyte growth factor   β-D-fucosidase 
High molecular weight kininogen   β-D-galactosidase 
Histidine-rich protein   β-D-glucuronidase 
Insulin-like growth factor 1   β-N-acetyl-D-hexosaminidase 
Integrin αIIbβ3      
Integrin αvβ3     
Interleukin 8     
Macrophage inflammatory protein 1 α     
Monocyte chemotactic protein 3     
Neutrophil activating protein     
PECAM-1     
Plasminogen     
Plasminogen activator inhibitor 1     
Platelet derived growth factor     
Platelet factor 4     
Protein S     
P-selectin (CD62P)     
RANTES     
Thrombospondin     
Vitronectin     
von Willebrand Factor      
α2-antiplasmin     
α2-antitrypsin     
α2-Macroglobulin     
β-thromboglobulin      
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1.2 Platelet adhesion and aggregation 
In the circulation and under physiological conditions, platelets are in a non-adherent state and their 
activation is prevented by nitric oxide (NO) and prostacyclin (PGI2) released from endothelial cells [20]. 
NO activates guanylyl cyclase and PGI2 activates adenylyl cyclase leading to an increase cGMP and cAMP 
which inhibits platelet activation [21]. Extracellular matrix proteins such as collagen and fibronectin or 
plasma proteins such as fibrinogen bind to integrin receptors on the platelet surface [11]. The same 
ligand can bind multiple integrins and some integrins (e.g. αIIbβ3, or GPIIb/IIIa ) can recognise several 
proteins (fibrinogen, fibronectin, vWF and vitronectin) [11]. Platelets’ integrin αIIbβ3  undergoes a 
conformational change and acquires the capacity to bind fibrinogen only upon platelet activation, a 
process that is normally prevented by intact endothelial monolayer.  When the endothelial monolayer is 
disrupted platelet activation follows (Figure 1.4) [22]. The process of activation consists of platelet shape 
change followed by the primary and reversible phase of aggregation and then the secondary phase and 
irreversible aggregation [23].  
During the initiation of platelet activation process at the site of vascular injury, the subendothelial layer 
that contains both vWF and collagen becomes exposed. Under high shear conditions (more than 800 s
-1
) 
vWF bound to subendothelial collagen undergoes a conformational change that exposes the binding site 
for GPIb [3]. This facilitates subendothelial  vWF binding to platelets and the tethering and adherence of 
platelets to the exposed tissues [24]. Binding of vWF to GPIb/IX/V is important for platelet adhesion at 
high shear conditions, while collagen and fibrinogen binding to platelets at low shear  rates is sufficient 
for platelet attachment [24, 25]. Binding of vWF to GPIb/IX/V complex on platelets induces rapid actin 
polymerisation and cytoskeletal reorganisation which leads to sphere cell formation and filopodia 
extension [26]. This bond formation leads to a spike in cytosolic calcium level promoting a mild 
activation of integrin αIIbβ3  [27]. Von Willebrand factor binds to integrin αIIbβ3  and produces a 
sustained calcium flux resulting in the full integrin αIIbβ3  activation required for platelet adherence and 
the process of platelet ‘outside in’ signaling [27]. Once platelets are tethered to vWF, this interaction is 
strengthened by the two main collagen receptors GPVI and integrin α2β1. [28]. Integrin α2β1 binding to 
collagen is required for firm platelet adhesion, while collagen binding to GPVI initiates the intracellular 
signaling pathways and induces platelet activation [28, 29]. Platelet GPVI mediates platelet rolling by 
binding to the extracellular matrix metalloproteinase inducer, CD147 [30] and platelet adhesion by 
binding to fibronectin [31]. 
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Binding of platelets to subendothelial proteins increases platelet calcium levels, leads to the platelet 
release reaction, integrin activation and sensitises platelets to low doses of thrombin [32]. Strong 
agonist stimulation leads to platelet secretion with the release of platelet granule proteins and 
recruitment of additional platelets to the site of vascular injury, giving rise to the secondary irreversible 
phase of aggregation [23]. This involves the binding of fibrinogen to the platelet integrin αIIbβ3 [23].  
Subsequent platelet adherence is mediated by the expression of P-selectin on endothelial cells [28].  In 
parallel to these events the coagulation cascade is activated and leads to formation of fibrin that 
crosslinks and stabilises the platelet aggregates [1]. 
Therefore, the accumulation of platelets at sites of vascular injury, after exposure of immobilised 
adhesive proteins and the rapid positive feedback loop of platelet release of granule contents that 
amplifies the original activation signal [33] together with coagulation cascade, results in the formation of 
a stable vascular plug [33]. 
1.3 Platelet agonists and signaling 
Platelet agonists, released from platelets, damaged cells and associated inflammation bind to their 
platelet receptors, which are mainly G-protein coupled receptors (GPCR) that transmit signal through 
heterotrimeric G proteins (Figure 1.5)[32].  Weak agonists or low concentrations of strong agonists 
require the ‘outside-in’ signaling to induce the release reactions. On the contrary, strong agonists cause 
platelet aggregation without the requirement for ‘outside-in’ signaling [34]. Platelets express receptors 
linked to Gq, G12/13, Gi/Gz and Gs proteins, as presented in Table 1.2 [32]. Stimulation of all GPCR 
except Gs leads to platelet activation, while stimulation of Gs pathway inhibits platelet activation [32]. 
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Figure 1-4: Platelet adhesion and aggregation [22]. 
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Figure 1-5: Platelet signaling pathway [32]. 
 
 
Figure  1.5: Platelet signaling pathway (32).  
Majority of platelet receptors are linked to Gq pathway that activate PLC which catalyses hydrolysis of phosphatidylinositol 4,5-
biphosphate to release inositol triphosphate and DAG.  DAG activates PKC while IP3 increases calcium level  stimulating platelet 
shape change, degranulation,  integrin αIIbβ3 activation and arachidonic acid liberation. Activation of Gi pathway leads to 
inhibition of cAMP and PI3K formation which potentiates Gq signaling. 
Prostacyclin inhibits platelet activation by binding to the IP receptor, coupled to the Gs pathway that increases cAMP levels.  
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Table 1-2: G protein coupled receptors expressed in human platelets [32]. 
G protein family  Effectors  Function  Receptor  Agonist  
Gi 
(Gi1, Gi2, Gi3, Gz)  
Adenylyl 
cyclase  
↓cAMP  PAR 1  Thrombin  
P2Y12  ADP  
PLCβ  ↑IP3/DAG→↑Calcium/PKC 
activation  
α2a-
adrenergic 
Epinephrine 
CXCR4 Stromal derived factor 1 
Gq 
(Gqα, G11α, G16α)  
PLCβ  ↑IP3/DAG→↑Calcium/PKC 
activation  
PAR1  Thrombin  
PAR4  Thrombin  
P2Y1  ADP  
Shape change TPα/β  TxA2 
V1  Vasopressin  
 Protease activated receptor  
G12 
(G12α, G13α)  
Rho-
dependent 
activation of 
kinases  
Actin cytoskeleton → shape 
change  
PAR1  Thrombin  
PAR4  Thrombin  
P2Y1  ADP  
TPα/β  TxA2 
Gs  Adenylyl 
cyclase 
↑cAMP IP PGI2 
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1.3.1 Gq signaling 
Platelet receptors that are linked to the Gq pathway include the ADP's P2Y1 receptor, TxA2 receptor α 
isoform (TPα) and the thrombin's protease-activated receptors 1 (PAR1) and 4 (PAR4).  Calcium 
mobilisation and PLC activation in the Gq deficient mice is impaired in response to thrombin, U-46619 
and ADP, while ATP release and platelet aggregation are normal in response to A23187 and phorbol 
ester phorbol-12-myristyl-13-acetate (PMA), suggesting that the pathway is responsible for regulation of 
PLC [35]. Activation of the PLC is required for catalysis of the the hydrolysis of phosphatidylinositol 4, 5-
biphosphate to release the second messengers inositol 1, 4, 5 triphosphate (IP3) and diacylglycerol 
(DAG). IP3 triggers release of intracellular calcium from dense tubular system and DAG is critical for PKC 
activation required for platelet integrin αIIbβ3  activation and degranulation [36]. Sustained calcium 
elevation is maintained due to influx of extracellular calcium which induces actin-myosin interaction, 
activates calmodulin, NO synthases (NOS) and calcium dependent proteases [32]. 
Experiments described below demonstrate that while the Gq pathway represents the initial step in 
platelet activation, it is not strictly required for integrin αIIbβ3  activation. Stimulation of the Gi 
pathway, which leads to a decrease in cyclic adenosine monophosphate (cAMP) is necessary to elicit full 
platelet activation [37, 38]. Even though stimulation of the Gq pathways activates PLC which leads to 
calcium mobilisation, PKC is only partially activated through this pathway.  Stimulation of the Gi 
pathways is essential for full PKC activation [39]. Similarly, although activation of the Gq pathway 
initiates DAG formation, effective accumulation of DAG also requires activation of the Gi pathway.  The 
Gi pathway inhibits diacylglycerol kinase an enzyme that metabolises DAG and decreases its effects as a 
second messenger [39]. 
While serotonin (Gq) and epinephrine (Gi) alone are not sufficient to cause platelet aggregation, the 
combination of both leads to full aggregation [37]. Platelets with blocked P2Y12 are capable of 
aggregating only upon addition of adrenaline that through its GPCR receptor activates Gi pathway 
signaling [37]. Platelet shape change in the Gq deficient mice occurs in response to thrombin, AA and 
TxA2 analogue (U-46619), but platelet aggregation and the ATP release reaction are impaired [35]. These 
mice also have impaired primary haemostasis, demonstrated by increased bleeding time (more than 30 
minutes). Injection of collagen and adrenaline to wild type mice causes death within 5 minutes, while Gq 
deficient mice survive for at least an hour (length of observation period) [35]. Gq pathway deficiency, 
however, can be overcome by concomitant stimulation of the Gi (coupled to P2Y12 and α-adrenergic 
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receptor) and G12/13 (coupled to thrombin and TP receptors) pathways. U-46619 induced platelet 
activation of Gq deficient mouse platelets occurs upon addition of exogenous ADP (5 µM) or adrenaline, 
both of which are capable of activating the Gi pathway [40]. Similar results were observed in thrombin 
induced activation of Gq deficient platelets, which aggregated only upon addition of exogenous ADP 
[40]. 
Platelet Gq deficiency however does not prevent collagen induced platelet activation and subsequent 
release reaction at collagen concentrations greater than 10 µg/mL [40]. This occurs due to stimulation of 
platelet release reaction which produces TxA2 and ADP leading to activation of G12/13 and Gi pathways. 
Combination of Gq deficiency and blockage of TP or P2Y12 receptor, however inhibits platelets’ 
response to collagen [40]. These experiments suggest that coactivation of both Gq and Gi is necessary 
for full platelet activation. 
1.3.2 Gi signaling 
Human platelets express 4 members of Gi family; Gi1, Gi2, Gi3 and Gz [41]. Platelet receptors linked to 
Gi pathway are the ADP’s P2Y12 receptor and α2 adrenergic epinephrine receptors. Sole activation of 
the Gi pathway is not sufficient to activate platelets, but it synergises with the Gq pathway to produce 
fully activated integrin αIIbβ3  [36]. Addition of epinephrine or moderate ADP concentration (10 µM) to 
the Gq deficient platelets  is not sufficient to induce platelet aggregation, but can restore platelet 
response to collagen [42]. Blocking of the P2Y1 receptor in platelets prevents ADP induced activation 
since the Gq linked P2Y1 is required for calcium mobilisation and platelet shape change. 
One of the roles of the Gi signaling in platelets is to inhibit adenylyl cyclase consequently lowering cAMP 
levels, normally elevated by stimulation of the Gs pathway [43]. Mice lacking Gi pathway activation 
show 40-50% increase in the basal cAMP in comparison to wild type mice [41]. Even though the addition 
of ADP to the Gq deficient mouse platelets (up to 10 µM) is insufficient to cause platelet aggregation, 
shape change or calcium increase, it lowers platelet cAMP levels [42]. Activation of the Gi pathway is not 
solely responsible for the full suppression of the cAMP level as in the absence of PGI2 neither ADP nor 
epinephrine change cAMP levels.  Also the addition of adenylyl cyclase inhibitors to the Gi deficient 
mouse platelets is insufficient to induce platelet activation [41], suggesting that apart from lowering 
cAMP levels,  stimulation of the platelet Gi pathway has additional roles in the activation process. 
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Activation of Gi signaling leads to activation of phosphoinositide 3-kinase (PI3K) required for Akt [44, 45] 
and Rap1B [46] activation. Activation of Gi pathway and subsequent activation of PI3K mediates ADP 
and epinephrine induced extracellular signal-regulated kinase (ERK) phosphorylation and TxA2 
generation [45]. Activation of Rap1b is Gi-dependent, as demonstrated in experiments that show mouse 
platelets deficient in Gi have decreased Rap1b activation unlike platelets lacking Gq [46]. ADP binding to 
its P2Y12 as well as epinephrine activate Rap1B which in turn associates with actin cytoskeleton and is 
required for integrin αIIbβ3  activation, a process that does not occur upon stimulation of Gq-associated 
receptor agonists [47]. 
1.3.3 G12/13 signaling 
Studies in the Gq deficient mice identified that the activation of the G12/13 pathways causes platelet 
shape change [48]. Activation of these pathways leads to Rho kinase activation and myosin light chain 
phosphorylation allowing subsequent platelet degranulation [48].  G12/G13 pathway activation 
potentiates response of platelets to other weak agonists, not capable of inducing full activation on their 
own. This is demonstrated in experiments where mouse platelets were stimulated with low (0.03 µM) U-
46619, sufficient to cause platelet shape change but not the full aggregation due to lack of Gq signaling. 
Upon addition of adrenaline (10 µM), platelet aggregation occurred suggesting that G12/13 synergises 
with other platelet pathways to produce fully activated integrin αIIbβ3  [40]. 
G13 is required for platelet shape change in response to low and intermediate concentrations of TxA2, 
thrombin and collagen, since the mouse platelets deficient in G13 and G12/G13 do not change shape or 
aggregate unless high agonist concentrations are used [49]. Shape change and aggregation was weaker 
than in wild type platelets. There was no RhoA activation and myosin light chain phosphorylation in 
those platelets in response to 10 nM U-46619, while in wild-type platelets, 10 nM U-46619 induced 
maximal RhoA activation and myosin light chain phosphorylation [50]. G13 and G12/13 deficiency 
prolongs bleeding time in vivo, while in ex vivo model of thrombus formation, deficient platelets are 
capable of adhering to collagen fibrils similarly to wild-type platelets but show no thrombi formation 
[50]. In vivo model of arterial thrombus formation, also confirmed that G13 deficient platelets can 
adhere to injured carotid artery but are not able to form stable thrombi [50]. 
G12 deficiency is less severe than G13 deficiency, since the absence of G12 in mouse platelets does not 
prevent platelet shape change and aggregation in response to low and high agonist concentrations, or 
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RhoA activation and MLC phosphorylation in response to U-46619, and does not increase bleeding time 
in mice  [50]. 
1.3.4 Gs signaling 
Prostacyclin is potent platelet inhibitor and vasodilator that acts on platelets via binding to its 
prostacyclin (IP) receptor. IP receptor is GPCR linked to the Gs pathway [51]. Binding of PGI2 to the IP 
activates Gs pathway and increases cAMP levels in platelets [52]. Mouse platelets lacking the IP receptor 
show 30% decrease in basal platelet cAMP levels in comparison to wild-type animals [41]. Increased 
cAMP levels prevent platelet activation by inhibiting platelet calcium increase and PKC activation, 
degranulation and integrin αIIbβ3  activation [53]. 
1.3.5 Arachidonic acid/Thromboxane A2/Prostanoid receptors 
Arachidonic acid (20:4 n-6) is one of the omega-6 polyunsaturated fatty acids (n-6 PUFA) made from 
linoleic acid and metabolised by cyclooxygenase (COX) and lipooxygenase (LOX) enzymes [54]. 
Prostanoids are the superfamily of eicosanoids derived from AA (Figure 1.6) [55]. The formation of 
eicosanoids from AA in endothelial cells is catalysed by constitutively expressed COX-1 and inducible 
COX-2, present at the site of inflammation and in vascular endothelium exposed to high shear stress 
[55]. Arachidonic acid is converted to the prostaglandin (PG) endoperoxides, PGG2 and PGH2 which 
become substrates for various synthases, such as TxA2 synthase (TxAS) in platelets and prostacyclin 
synthase (PGIS) in endothelial cells. They are formed by the action of COX while leukotrienes (LT) are 
formed by the action of LOX. All of these molecules are biologically active [56]. On exposure to agonists, 
platelets liberate AA stored in membranes through the activation of cytosolic PLA2 [57]. Thrombin, 
physiologically generated from coagulation, is considered one of the main activators of platelet PLA2 and 
consequently COX-1 [58]. PLA2α releases AA from the sn-2 position of glycerolphospholipids which 
serves as a substrate for COX-1 and/or 12-LOX in platelets [59]. 
12-LOX converts AA to 12-s-HPETE, then to 12-HETE by glutathione peroxidise. Glutathione peroxidise 
may be prone to abnormal glycation in people with diabetes and its level decreases with age, therefore 
leading to an accumulation of 12-HpETE. The accumulation of 12-HpETE accelerates the AA cascade by 
increasing COX-1 and 12-LOX activity. 12-HpETE activates cPLA2 by stimulating P38 mitogen-activated 
protein kinase phosphorylation and decreases the threshold for platelet activation by AA [60]. 
Nanomolar concentrations of 12-HpETE have been shown to increase AA by activating cPLA2 [61]. 
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Platelet 12-HETE synthesis occurs for at least 2 hours after collagen stimulation, and is fully active 
without exogenous calcium [56]. Spontaneous and non-enzymatic peroxidation of AA leads to the 
formation of isoprostanes that are biomarkers of oxidative stress and have biological activity [62]. 
Thromboxane A2 is an eicosanoid released from activated platelets with a half-life of about 30 seconds 
[49]. Therefore, its site of action is near TxA2 producing cells as it is rapidly converted to the more stable 
but inactive Thromboxane B2 (TxB2). Serum TxB2 and urinary 11-dehydroxy TxB2 are more specific 
markers of TxA2 production in vivo [63, 64]. Thromboxane A2 is crucial for normal platelet aggregation 
and haemostasis as it acts as a positive feedback mediator in the activation and recruitment of platelets 
to the site of injury [65]. It has a wide variety of actions and apart from platelets, also acts on 
endothelium, smooth muscle cells (SMC) and kidney. The effects of TxA2 include accelerated surface 
expression of adhesion proteins (Intercellular Adhesion Molecule-1 (ICAM-1), Vascular cell adhesion 
protein 1 (VCAM-1) and Endothelial-Leukocyte Adhesion Molecule 1 (ELAM-1) in endothelium and 
endothelial cell migration and angiogenesis, contraction of smooth muscle cells, inflammation in asthma 
and allergy, increase in messenger ribonucleic acid (mRNA) levels of fibronectin, laminin, collagen, tissue 
plasminogen activator and plasminogen activator inhibitor 1, and the initiation and progression of 
atherosclerosis [62]. Levels of TxA2 are increased in patients with cardiovascular disease (CVD), following 
acute myocardial infarction (AMI), diabetes and elderly [62, 66]. People with diabetes may have 
increased levels of PLA2, which ultimately leads to increased TxA2 production, whereas in the elderly 
high TxA2 levels have been attributed to COX-1 hyperactivity [67]. 
Results from studies of Apolipoprotein E (ApoE) (–/–)/TP (–/–) mice and ApoE (–/–)/IP (–/–) mice 
showed that TxA2 promotes, whereas PGI2 inhibits, the initiation and progression of atherosclerosis as 
ApoE (–/–)/TP (–/–) mice showed delayed atherogenesis compared with ApoE (–/–) mice [68]. ApoE (–/–
)/IP (–/–) mice had enhanced atherosclerosis as their platelets were more reactive to thrombin 
activation, and the expression of ICAM-1 was higher and Platelet Endothelial Cell Adhesion Molecule-1 
(PECAM-1) lower than those in ApoE (–/–) and ApoE (–/–)/TP (–/–) mice [68]. The adherence of 
leukocytes was also more prominent in the ApoE (–/–)/TP (–/–) mice [68].  
Thromboxane A2 exerts its effect by binding to the G-coupled TP receptor [69]. Platelet aggregation 
induced by TxA2 depends on the secretion of Gi-activating agonists, such as ADP [38]. The human TP 
receptor is widely distributed (platelets, endothelial cells, SMC) [62] and is a 7-transmembrane domain 
[70] G protein-coupled receptor that consists of two alternatively spliced isoforms: α, which is mainly 
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expressed on membranes, and β, which is present within cells. The TPα receptor couples to the Gq 
pathway and the TPβ receptor to the G12/13 pathway [49]. The two isoforms regulate cAMP production 
differently: the TPα receptor stimulates cAMP production whereas the TPβ receptor inhibits cAMP 
production [38]. The activation of the G12/13 pathway linked to the TPβ receptor can synergise with Gi 
signalling and cause α granule release [71] and activation of integrin αIIbβ3  [40]. Although TxA2 causes 
intracellular calcium mobilisation and shape change in platelets, the α granule release and platelet 
aggregation depend exclusively on the secretion of other agonists that activate Gi-coupled receptors, 
P2Y12 receptors or α-2 adrenergic receptors [69, 71]. The TP receptor is also responsible for the adverse 
effects caused by isoprostanes, in particular 8-iso-prostaglandin F2α, a free radical-catalysed product of 
circulating low density lipoproteins (LDLs) and AA and a reliable marker of lipid peroxidation that binds 
to and activates the receptor.  8-iso-prostaglandin F2α formation correlates with the formation of TxA2 
[49]. 
The activation of the TP receptor in endothelial cells is known to cause vascular injury. One mechanism 
by which it does this is by increasing O2 and ONOO- levels in bovine aortic endothelial cells, 
consequently reducing cGMP levels, an index of NO bioactivity. This is mediated by PKC, and leads to 
endothelial nitric oxide synthase (eNOS) uncoupling from endothelial cells and a decrease in 
tetrahydrobiopterin, the eNOS cofactor [72]. Thromboxane receptor activation also promotes 
upregulation of TP receptor expression through a reactive oxygen species (ROS)-dependent mechanism 
[73]. 
Importantly, individual prostanoid receptors have up to 30% sequence identity and encode specific 
motifs common only to prostaglandin receptors. This similarity therefore enables various prostaglandins 
to bind to the same receptor [74]. The importance of this phenomenon is highlighted in failures of trials 
assessing the use of TxAS inhibitors as a possible antiplatelet therapy. After failure of therapy using only 
TxAS inhibitors, the agents blocking the TP receptor or the TP receptor and TxAS are being investigated 
[75]. 
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Figure 1-6:  Arachidonic acid metabolism. 
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1.3.6 ADP and the P2Y receptors 
ADP is released from platelet dense granules and it promotes stable platelet aggregation by binding to 
own and neighboring platelets ADP receptors thus amplifying platelet activation [34, 76]. ADP by binding 
to its P2Y1 and P2Y12 receptors, linked to Gq and Gi pathways respectively, causes platelet shape 
change, degranulation, activation of integrin αIIbβ3 , aggregation and TxA2 release. 
Both P2Y1 and P2Y12 are seven-transmembrane G protein-coupled receptors [71]. Binding of the ADP to 
the P2Y1 (Gq) receptor activates PLC, mobilises calcium and amplifies aggregation induced by other 
agonists [77, 78]. Binding of ADP to the P2Y12 (Gi) receptor, targeted by thienopyridines and  exclusively 
expressed in platelets with minor levels of expression detected in the brain [79], plays a crucial role in 
ADP-induced activation and the amplification of the platelet response induced by other agonists [80, 
81]. Binding of ADP to the P2Y12 receptor consequently lowers cAMP levels whose role is to mediate 
phosphorylation of VASP needed to inhibit the integrin αIIbβ3  activation which would otherwise lead to 
platelet aggregation [77, 82]. The activation of the P2Y12 receptor is not sufficient to mobilise calcium; 
however, its activation sustains the activation of the P2Y1 receptor [83]. The release of α granules from 
aspirin-treated platelets induced by ADP requires the activation of both the Gi and Gq pathways [71]. 
ADP activation of the P2Y12 receptor potentiates TxA2 release [45]. The importance of the P2Y12 
receptor was shown in experiments of mice treated with clopidogrel and prasugrel whose TxB2 levels 
were decreased by >80% and >90%, respectively, compared with untreated mice [84]. In a pilot study of 
healthy human subjects treated with clopidogrel, TxB2 levels were decreased by >70%, suggesting that 
the P2Y12 receptor regulates TxA2 levels and the inhibition of this receptor decreases its formation [84].  
The addition of aspirin to samples that had blocked P2Y12 receptor had no effect on enhancing the 
inhibition of platelet activation [85]. Platelets from Fawn Hooded rats that have delta storage pool 
deficiency have impaired collagen induced aggregation, restored only upon addition of ADP, suggesting 
the importance of released ADP in potentiating response of platelets to collagen [86]. 
Blocking the P2Y1 receptor with MRS 2179, or using P2Y1 deficient mouse platelets increases the lag 
phase before the onset of aggregation and ATP release of platelets stimulated with up to 100 µg/mL and 
5 µg/mL of collagen respectively, suggesting an important role of P2Y1 in collagen induced platelet 
activation [86]. P2Y1 deficient mice are partially protected from thromboembolism upon injection of 
thromboplastin, with occlusive thrombi occurring mainly in small lung vessels only [87]. 
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Adenosine triphosphate is also stored in platelet dense granules and is the agonist of the P2X receptor 
and antagonist of the P2Y12 receptor [88]. The P2YX receptor is a cation channel that consists of two 
transmembrane domains that associate in trimers to form a channel [89]. This receptor is activated by 
ATP, and on activation, it triggers calcium entry and induces minor changes [88]. Studies have shown 
that the P2YX receptor is crucial for shear-induced platelet aggregation and amplifies collagen-induced 
platelet activation through ERK activation [88]. ATP also contributes to epinephrine induced calcium 
mobilisation in platelets pre-treated with low dose thrombin [90]. 
1.3.7 Collagen/GPVI/Integrin α2β1 
As previously described, primary haemostasis is maintained due to contact of platelets with exposed 
collagen in damaged endothelium. Interaction with collagen promotes platelet adhesion and aggregate 
formation and is important in medium and high shear rates [91]. Collagen binds to integrin α2β1, GPVI, 
integrin αIIbβ3 and GPIb/IX/V via vWF [91]. Platelet adhesion to damaged endothelium is mediated 
through binding platelets' integrin α2β1 to subendothelial collagen, and blockade of this integrin 
reduces platelet adhesion, although it is insufficient to prevent platelet aggregation [92]. Platelets 
contain 2000-4000 copies of this receptor, which is normally expressed in low-affinity state in resting 
platelets until platelet activation, although it can exist in multiple activation states [93]. During the 
process of platelet adhesion, collagen also binds to GPVI, member of the immunoglobulin superfamily, 
expressed on platelets and megakaryocytes and required for collagen induced platelet activation [93].  
Both receptors are required for platelet adhesion under flow conditions and mice deficient in both GPVI 
and integrin α2β1 show less adhesion to collagen that those lacking one of those receptors [92]. 
Supportive, rather than crucial role of α2β1 is demonstrated in  experiments with mice that lacking β1 
integrins,  having no increased bleeding tendency and β-null platelets adhering to fibrillar collagen in all 
flow conditions [28]. A systemic lupus erythematosus patient with auto-anti GPVI antibody showed mild 
subcutaneous bleeding. While her collagen induced platelet aggregation was absent, platelet adhesion 
to collagen surface under static condition occurred, although it was reduced, suggesting the role of 
integrin α2β1 in initial platelet adhesion, without ability to induced platelet activation [94]. Integrin 
α2β1 plays important role in promoting primary platelet adhesion on collagen, but may be less 
important for thrombus growth [91]. 
Collagen binding to GPVI/Fc receptor γ (FcRγ) chain complex, initiates signaling through FcRγ  
immunoreceptor tyrosine activation motif (ITAM), which becomes phosphorylated by Src family kinases. 
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This induces a cascade of signaling events that results in phospholipase C γ2 (PLCγ2) activation which 
produces intracellular calcium mobilisation and PKC activation [95]. Platelet activation induced by 
collagen is dependent on ADP and TxA2 secretion [40, 86] as fibrillar collagen is insoluble and only a 
small number of platelets are capable of binding to it, therefore making platelet activation dependent 
on the platelet release reaction [28, 40]. Collagen alone is insufficient to lower cAMP levels in platelets. 
The decrease in cAMP levels observed upon collagen stimulation occurs due to ADP release, as 
demonstrated in experiments where the addition of clopidogrel and ARC69931MX blocks cAMP 
suppression [42].  Collagen, however, decreases platelet NO production [96]. Collagen binding to its 
GPVI/FcRγ-chain complex is important event in platelet activation at the site of vascular injury.  
Importance of GPVI was demonstrated in the  study where the blockage or the absence of the GPVI 
prevented platelet adhesion and aggregation under flow conditions [28].   
Binding of collagen to GPVI can also promote early atherogenesis by interaction with activated 
endothelium and mediation of platelet adhesion even in cases without plaque rupture [31]. Blockade or 
inhibition of platelet GPVI reduces platelet adhesion in Apo-/- mice [31]. Advanced plaques contain high 
levels of type I and III fibrillar collagens and increase the risk of complications [97]. Even though collagen 
interaction with platelet GPVI receptor promotes atherogenesis, and while FcRγ  deficient platelets  do 
not undergo shape change or spread on the collagen under static conditions, lack of this receptor in 
some in vivo experiments does not prevent arterial thrombotic occlusions in mice due to thrombin 
generation that overcomes the deficiency  [97].  While FcRγ deficiency does not prevent laser-induced 
thrombus formation in mice,  it prevents ferric chloride induced thrombus formation [98]. The 
difference observed is due to different collagen exposure in different thrombosis models. While in laser 
injury model (thrombin/TF mediated mechanism), collagen exposure to the blood circulation is 
undetectable, and thrombus formation may in that situation be dependent on P-selectin expression and 
thrombin formation, severe ferric chloride injury model, endothelial layer is striped off and type 1 
collagen was exposed [98].   
Since lack of GPVI can prevent thrombosis, and blockage does not increase bleeding tendency, anti-
platelet agents targeting GPVI may be beneficial [99].     
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1.3.8 Integrin αIIbβ3 
Each platelet expresses around 80 000 copies of integrin αIIbβ3, which has ability to bind several 
adhesive plasma proteins, including fibrinogen, vWF, fibronectin, and vitronectin, facilitating platelet 
adhesion and aggregation [100, 101]. Integrin αIIbβ3 also plays role in platelet spreading due to increase 
in calcium following adhesion, promotion of coagulation since it serves as prothrombin receptor, and in 
platelet-mediated clot retraction as integrin bound to ligand on platelet pseudopodia interacts with 
cytoskeleton [102]. Integrin αIIbβ3 is present in low-affinity state in resting platelets, and upon platelet 
activation, a conformational changes occurs making it high-affinity receptor that allows binding of 
soluble ligands including fibrinogen that cross-links receptors on adjacent platelets producing a growing 
thrombus [101, 103]. The importance of this integrin in platelet adhesion and aggregation is 
demonstrated in patients with Glanzmann thrombasthaenia, a rare autosomal recessive disorder caused 
by qualitative and quantitative abnormalities of integrin αIIbβ3. Disease is characterised by 
mucocutaneous bleeding of variable severity, lack of platelet aggregation in response to all agonists due 
to abnormalities of both inside-out and outside-in signalling and absence of clot retraction in patients 
with no integrin expression [104]. Similarly β3-null mice, which have undetectable levels of integrins 
αvβ3 and αIIbβ3,  show spontaneous haemorrhages, prolonged bleeding time (greater than 600s), 
impaired clot retraction, fibrinogen uptake and reduced thrombus formation [104].  Mice with impaired 
in outside-in αIIbβ3 signaling, show impaired platelet aggregation and clot-retraction, prolonged 
bleeding with high re-bleeding tendency [105].  
Binding of integrin αIIbβ3  to immobilised fibrinogen induces ‘outside-in’ signaling promoting 
cytoskeletal reorganisation and granule secretion, increasing cytosolic calcium through tyrosine 
phosphorylation and activation of PLCγ2 [106]. The stability of the platelet-fibrinogen bond depends, 
however, on elevation of calcium achieved by the release of ADP from dense granules and ADP induced 
platelet activation [106]. Activation of the P2Y12 receptor and the Gi pathway signaling activates Rap1b, 
a small guanosine triphosphatase, with the help of IP3, which interacts with Rap1-guanosine 
triphosphate and activates and regulates integrin affinity for fibrinogen, in a process independent of 
calcium [107]. Rap1b deficient mice show prolonged bleeding time, and delayed and impaired 
aggregation in response to ADP, epinephrine, collagen, calcium ionophore and PAR4 activating peptide 
[108]. Rap1b deficient platelets have impaired fibrinogen binding to the integrin αIIbβ3  and mice did 
not show thrombus formation in carotid artery thrombosis model within 30 minutes observation while 
wild-type animals formed occlusive thrombus within 7 minutes [108]. These results suggest an 
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important role of Rap1b in regulation of integrin αIIbβ3  activation. Apart from release of ADP, 
fibrinogen binding to integrin αIIbβ3  promotes the activation of cPLA2 in platelets and consequent TxA2 
formation [109]. Prothrombin is capable of binding to the integrin αIIbβ3  and resting and activated 
platelets in a process that depends of calcium ions, and potentiates prothrombin activation by 
coagulation factors [110]. 
1.3.9 Other platelet agonists 
Once platelets are bound and activated, they release soluble mediators and facilitate thrombin 
generation. Thrombin is a potent platelet activator that is produced on the surface of activated platelets 
via the coagulation cascade. Thrombin mediates the generation of fibrin and has diverse effects on 
various cells, such as promoting chemotaxis, adhesion and inflammation through its effects on 
monocytes and neutrophils, vasoconstriction and mitogenesis in SMCs [89].Thrombin mediates platelet 
activation by binding to the PAR 1 and PAR 4. Binding of thrombin to PAR receptors linked to Gq, G12/13 
and possibly Gi results in activation of PLC and PKC, release reaction and amplification of platelet 
response [89]. Thrombin receptors contain ligand that becomes created upon thrombin cleaving  the 
receptors’ N-terminal [111]. PAR 1 activation is sufficient to induce the degranulation [90]. These events 
amplify the thrombin signal, generating more thrombin on the platelet surface [89]. PAR 1 and PAR 4 
activation and signalling, depends on the released ADP and consequent activation of Gi pathway since 
blocking of the P2Y12 receptor and PKC (to stop degranulation) diminishes Akt phosphorylation in 
thrombin stimulated platelets [44]. PAR signaling mediates the activation of ERK 1/2, which leads to the 
phosphorylation of PLA2 and mobilisation of AA [112]. Purinergic receptors play a role in PAR-mediated 
TxA2 release, as the P2Y12 receptor-mediated signaling potentiates PLA2 phosphorylation and hence AA 
release in response to thrombin receptor activating peptide (TRAP), by potentiating thrombin-induced 
ERK1/2 activation [80]. 
While free thrombin activates coagulation cascade and converts fibrinogen to fibrin, low levels of 
thrombin bind thrombomodulin forming a complex that activates protein C,  preventing blood clotting 
[113]. Thrombin has also been shown to indirectly induce thrombus destruction, by enhancing 
endothelial secretion and cleavage of ADAMTS-18 [114]. Thrombin cleaved ADAMTS-18 peptide is then 
capable of binding to GPIIIa receptor promoting 12-HETE dependent oxidative platelet fragmentation 
and thrombus dissolution [114]. Cleaved ADAMTS-18 protects mice from cerebral infarction by 50% in 
experimental cerebral stroke model induced by ischaemia, without affecting bleeding time and ADP and 
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collagen induced platelet aggregation and without causing thrombocytopenia [114]. Catecholamines, 
adrenaline and noradrenaline stimulate platelet activation by binding to α2 and β2 adrenergic 
receptors. Although many consider these factors as potentiating stimuli, the role of catecholamine 
activation is highlighted in studies that show most AMIs occurred after strenuous physical exercise or 
stress when adrenalin levels were increased [115].  The correlation between platelet activation and 
stress-induced CVD complications was established in some studies [116, 117].  Adrenaline is considered 
a weak agonist that decreases cAMP levels and potentiates the mobilisation of calcium that is induced 
by thrombin and other agonists, without the ability to activate PLC on its own [43]. Protease-activated 
receptors interacts with α2 adrenergic receptors synergistically to cause pronounced activation, since 
only platelets pre-treated with subthreshold thrombin concentrations (but not other agonists) showed 
increased calcium mobilisation upon stimulation with epinephrine [90].  Pre-treatment of platelets with 
PAR 4 activating peptide before addition of adrenaline causes full dense granule release reaction [90].  
Addition of adrenaline to Gq-deficient mouse platelets restores impaired response to collagen induced 
activation [42]. 
1.4 Cardiovascular disease 
Atherothrombotic disease causes more than 25% of all deaths worldwide [118]. In addition to a high 
mortality rate, treatment of CVD costs more than any other disease and currently constitutes 17% of 
overall US health expenses [119, 120].  By 2030, the incidence of CVD is expected to increase to 40.5% in 
the United States, with cost to health expenses increasing by 61% [119]. Atherosclerosis is a polygenic 
chronic thrombo-inflammatory disease of the vasculature and its main components are activated 
endothelium, smooth muscle cells, inflammatory leukocytes and platelets [118]. Even though 
atherosclerotic complications increase with age and other risk factors such as sedentary lifestyle, 
hypertension, smoking, abnormal lipid profile and diabetes  they can occur in the absence of any other 
CVD risk factors [115]. 
It was originally believed that  atherosclerosis develops due to abnormal interaction of endothelium, 
lipids, leukocytes and smooth muscle cells, while platelets and coagulation cascade participate in 
atherothrombosis which occurs when plaque ruptures [118]. The development of atherosclerosis is 
presented on Figure 1.7 [121]. During the initial stages of atherosclerosis, endothelial layer is inflamed 
or damaged and loses its anti-thrombotic and anti-inflammatory potential, which in turn permits 
platelets, leukocytes and lipids to interact, localise and adhere to the monolayer [115]. These cells 
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produce pro-thrombotic and inflammatory mediators that further accelerate the process [115]. The 
atherosclerotic plaque consists of a core of lipid and collagen covered by a layer of connective tissue. 
Migrating monocytes  differentiate into macrophages and express scavenger receptors CD36 and LOX-1, 
which will internalise cholesterol and cholesterol esters contained in modifies LDLs, or LDL-laden 
platelets, leading to foam cell formation, a component of atherosclerotic lesions capable of secreting 
cytokines growth factors and tissue factor and ROS [76, 122]. These cells will continue to produce 
chemoattractants, enhance macrophage replication and increase scavenger receptor expression [76]. 
Foam cells are present in the core and they cluster together and form necrotic atherosclerotic core 
which continues growing and is covered with fibrous cap composed of smooth muscle cells and 
extracellular matrix proteins [121, 123]. 
The presentation of atherosclerosis varies from stable and asymptomatic lesions to high-risk atheromas. 
Vulnerable atherosclerotic lesions accumulate matrix metalloproteinases which enable monocytic 
migration and degrade extracellular matrix, leading to destabilisation and rupture of the atherosclerotic 
plaque [124]. Thrombotic occlusions occur when vulnerable plaques rupture or erode. This commonly 
occurs in coronary arteries and represents the main cause of ischaemic events that lead to acute 
coronary syndromes (ACS) and cerebral infarctions [118]. When plaques ruptures, platelets adhere, 
aggregate, activate and recruit more platelets to the site of injury causing vasoconstriction, decreased 
blood flow and thrombus formation [33, 118]. As platelets are the main constituents of thrombi, 
antiplatelet drugs have been used for their treatment [125]. 
The widely recognised and described role of platelets in CVD is in the later stages of atherosclerosis 
when the atherosclerotic plaque ruptures and thrombus forms. Platelets contribution to CVD initiation 
and development was possibly underestimated due to the fact that there is only a transient 
accumulation of platelets to endothelial atherosclerotic wall [126]. Platelets however, play role in all 
stages of atherosclerosis. Transient and firm platelet-endothelial interactions, virtually absent in wild-
type mice, occur at age of 6 weeks in ApoE-/- mice, precede atherosclerotic lesion development or 
leukocytic recruitment, increase with age and do not require any vascular damage [127]. It is only after 
platelet adhesion and lesion development that recruitment of leukocyte was detectable in these mice, 
while blocking of platelet adhesion decreased leukocytic recruitment and atherosclerotic development 
[127]. These experiments suggest that platelet-endothelium interactions not only initiate lesion 
development but promote its progression. 
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Figure 1-7: Atherosclerotic plaque formation. 
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1.4.1 Platelet-endothelium interaction 
Selectin family (P- and E- selectin) and PSGL-1 play a major role in the initiation and advanced stages of 
atherosclerotic lesion development [128] by promoting platelets [129] and leukocyte adherence to 
endothelium [130]. While E-selectin mediates loose contact, endothelial P-selectin mediates leukocyte 
and platelet rolling of even inactive and P-selectin deficient platelets [129, 131].  Activated platelets are 
not necessary for initial platelet-endothelium bond, however platelet activation leads to platelet P-
selectin expression which can activate endothelium and stimulate secretion of more endothelial P-
selectin and vWF [132]. Experiments in PSGL-1 deficient mice demonstrate that the interaction of P-
selectin and PSGL-1 is required for the early migration of neutrophils, leukocyte rolling and the initial 
stage of the inflammatory response [133]. In mice lacking P-selectin, the initial rolling of neutrophils in 
venules is almost absent and the influx of neutrophils into the inflamed peritoneum is delayed [133]. 
Healthy endothelial cells prevent platelet binding due to release of PGI2, NO and ecto-ADPases that 
metabolise ADP [22].  Resting platelets can bind to damaged and also intact but inflamed endothelium 
that loses its antithrombotic properties as presented in Figure 1.8 [22]. Platelet-endothelium 
interactions are mediated by expression of endothelial P-selectin [131]. Wild-type and P-selectin 
deficient activated or resting platelets are capable of rolling and adhering to P-selectin expressing 
endothelium, an interaction not observed in mice with P-selectin deficient endothelium [131]. 
Endothelial activation increases bond formation [131]. Platelets bind to endothelium through 
interaction of platelet P-selectin glycoprotein ligand-1 (PSGL-1) and endothelial P-selectin [134]. 
However, while blockage of PSGL-1 in leukocytes completely abolishes their adherence, blockage of 
platelet PSGL-1 only partially inhibits platelet rolling, suggesting that additional bonds contribute to the 
process [134]. It has been shown that the initial contact between platelets and endothelium is mediated 
through platelets' GPIb (componenet of GPIb-V-IX) interaction with endothelium [127], which is 
structurally similar to PSGL-1, and  also has ability to bind P-selectin [135]. This bond is further 
strengthened by expression of β3 integrins, platelets αIIbβ3 [127], and endothelial αvβ3, whose 
expression is stimulated by endothelial activation [136]. αvβ3 is the major integrin expressed on 
endothelial cells and serves as adhesive glycoproteins such as fibrinogen, vitronectin or thrombospondin 
[136]. It mediates platelet and platelet-derived microparticle adhesion to endothelial surface  by binding 
to αIIbβ3 bound fibrinogen [136]. During this process, platelets activate and degranulate releasing 
mediators that can attract, activate and help arrest leukocytes [137, 138] on previously activated 
endothelium [139].  Activated platelets are able to increase expression of integrin αvβ3 on endothelial 
38 
 
cells [140] and by interleukin-1 (IL-1) mediated mechanism activate NF-ĸB and induce secretion of MCP-
1, a chemokine that induces monocytic chemotaxis, and expression of ICAM-1 and VCAM-1 [140]. 
Adherent platelets recruit CD34+ progenitor cells and induce their differentiation into mature 
endothelial and foam cells [141]. 
Release of platelet CD40L, a TNF family member, from activated platelets, together with PDGF, 
thrombospondin and RANTES induces inflammatory response [142] . CD40L binds to CD40 on leukocytes 
after P-selectin-PSGL-1 bond formation, which stabilises the leukocyte platelet aggregates (LPA) and 
integrin αIIbβ3 receptor, causing platelet activation by outside-in signaling [143]. Platelet CD40L also 
binds to CD40 on endothelial cells and promotes leukocyte recruitment to the arterial wall by 
upregulating endothelial secretion of IL-8, MCP-1, ICAM-1 and VCAM-1 [144], TF [145], increases platelet 
P-selectin release and leukocyte expression of Mac-1 and MMPs that further degrade endothelium [143, 
146]. CD40L is also capable of binding to the GPIIb/IIIa receptor directly, which allows platelet activation 
by outside-in signaling [143]. Soluble CD40L (sCD40L) is considered a marker of inflammation and a good 
predictor of the risk of death or other adverse CVD events in healthy females [147] and patients with 
ACS [148, 149]. Increased levels were found in patients with unstable angina and AMI [149, 150]. 
1.4.2 Platelet-leukocyte interaction 
While resting and activated platelets can bind to endothelial P-selectin expressing cells, activated 
platelets preferentially bind to leukocytes and formed complexes then roll on endothelium [131]. The 
molecular interactions between those cells, initiated by P-selectin-PSGL-1 bond, are presented on Figure 
1.9 [142]. The cross-talk between platelets, endothelium and leukocytes is presented on Figure 1.10 
[151]. 
Various studies postulated that leukocyte-platelet interactions contribute to the development of 
atherosclerosis. Under high shear rate, platelets can bind to leukocytes, preferentially to monocytes 
over neutrophils, and this interaction is further enhanced upon platelet activation [152]. The formation 
of LPAs occurs within 1 minute of thrombin stimulation [153]. The in vivo half-life of monocyte-platelet 
aggregates (MPA) is 30 minutes, whereas that of neutrophil-platelet aggregates (NPA) is 5 minutes 
[153]. As previously described this interaction allows recruitment of monocytes and other inflammatory 
cells to vascular wall and is mediated by binding of platelet P-selectin to leukocyte PSGL-1 [154]. This 
together with cytokines and chemokines secreted by platelets, activates leukocytes, triggers 
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phosphorylation of various proteins and facilitates recruitment to the endothelium, rolling and adhesion 
[154-156]. The formation of MPA is important as it triggers the expression and secretion of IL-1b, IL-8, 
and MCP-1. These cytokines are responsible for inflammatory cell recruitment and activation, which 
could ultimately lead to a continuous cycle of monocyte and macrophage recruitment to the 
atherosclerotic plaque, causing its instability [142].  Activated monocytes produce inflammatory 
cytokines and free radicals, therefore promoting the uptake and esterification of oxidised LDLs (oxLDLs) 
[142] . 
A key molecular event in LPA formation is binding of platelet P-selectin to PSGL-1 on leukocytes which 
serves to tether the platelets to other cells and transmit outside-in signals that alter functional 
responses [152]. The P-selectin-PSGL-1 interaction is necessary and sufficient for MPA formation, 
without the need for any exogenous agonists under all shear rates [152]. Blocking of P-selectin by LYP20, 
a monoclonal, highly specific P-selectin antibody, inhibits the adhesion of polymorphonuclear cells to 
resting and thrombin activated endothelial cells and platelets [15].  Injection of only P-selectin 
expressing, but not P-selectin deficient platelets, promotes monocytic recruitment to the surface of 
atherosclerotic lesions in ApoE-/- mice, and accelerates formation of atherosclerotic lesions [126]. 
The interaction between P-selectin and PSGL-1 leads to activation, increased expression of and is 
stabilised by the integrin CD11b/CD18 (Mac-1) [152]. The binding of P-selectin to PSGL-1 in neutrophils 
and monocytes enables rolling of these cells on a stimulated, immobilised platelet monolayer, their 
tethering and adhesion in high shear conditions and a firm adhesion,  mediated by Mac-1 [154, 157]. 
Mac-1 itself is a major proinflammatory β2 integrin that serves as a receptor for C3bi,  FX, fibrinogen and 
LPS [158]. Activation of Mac-1 mediates outside-in signaling and results in the phosphorylation and 
activation of ERK1, ERK2, and p38/SAPK2 MAP kinases [159] which leads to expression or release of 
MCP-1, MIP-1b, IL-1b, IL-8, MMP-9, PAF and TF [158]. Although the expression of CD11b and activation 
of Mac-1 is mainly independent of platelet binding to leukocytes, the consequential conformational 
change in its surface allows both activated FXa and fibrinogen binding and TF expression [157]. Tissue 
factor, a transmembrane GP,  is the main initiator of in vivo coagulation that accelerates fibrin formation 
and deposition [160] whose levels are increased in patients with CAD, hyperlipidemia, diabetes and 
other haematological disorders that can lead to excessive coagulation [161]. 
Activated platelets deliver RANTES and PF4, released from α granules to endothelium and leukocytes 
[126]. After platelet activation and binding of P-selectin to PSGL-1, chemokines RANTES and PF4 are 
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released from platelet α granules and are important for monocyte activation. RANTES can bind to the 
surface of activated endothelium and induce adhesion and vascular recruitment of monocytes under 
flow conditions, while PF4 enhances the arrest of RANTES-stimulated monocytes [162]. 
Recruitment of leukocytes to atherosclerotic lesions is followed by their disappearance from circulation 
and increased monocytic adhesiveness [126]. The triggering receptor expressed on myeloid cells 1 
(TREM-1), involved in innate immunity and sepsis expressed in neutrophils and monocyte has its natural 
ligand on platelets. The interaction between TREM-1 and TREM-1 ligand is not necessary for LPA 
formation but induces respiratory burst and IL-8 secretion [163]. Immunoglobulin-like glycoprotein 
extracellular matrix metalloproteinase inducer (EMMPRIN, CD147) is localised in platelets open 
canalicular system and α-granules and translocated on platelet surface during platelet shape change. 
Binding of EMMPRIN to its ligand induces platelet activation and degranulation and mediates platelet 
binding to monocytes. EMMPRIN then activates NF-ĸB inducing secretion of MMP and cytokines on 
monocytes [164]. 
Platelets activated by P-selectin mediated binding then transfer platelet-derived chemokines and PF4 to 
the endothelium and monocytes, and promote the binding of vascular cell adhesion molecule 1 (VCAM-
1) and increase leukocyte adhesiveness at the site of injury [126]. Platelet factor 4 is a cationic protein 
released in high concentrations from activated platelets that induces differentiation of monocytes to 
macrophages and foam cell formation [165]. PF4-oxLDL complex binds to endothelium and 
macrophages and localise in atherosclerotic lesions and foam cells [165].  In addition to that PF4 inhibits 
the catabolism of LDL [166].  Initial treatment options for atherosclerosis focused on the role of 
dyslipidemia in atherogenesis and the use of statins that lowered low-density lipoprotein (LDL) 
cholesterol, which consequently decreased mortality from CVD. Statins in fact reduce platelet-mediated 
foam cell formation and MMP-9 activity [141]. A recent meta-analysis that assessed the efficacy of more 
intensive statin therapy for lowering LDL cholesterol in comparison to placebo or standard therapy (20-
40 mg simvastatin per day) confirmed that reductions in LDL cholesterol, especially with  more powerful 
statins (40-80 mg atorvastatin or 10-20 mg rosuvastatin per day), lead to a reduction in acute myocardial 
infarction (AMI), revascularisation and ischaemic stroke incidence [167]. A 2–3 mmol/L decrease in LDL 
reduced the risk of CVD by 40–50% [167]. Tethering of monocytes to platelets induces COX-2 synthesis 
and production of eicosanoids [168]. Unregulated COX-2 expression enhances atherosclerosis and 
associated complications [169]. 
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Increased levels of MPA are found in patients with stable CAD compared with healthy volunteers [170] 
and increased levels of MPA and NPA are found in patients with AMI compared with patients with non-
AMI CAD or non-CAD [171]. Patients with CAD are shown to have increased levels of P-selectin and LPA 
[170]. Monocyte-platelet aggregates are increased in patients with stable and unstable angina after AMI 
[172] and in patients with PCI [153] and their increase precedes the elevation of the standard cardiac 
markers troponins and Ck-MB that increase 4 hours after the onset of injury [172]. Results from one 
study have shown that in patients with ACS after PCI, the increase in levels of MPA was higher than that 
of NPA, whereas the level of P-selectin remained unchanged [153]. Patients with ACS also have a higher 
amount of MPA than patients with stable angina pectoris and control patients [173]. The levels of IL-6, 
IL-8, MCP-1, sCD40L, soluble P-selectin and C-reactive protein (CRP) were also significantly higher in 
patients with ACS than patients with stable angina pectoris and control patients. The levels of P-selectin 
and IL-6 correlated with levels of MPA,  and authors suggested that high levels of circulating MPA and 
regulated biomarkers may be used as predictors of unstable coronary syndromes, and could potentially 
be used for monitoring the progression of disease and prompting early interventions, if needed [173] 
while other claimed no correlation between P-selectin and  MPA [174] suggesting that the MPA 
formation may be largely dependent on other factors. 
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Figure 1-8: Platelet-endothelium interactions. 
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Figure 1-9: Platelet-leukocyte interactions. 
 
 
 
 
Figure 1.9: Platelet-leukocyte interactions (143). 
Platelet P-selectin mediates the initial interaction between monocytes and platelets by binding to PSGL-1 and CD15. This bond 
activates  and increases the expression of monocytic Mac-1 (integrin αMβ2), which can bind fibrinogen and FXa, promoting 
coagulation. Subsequent bonds are formed between platelet CD40L and monocytic CD40 and TREM-1 Ligand and TREM-1.  
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Figure 1-10: Platelet-leukocyte-endothelium interactions. 
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1.4.3 Other contributors to cardiovascular disease development 
1.4.3.1 Lipids 
Hypercholesterolemia and elevated LDLs are important risk factors for atherosclerosis development. 
Native LDLs can enter intima, but they do not initiate inflammation and atherosclerosis [175]. However 
in subendothelial space, LDLs become modified (glycosylation and oxidation in particular) increasing 
their atherogenicity and retention in vascular wall [76]. They promote leukocyte rolling and adhesion to 
endothelium and the formation of LPAs [176]. They up-regulate lipoprotein-associated PLA2 expression 
in monocytes through the phosphatidylinositol 3-kinase (PI3K) and p38 MAPK pathways, which 
promotes lipoprotein uptake by macrophages [177]. 
Both native and modified LDLs decrease the bioavailability of endothelial NO, NOS and their 
biodegradation through superoxide ion formation, leading to formation of peroxynitrites that can inhibit 
prostacyclin production [76]. Modified LDLs increase the expression and secretion of VCAM-1, MCP-1 
and IL-8 and activity of NF-ĸB, enhancing chemotactive, adhesive and proinflammatory endothelial 
properties [76, 178] . They are taken up by macrophages via scavenger receptors [175]. 
Oxidised LDLs are potent platelet activators [179] that interact with CD36, a transducer of intracellular 
signals, which allows them to activate platelets at lower agonist concentrations [180] and promote 
endocytosis in macrophages leading to foam cell formation and increase in macrophages CD36 [181]. 
LDLs induce synthesis and translocation of platelet membrane phospholipids [76] and modify platelet 
membrane fluidity [182] inducing the phosphorylation of myosin light chain which leads to platelet 
shape change [183] and platelet activation. Oxidised LDLs are internalised by activated platelets and 
localised in dense granules. Oxidised LDL laden platelets induce endothelial ICAM-1 expression, foam 
cell formation  and prevent endothelial regeneration [122]. Block of ox-LDL, reduces plaque extension, 
increases stability of atherosclerotic plaque and reduces T-cell and macrophage infiltration [184]. 
1.4.3.2 Reactive oxygen and nitrogen species 
Reactive oxygen species are products of cell metabolism capable of reacting with various types of 
biological molecules; however, oxidative stress occurs when the ROS outweigh the antioxidant 
capabilities of the cell [185]. Increased oxidative stress is responsible for the activation of transcription 
factors and the enhancement of endothelial expression of adhesive substances, necrosis and apoptosis 
[186]. Reactive nitrogen species (RNS) are also highly reactive substances capable of damaging various 
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cells. There are several mechanisms by which ROS and RNS, that can also be produced by activated and 
resting platelets, enhance CVD by inducing platelet adhesion and aggregation [187, 188]. 
Enhanced ROS released from the vascular wall can indirectly increase platelet activation by scavenging 
NO, thereby decreasing the anti-aggregating potential of the endothelium, impairing vasodilation and 
mediating leukocyte adhesion [189, 190]. Increased ROS amplify platelet reactivity to various agonists, 
and have a great impact on modification of AA pathway [188].  Collagen induced platelet activation 
produces oxidative burst, and H2O2 then acts as a second messenger to activate PLC, thereby increasing 
calcium levels, and PLA2 release [191]. During high oxidative stress and low glutathione peroxidase 
activity, 12-HpETE is formed from AA by 12-LOX which phosphorylates p38 MAPK and cPLA2 increasing 
AA release and pathway activation, contributing to the imbalance between TxA2 and PGI2 production in 
favor of TxA2 [60]. Oxidative stress is also capable of modifying the AA pathway resulting in the 
production of isoprostanes, molecules structurally similar to prostaglandins that are capable of binding 
to the TP receptor and activating platelets [192] . The impact of ROS on the AA pathway raised the 
question if high levels of ROS may explain aspirin resistance in some patients. Results from the study of 
Lordkipanidze and colleagues revealed that oxidative stress, measured by urinary 8-iso-PGF2α, was not a 
contributor to aspirin resistance  in their study population [193]. However only 8 of the 200 patients 
with CAD were deemed aspirin resistant by AA induced aggregometry, which may be too small group 
size to determine the link between ROS and aspirin resistance. However, when 8-iso-PGF2α levels were 
compared between patients with CAD and ACS, 8-iso-PGF2α levels were found to be higher in patients 
with ACS than patients with CAD and were correlated with markers of platelet activation, soluble P-
selectin and sCD40L [194]. 
Apart from AA, oxidative stress affects other platelet activation pathways. Collagen induces NADPH 
oxidase-dependent O2 release in platelets, which in turn increases ADP release, therefore amplifying 
platelet activation [195]. In platelets exposed to oxygen radicals even subthreshold ADP concentrations 
lead to irreversible aggregation [195]. Excess of superoxide ions increases the intracellular levels of 
platelet free iron leading to the appearance of cytosolic oxidising species and the activation of integrin 
αIIbβ3 [196]. RNS, like peroxynitrites, are reactive diffusible molecules that penetrate the platelet 
membrane and damages cells by oxidation and nitration of various cellular components [197]. 
Peroxynitrites also decrease and oxidise platelet thiols, deplete glutathione, and induce platelet lipid 
peroxidation [198]. 
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1.4.3.3 Strenuous Exercise 
Low to moderate exercise has been shown to be cardioprotective, however, a strenuous exercise in 
sedentary individuals increases CVD risk factors increasing the adverse events risk a 100-fold [199, 200] 
with 40-50% of AMI patients reporting moderate/heavy physical activity as a trigger [201]. Similarly, 
reports have shown that late stent thrombosis, a PCI complication that causes high morbidity and 
mortality, may be triggered by vigorous exercise, particularly in patients who are sedentary [202] . 
The effects of strenuous exercise on increasing thrombotic risk factors are multifactorial [203-205]. It  
leads to increased oxygen flux leading to generation of reactive oxygen species (ROS) and reactive 
nitrogen species (RNOS), eventually decreasing or depleting the antioxidant status and damaging the 
host tissue [200, 206, 207].  The inability of host tissue to neutralise ROS generates ox-LDL that induces 
platelet activation and decreases platelet ability to generate NO [205, 208-210]. During strenuous 
exercise, there is an increase in the inflammatory response, platelet count [211], vWF [212] levels and 
catecholamines levels [213]. Together, these factors contribute to a prothrombotic phenotype. 
Increased shear stress found after acute exercise induces platelet procoagulant activity, promoting FV 
and FVIII binding to platelets and platelet-derived microparticle formation, while triggering thrombin 
generation in blood that returns to normal only 2 hours after exercise [214]. This may explain the 
prothrombotic tendency even though both coagulation and fibrinolysis are equivalently increased after 
strenuous and moderate exercise in both sedentary and trained healthy volunteers [215]. Similarly, 
coagulation and fibrinolysis are increased after exercise in patients with CAD, but the equilibrium is in 
favour of coagulation after recovery [216]. However, while this exercise induced imbalance of 
coagulation and fibrinolysis may predispose to thrombosis, the majority of exercise induced 
complications appear to be platelet-mediated, resulting in occlusion of coronary arteries by platelet-rich 
thrombi [199]. A brief increase in platelet count is thought to be due to dehydration induced 
haemoconcentration and release of platelets from the spleen, bone marrow and lungs [217]. After 
strenuous exercise, platelets become hyperactive [213], form conjugates with other platelets [213] and 
leukocytes [213, 218] and develop NO hyposensitivity [219]. Increased platelet aggregation induced by 
exercise or LPA formation is not attenuated by aspirin [213], clopidogrel [220] or the combination when 
activity is measured by PFA-100, which can be partially attributed to an increase in vWF [212]. Increase 
in shear stress and vWF antigen and activity have been shown to allow vWF to bind to platelets and 
enhance their binding to fibrinogen, thereby stabilising platelet-platelet aggregates [221]. Exercise also 
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results in release of catecholamines and has been shown to increase the density of α2-adrenoreceptors 
on the platelet surface [222]. Binding of adrenaline to these receptors results in conformational changes 
in integrin αIIbβ3, rendering it more receptive to fibrinogen binding in the presence of other agonists. 
The concentration of adrenaline associated with moderate to strenuous exercise in sedentary 
individuals is not sufficient to increase platelet aggregation alone, but can amplify the effects of other 
agonist [222, 223]. 
The effects of a 20 minute bout of moderate treadmill exercise were compared between normotensive 
and hypertensive subjects. The results showed an increase in platelet P-selectin expression, and integrin 
αIIbβ3 activation and aggregation that continued 25 minutes after recovery. The changes seen were 
more pronounced in subjects with hypertension, especially 25 minutes post exercise when platelet 
activation continued to increase. As normotensive subjects showed clear recovery signs, these results 
suggested that in vulnerable individuals the recovery period is a critical period for the occurrence of 
adverse cardiovascular events [224].  These results could be partially explained by the effects of low 
intraplatelet NO bioactivity that is normally found in patients with hypertension and is further reduced 
by strenuous exercise. This deleterious effect can be overcome by regular exercise which increases L-
arginine transport, thereby increasing platelet NO synthase activity and cGMP levels and causing 
reduced platelet aggregation [225]. In addition to improving NO levels, chronic exercise, even in subjects 
with hypertension, reduces CRP levels, fibrinogen levels and blood pressure [225]. 
The hypercoagulable state created after exercise is in part attributed to increased oxidative stress, and 
high ROS production with the depletion of antioxidants. Results from experiments in mice showed 
decreased total antioxidant status after 1 hour of moderate exercise with enhanced collagen-induced 
platelet ATP release [207]. Vigorous exercise, as opposed to moderate exercise, in sedentary male 
subjects increased lipid peroxidation and oxLDL formation, decreased total antioxidant capacity, and 
plasma and platelet NO bioavailability. These changes, accompanied by increased ADP levels and 
collagen-induced platelet aggregation, could be caused by a lack of NO desensitisation and oxLDL 
activation [226]. High antioxidant levels induced by moderate regular exercise inhibit LDL oxidation and 
increase NO bioavailability, thereby decreasing platelet activation [227]. The improvement in 
antioxidative defence can therefore be achieved by regular exercise or possibly by antioxidant 
supplementation. 
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1.4.4 Role of nitric oxide in cardiovascular disease development 
Nitric oxide is synthesised from L-arginine and the reaction is catalysed by nitric oxide synthase 
(NOS)[228]. It acts by activating soluble guanylyl cyclase (sGC) thereby increasing cyclic guanosine-3’5’-
monophosphate (cGMP) in target cells. Nitric oxide synthase has three major isoforms: endothelial NOS, 
inducible NOS and neuronal NOS  that have the same mechanism of NO production [228]. Endothelial 
NOS is constitutively expressed, whereas inducible NOS is usually undetectable but is expressed by 
leukocytes and vascular SMCs in response to inflammation [228]. Endothelium-derived NO causes 
vasodilation and inhibits platelet adhesion, but decreases with age [229]. In atherosclerosis, a reduction 
in endothelium-derived NO impairs endothelium-dependent relaxation before structural changes to the 
vasculature arise [230]. Nitric oxide has been shown to inhibit the oxLDL induced activation of NF-ĸB, 
expression of VCAM-1 and adhesion of endothelium to monocytes in human aortic endothelial cells, 
therefore decreasing leukocyte recruitment to the endothelium [178]. In addition to having a direct 
effect on platelets, NO inhibits cytokines and cell adhesion molecules that attract and help adhesion of 
inflammatory molecules and the activity of growth factors released from platelets and endothelial cells 
[231]. Decreased NO levels leads to vascular inflammation that can also lead to oxidation of lipoproteins 
and foam cell formation. Decreased production of NO and the hyporesponsiveness of platelets to NO 
have been implicated as reasons for cardiovascular complications in patients with CVD and diabetes 
[231]. 
Platelets are capable of producing NO as they express NOS2 and NOS3, with NOS3 being the 
predominant isoform [232]. Platelet-derived NO inhibits platelet aggregation, adhesion to vascular 
endothelium, recruitment to growing thrombi and the formation of LPA. Platelet NO production and 
responsiveness decrease with age and this is reflected by increased circulating levels of MPA [229]. NO 
exerts the inhibitory effect on platelets through activating soluble guanylate cyclases and increasing 
cGMP levels [233]. 
Arachidonic acid released from membrane phospholipids activates PKC, decreases endothelial NOS 
activity and reduces NO production dose-dependently. These effects can be reversed by inhibiting one 
of the TP receptors, or the PKC or PLC pathways [232].  Similarly, collagen induced platelet activation, 
which enhances PKC, decreases NO formation and L-arginine uptake, possibly by phosphorylation of 
specific cNOS residues [96]. Inhibition of NO synthesis promotes P-selectin expression on platelets and 
endothelial cells through activation of PKC [234]. 
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The biological activity of NO is however limited by the large amounts of superoxide (and hydroxyl 
radicals) produced by activated platelets, which react together and form peroxynitrites, which can 
penetrate platelet membrane and induce oxidative damage [235]. Peroxynitrites are also produced 
during inflammation from neutrophils and macrophages, contributing to increase platelet activation 
during the process [197]. 
1.5 Antiplatelet therapies and resistance 
1.5.1 Aspirin other antiplatelet therapies interfering with AA metabolism 
Aspirin, a nonsteroidal anti-inflammatory drug (NSAID), is considered to be the reference antiplatelet 
drug [77]. Aspirin exerts its antiplatelet effect by binding to and irreversibly acetylating Ser 529 of COX, 
which prevents AA binding and, consequently, inhibits TxA2 formation. While aspirin reaches the 
circulation relatively soon after ingestion (30–40 minutes for standard preparations or 3–4 hours for 
enteric coated aspirin) and the plasma half-life of aspirin is relatively brief at 15–20 minutes [77], the 
effect on TxA2 production lasts the lifetime of the platelet, as platelets lack a nucleus are unable to 
generate new, unacetylated COX-1 [77]. Aspirin is prescribed for both primary and secondary 
preventions of CVD although the beneficial effects are only seen in some but not all clinical situations 
[236, 237] and its use is associated with increased risk of bleeding [236, 237]. 
Aspirin fails to elicit a response in some patients, frequently classified as ‘aspirin resistant’.  Aspirin 
resistance is associated with increased risk of adverse CV events [238-241], but is a poorly defined term 
that includes both clinical and chemical (pharmacological) resistance, and whose causes are 
multifactorial. Clinical resistance to aspirin occurs when despite full inhibition of AA-induced activation, 
patients still present with adverse CVD events [242].  Chemical resistance to aspirin occurs when aspirin 
cannot inhibit a predetermined level of agonist-induced platelet activation [242]. Chemical resistance 
should, theoretically, be easily identified in the diagnostic laboratory; however, the amount of residual 
on-treatment platelet activation needed to classify someone as resistant varies based on the diagnostic 
method used and the cut off values used are discrepant in the literature. 
 
Some authors do not support theory that chemical aspirin resistance exists, since the production of TXB2 
decreases in almost all patients treated with aspirin and addition of aspirin to all samples ex vivo 
attenuates AA-induced platelet activation, suggesting ‘aspirin resistance’ is due to non-compliance or 
underdosing [243].  Both environmental and hereditary factors have been suggested as contributors to 
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aspirin resistance. In addition to a lack of adherence to antiplatelet therapy, the most commonly 
suggested reasons for resistance are non-COX-1 mediated TxA2 synthesis, interference by other drugs 
and increased activity of other platelet pathways during aspirin treatment [242]. Aspirin resistance may 
occur due to difference in COX-1/2 protein levels [244] or due to the non-linear relationship between 
platelet activation and TxA2 synthesis [245]. More than 95% of TxA2 inhibition is required to suppress 
TxA2-dependent platelet aggregation, the effect which may be impossible to obtain in some patients 
with high platelet turnover or increased inflammation with standard aspirin doses [245].  Apart from 
platelet turnover, the pre-existing platelet activation variability [246] and platelet count [193] may 
partially determine patients response to aspirin, making it a process unrelated to aspirin itself.  Since 
COX-dependent platelet activity is recoverable in some participants within 24 hours suggests that some 
resistance may occur due to dosing issues or less likely  the potential ability of platelets to synthesise 
new COX [247]. Some studies have claimed that the presence of COX-2 in platelets explained the 
resistance and attributed its presence to leukocyte-inducible COX-2 that is less responsive than COX-1 to 
aspirin [248]. Increased aspirin clearance and poor absorption may lead to inadequate COX inhibition by 
aspirin. In those cases, AA induced platelet activation may be sufficient to identify such patients who 
could benefit from higher or more frequent doses or in some cases alternative anti-platelet agents. 
 
Other commonly suggested causes of aspirin resistance are not directly linked to the expected aspirin 
effect (inhibition of COX-1 and subsequent lack of TxA2 production) and investigation of such may 
identify population with clinical aspirin resistance which could benefit from additional, rather than 
different antiplatelet therapy.  While pharmacological aspirin resistance can easily be identified using 
aspirin specific methods, there are currently no evaluated markers from prediction of adverse CVD 
events in clinically resistant patients, nor guidelines on their identification. The identification and 
investigation of aspirin resistance (described later) described in literature by currently used 
methodologies poses the problem due to the lack of clear separation of clinical and chemical resistance, 
both terms frequently called ‘resistance’. 
 
Some patients, classified as ‘aspirin resistant’ may have structurally different platelets to those of 
‘responsive’ patients due to  different levels of proteins associated with oxidative stress and cell survival 
[249]. Ingestion of aspirin can increase platelet aggregation in response to U-46619 in at least 13% of 
healthy participants and its effect is mediated through the activation (or maybe upregulation) of the 
ADP-induced Gi pathway [250], although it is possible that upregulation or hyperresponsiveness of the 
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TP receptor is responsible. On the other hand, it was shown that high residual AA-induced platelet 
activation after aspirin treatment in certain patients was not further inhibited by aspirin or 
indomethacin [243].  Neither U-46619 induced platelet activation nor Gi pathway upregulation are 
targeted by aspirin, and even though this patient population may be at high risk of adverse CVD events, 
they should be deemed clinically resistant to aspirin and additional therapy for prevention of CVD may 
be beneficial. But patients in Frelinger’s study show chemical aspirin resistance and may have more 
benefits from different anti-platelet agents. 
 
Although the differentiation between pharmacological and clinical resistance to aspirin is important in 
clinical settings, the question is if the pharmacological effects of aspirin and pharmacological resistance 
as measured by the production of thromboxane metabolites are more important than the clinical 
resistance as measured by other assays on the overall wellbeing of patients with CVD. The identification 
of pharmacological resistance, which has a much lower prevalence, may be solved by a change of 
antiplatelet agent. However, functional resistance is linked with adverse outcomes and may not 
necessarily be overcome by a change or addition of another antiplatelet agent, therefore giving some 
advantage to non-specific platelet assays, such as LTA, PFA-100 and VerifyNow, in diagnostic settings. 
 
Considering that TxA2 is one of the most potent amplifiers of platelet aggregation, agents that block TxA2 
synthesis or action were potential antiplatelet therapies. Thromboxane synthase inhibitors were initially 
investigated. If TxAS was inhibited, PGH2 would preferentially be converted to PGI2, thereby improving 
the overall CVD profile of patients. Inhibition of TxAS, however, contributed to an excess of 
endoperoxides, which paradoxically induced platelet activation [75]. Because of receptor homology, the 
endoperoxides were capable of binding and activating the TP receptor [49, 75]. The next line of 
investigation was to examine agents capable of blocking either the TP receptor or the TP receptor and 
TxAS. Blockage of the TP receptor and TxAS was shown to surpass the effects of aspirin [251]. However, 
few agents progressed beyond the phase II trial because of safety issues [75]. Terutroban is a rapid and 
potent TP inhibitor that suppresses platelet activation in a porcine model of stent thrombosis as 
effectively as aspirin and clopidogrel, but without major bleeding [62]. 
1.5.2 Thienopyridines 
Another key mechanism of platelet inhibition is the block of the ADP receptor P2Y12, linked to platelets’ 
Gi pathways, by thienopyridines. Antagonism of P2Y12 had benefits in patients with ACS including those 
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undergoing PCI [252]. The first generation of thienopyridines included ticlopidine, whose active 
metabolite, thiol, irreversibly binds to P2Y12. Ticlopidine was capable of reducing complications due to 
platelet activation in various patients with CVD, but its use was accompanied by unwanted side effects, 
such as life-threatening neutropenia, aplastic anaemia, thrombotic thrombocytopenic purpura and 
digestive side effects [77]. 
Clopidogrel is a second generation thienopyridine, as efficient as ticlopidine, in attenuating platelet 
activation induced by ADP and decreasing the risk of CVD complications, but with fewer side effects [77]. 
Clopidogrel was, in addition to attenuating platelet function, capable of decreasing the expression of P-
selectin and TF on platelets, the adhesion of LPA and the production of ROS. The use of clopidogrel also 
reduced the levels of sCD40L in CAD patient [253]. Even though clopidogrel was a promising anti-platelet 
agent that is rapidly absorbed [254] and is superior to aspirin [255], particularly if higher loading (LD) 
and maintenance (MD) doses are given [256], without any statistically significant increase in major or 
minor bleeding [257], it is a pro-drug that require metabolism by the liver cytochrome P450 enzymes to 
produce its active thiol derivative [258]. Up to 90% of the absorbed clopidogrel is hydrolysed to an 
inactive carboxylic acid metabolite and up to 15% is metabolised to its active thiol derivative in a 2-step 
process [259]. The metabolism of clopidogrel is predominantly done by cytochrome P450 3A4 and 3A5 
with input from 2C19, CYP1A2, 2B6 and 2C9, and its metabolism delays its onset of action [258, 259]. 
Clopidogrel is currently recommended as an alternative to aspirin for secondary CVD prevention and as 
combination therapy with aspirin for patients with an ACS or undergoing stent implantation [255, 260]. 
Although clopidogrel is the recommended therapy, with or without aspirin, for a variety of CVD 
conditions, its downsides are a delayed onset of action and resistance partially due to the requirement 
for CYP450 metabolism [261]. Between 4% and 30% of patients are alleged to be clopidogrel resistant, 
and this includes both chemical and clinical resistance [262]. Similarly to aspirin resistance, the 
prevalence of clopidogrel resistance depends on the methodology used to evaluate it [49, 50]. There is 
evidence that clopidogrel resistance is caused by pre-existent variability in platelet response to ADP 
[263], and high platelet reactivity despite clopidogrel use has been linked with increased prevalence of 
both short- and long-term major adverse coronary events (MACEs) [264-266]. 
 
Cytochrome P450 enzymes can have polymorphisms which affect the response to clopidogrel [258, 267, 
268]. The effect of P2Y12 polymorphisms on platelet aggregation is more debatable. Initially, the H1 and 
H2 haplotypes were reported to create a difference in platelet aggregation after clopidogrel 
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administration, with patients carrying the H2 haplotype having an increased risk of atherothrombosis 
[269], but this was rebutted in subsequent studies [270-272]. In 2009, Staritz and colleagues reported 
that after investigating 43 clopidogrel naïve participants and 557 patients with PCI on dual antiplatelet 
therapy, the presence of the homozygous H2 haplotype (n = 14) increased platelet aggregation 
compared with the presence of at least one H1 allele (p=0.02) and was associated with clopidogrel 
resistance [273]. The possibility of high variability in patient responsiveness to clopidogrel was also 
attributed to the expression of the P2Y12 receptor on leukocytes [274]. Although only one study 
identified the P2Y12 receptor on leukocytes, the researchers could not explain why patients with a low 
or no response to clopidogrel were more likely to have chronic inflammatory conditions. 
 
Adrenalin activates platelets by binding to the α2 adrenoreceptor linked to the Gi pathway. Adrenalin 
potentiated, whereas the α2-adrenoreceptor blocker, atipamezole, inhibited, ADP and collagen induced 
platelet aggregation in 121 patients with stable CAD on dual antiplatelet therapy [275]. Patients who 
had high adrenergic activity also had increased baseline platelet aggregation and more functional P2Y12 
receptors, suggesting the potential contribution of high levels of adrenalin and adrenergic receptors to 
clopidogrel resistance [275]. Patients with a low response to clopidogrel may benefit from increased 
loading and maintenance doses of clopidogrel or may be switched to alternative treatments such as 
prasugrel [276]. Prasugrel is the third generation thienopyridine whose active metabolite selectively and 
irreversibly inhibits the P2Y12 receptor [277]. Prasugrel is a prodrug that is metabolised by CYP3A4 in 
the liver; however, it is faster acting and its use shows less variability in patients’ response than 
clopidogrel [261, 278-280]. Prasugrel has been approved for use in the US and Europe [77]. However, a 
concerning side effect of prasugrel, in addition to an increased risk of major bleeds, is a 3-times higher 
rate of gastrointestinal cancer in patients, particularly female patients, treated with prasugrel compared 
with patients treated with clopidogrel [281, 282]. This effect is possibly due to an increase in platelet 
inhibition that disrupts platelet-tumour bonds, therefore, preventing localisation of the tumour and 
allowing fast metastasis [283]. An increased prevalence of cancer is also documented with use of other 
antithrombotic agents, such as heparin and aspirin [283]. 
Cangrelor is a rapid acting and reversible ATP analogue that directly inhibits the P2Y12 receptor. 
Cangrelor is administered intravenously, has a half-life of 2.6 minutes and is metabolised through the 
dephosphorylation pathway [284]. Platelet function normalises 20 minutes after discontinuing 
treatment and cangrelor has been shown to be safe and well tolerated [285] however it has no 
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superiority over clopidogrel and is associated with increased risk of major bleeds [286, 287]. Ticagrelor is 
a new, non-thienopyridine antiplatelet agent, also known as cyclopentyl-triazolo-pyrimidines, that is 
currently being investigated and that functions by blocking the P2Y12 receptor [261, 288]. Ticagrelor is a 
reversible inhibitor of the purinergic receptor that does not require hepatic metabolism and has the 
potential to cause more rapid and consistent platelet inhibition than the thienopyridines [261, 289]. The 
plasma half-life of ticagrelor is 12 hours and is, therefore, administered twice daily [261]. Ticagrelor was 
shown to be more effective and less variable than clopidogrel [289, 290] but side effects include 
transitory bronchoconstriction, arrhythmia that can cause ventricular pauses, anxiety, and increased 
levels of creatinine and uric acid in blood [261].  
Elinogrel is another potent reversible anti-platelet agent targeting the P2Y12 receptor, currently under 
investigation [291]. The superiority of elinogrel over clopidogrel is in it ability to access the internalised 
pool of P2Y12, unaccessible to clopidogrel [291]. While clopidogrel administration effectively inhibited 
ADP induced aggregation and vascular occlusions in mice with FeCl3 induced thrombosis, it failed to 
simulate the profile of P2Y12 deficient mice until elinogrel was administered, confirming that platelets 
possess intracellular pool of P2Y12, not inhibited by clopidogrel, which can become redestributed on 
platelet surface upon stimulation with strong agonist [292]. Further studies are required to evaluate the 
use of elinogrel in CVD patients. 
1.5.3 Dual antiplatelet therapy 
Since the resistance to clopidogrel and aspirin poorly defined, but well documented, the use of dual 
antiplatelet therapy is recommended in some cases, however it is associated with increased risk of 
major bleeds and some resistance [293-295]. After recognition that the first thienopyridine, ticlopidine 
was marginally superior to aspirin in reducing CVD risk factors, trials investigated the effect of dual 
antiplatelet therapy, and showed beneficial effects especially in patients with ACS undergoing PCI [294], 
and proved to be more beneficial than individual therapy particularly in high risk patients [296-298], 
however the CHARISMA researchers concluded that: ‘There was a suggestion of benefit with clopidogrel 
treatment in patients with symptomatic atherothrombosis and a suggestion of harm in patients with 
multiple risk factors’, and failed to show the effectiveness of dual antiplatelet therapy in this high-risk 
group of patients [299]. Despite the benefits of dual antiplatelet therapy of clopidogrel and aspirin, 
many patients continue to have recurrent atherothrombotic events. Aspirin resistance was one of the 
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main reasons for the introduction of dual antiplatelet therapy, however, patients resistant to aspirin also 
have a decreased response to clopidogrel,  with 47.4% of them being resistant to both therapies [293]. 
The TRILOGY ACS clinical trial is a Phase III, randomised, double-blind study that will enrol more than 
10 000 participants. This trial will investigate the differences between dual prasugrel and aspirin therapy 
and dual clopidogrel and aspirin therapy in NSTEMI ACS patients for a median duration of 18 months 
and will provide information regarding the optimal approach to oral antiplatelet therapy for these 
patients [300]. 
1.6 Prevention of cardiovascular disease by dietary modification 
Even though antiplatelet therapies improve morbidity and mortality in CVD patients, they inhibit both 
resting and activated platelets, disrupting normal process of haemostasis and are associated with 
increased bleeding [301]. Antiplatelet therapies are associated with resistance and have reported side-
effects and contraindications, which prompt for the investigations of natural products as alternatives for 
prevention and treatment of CVD [302, 303]. Natural therapies can delay the onset of CVD and their 
mechanism of action can serve as a potential therapeutic target for production of new generation of 
safer and more effective agents. Platelet hyperactivity,  inflammation and oxidative stress are well 
identified risk factors for CVD development and complications [304-306] and saturated fatty acids 
accelerate the process of CVD, polyunsaturated fatty acids (PUFA), in particular the omega-3  (n-3  
PUFA), as well as antioxidant supplementation, have potential to decrease atherogenesis [307, 308]. 
1.6.1 Omega-3 Polyunsaturated fatty acids and platelet function 
Dietary n-3 PUFAs, particularly the long chain eicosapentanoic acid (EPA; 20:5 n-3) and docosahexaenoic 
acid (DHA; 22:6 n-3) modify platelet membrane and eicosanoid synthesis [309] and may ameliorate 
atherogenesis by regulating platelet behaviour, the interaction between platelets and endothelial cells, 
inflammation and lipid profile [310]. American Heart Association recommends use of fish and fish oil 
supplements in CVD patients [311]. The recommended daily intake of EPA and DHA is 500 mg/day for 
healthy people and 800 mg/day for patients with CVD [308]. 
Omega-3 PUFA resemble the most commonly used CVD drug aspirin, as they act as both anti-platelet 
and anti-inflammatory agents. Similarly to aspirin, their main targets are COX and LOX enzymes and as 
such they have potential to decrease production of TxA2 and inflammatory leukotrienes [311]. The 
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membrane phospholipids of inflammatory cells taken from humans consuming Western-type diets 
contain approximately 20% of n-6 AA while is typically less than 1% of fatty acids, which makes AA the 
main substrate for eicosanoid synthesis [312]. Omega-3 PUFAs from the diet can replace the AA of 
cellular membranes and modulate the production of AA-derived eicosanoids. Apart from forming series 
3 prostanoids, n-3 PUFAs give rise to anti-inflammatory resolvins [313].  
The research about diets rich in n-3 PUFAs started after realisation that Eskimos have very low incidence 
of CHD, and their diet was rich in  n-3 PUFAs originating from seals, whales and fish [314]. Eskimos have 
lower TxA2 and TXA3 and higher PGI2 and PGI3 production than age and sex matched Danish volunteers 
[315]. Several lines of evidence support the use of n-3 PUFA supplements and compare their effect with 
standard anti-platelet agents. Burr et.al. in the DART clinical trial [316] demonstrated that eating fatty 
fish 2-3 times per week by volunteers recovered from AMI resulted in 29% decrease in 2 year all-cause 
mortality. Similarly, GISSI-Prevenzione trial [317] investigated the effect of 850-882 mg per day of EPA 
and DHA on patients with recent AMI and compared its effects with 300 mg α-tocopherol and the 
combination of n-3 PUFAs and α-tocopherol for 3.5 years. Supplementation with n-3 PUFA decreased 
mortality, non-fatal AMI and stroke, and the results were similar between n-3 PUFA and the 
combination groups, suggesting no beneficial effects of α-tocopherol supplementation. Lev and 
colleagues [318] investigated the effect of adding n-3 PUFAs to standard aspirin therapy versus 
increasing aspirin doses in patients resistant to aspirin. Aspirin resistance was reduced by 80% in the n-3 
PUFA group and by 73% in the 325 mg aspirin group [318]. 
Discrepancy is noted in some published papers. When hyperlipidemic volunteers were supplemented 
with concentrated ethyl ester compounds of n-3 PUFA, 2 g twice a day for 12 weeks, no effect was seen 
on bleeding time, FVII level, fibrinogen or TFPI [319]. Despite failing to reach clinical significance, the 
bleeding time was prolonged by 30s in the treatment group; however bleeding time is very subjective 
and inaccurate measure of platelet/vWf function, largely replaced by the use of PFA-100. This is on the 
contrary to the earlier observations where use of 300 mg EPA and 130 mg DHA per day for 28 days, 
decreased platelet aggregation in response to ADP, collagen and epinephrine and increased bleeding 
time in 11/15 patients without significantly increasing post-operative bleeding [320]. The lack of 
beneficial effects on platelet and coagulation parameters could have been caused by the use of n-3 
PUFA esters since McPhee at. al. [321] demonstrated that it was the free fatty acid fraction of Lyprinol, 
rich in n-3 PUFA, that was the most potent COX-1 and COX-2 inhibitor, while ester, sterol and 
phospholipid fraction were not only milder, but also selective COX inhibitors, targeting mainly COX-2.  
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A placebo controlled trial investigated the effect of long term supplementation with n-3 PUFA (850-882 
g/day EPA/DHA in the form of concentrated esters) alone or in combination with statins (20-40 mg 
simvastatin) on TF, FXIIa level and fibrin monomers in patients with recent AMI [322].  Neither 
parameter was affected, although this groups only measured plasma TF antigen levels, and they 
claimed, the test estimates both membrane bound TF form with procoagulant activity and soluble form 
that lacks procoagulant activity [322]. Since it has previously been postulated that the expression of TF 
on activated monocytes due to platelet binding may enhance the progression and complications of CVD 
as its procoagulant role is enhanced [323], an estimation of monocyte bound TF would be a better 
indication of the effectiveness of those supplements on this parameter. More recent trial in patients 
with advanced heart failure however demonstrated that the same n-3 PUFA preparation (concentrated 
esters) reduced MPA formation and soluble TF after 3 months in dose dependent manner, while the P-
selectin was reduced in the group receiving high (4 mg) preparation [324]. Monocyte-platelet aggregates 
are better markers of in vivo platelet activation than P-selectin and may therefore be more sensitive to 
slight changes induced by n-3 PUFA supplementation. The differences between those two studies may 
have also been caused by different profile of participants as hyperlipidemic volunteers may have more 
oxidative stress and inflammation than CHF patients and n-3 PUFAs in the form of ester may not have 
been adequate for this patient population despite their ability to improve lipid profile. 
A pilot study conducted in CVD patients with or without hypertension demonstrated that 
supplementation with 1 g/day n-3 PUFAs was capable of reducing collagen induced WBA, while there 
was no effect when ADP was used as an agonist [325]. Whole blood platelet aggregation may not be 
platelet specific since platelets in both activated and resting states may bind other cells and falsely 
increase the impedance measured. This study did not reveal the concentration of either ADP or collagen, 
however LTA in response to submaximal doses of ADP, epinephrine and collagen was reduced in patient 
receiving higher EPA and DHA doses for 28 days before CAGS [320]. Different authors also demonstrated 
that supplementation with 1 g/day of n-3  PUFA for 28 days inhibits collagen and ADP induced platelet 
aggregation as well as aspirin does [326]. Both aspirin and n-3 PUFAs inhibit the same platelet pathway 
(AA), and ADP induced platelet activation/aggregation, as previously discussed, is not specific for 
determination of the overall effect of AA pathway inhibition. Aspirin itself does not inhibit ADP induced 
platelet activation and platelet aggregation in response to maximal ADP doses.  However, the addition 
of 465 mg of EPA and 375 mg of DHA for one month to combination aspirin and clopidogrel therapy 
after PCI reduced the P2Y12 reactivity index and ADP induced aggregation, thereby potentiating platelet 
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response to clopidogrel therapy (n-3 fatty acids after PCI to modify responsiveness to dual antiplatelet 
therapy study) [327]. 
There are several mechanisms by which n-3 PUFAs inhibit platelet function (Figure 1.11). Omega-3  
PUFAs inhibit desaturase which leads to a decreased production of AA from linoleic acid [307]. The 
chronic use of n-3 PUFAs results in AA being displaced from membrane phospholipids, including 
platelets.  Eicosapentaenoic acid and DHA are oxygenated at much slower rate than AA [328]. Kitagawa 
et.al. showed that at least partial explanation for inhibitory platelet effect of n-3 PUFA including EPA is 
due to their ability to increase platelet membrane fluidity and induce platelet membrane perturbation 
[329] as well as increasing cAMP and preventing cytoplasmic calcium increase [330]. Omega-3 PUFAs 
enhance platelet negative surface charge density, creating another activation barrier, and at AA doses 
known to activate platelets, platelet membrane remained negatively charged [309]. The oxidation of 
EPA also leads to the production of series 3 prostanoids, TxA3 in platelets and PGI3 in endothelial cells 
[310]. The function of TXA3 is controversial. Some researchers have reported that TxA3 is weaker agonist 
than TxA2, whereas more recent research indicates that TxA3 binds to the TP receptor with almost the 
same affinity as TxA2, but other series three prostanoids, capable of increasing cAMP, exhibit a strong 
anti-aggregatory potential, making the overall effect of decreased platelet activation [310, 328, 331, 
332]. Docosahexaenoic acid is the most unsaturated and the longest chain fatty acid and has a slightly 
different action to EPA [333]. Docosahexaenoic acid is incorporated into, but is not readily released 
from, membrane phospholipids [334] and acts as a strong inhibitor of prostaglandin but not leukotriene 
synthesis, by inhibiting COX and possibly affecting PLA2 induced AA release [335-337]. Docosahexaenoic 
acid also acts as a vasorelaxant by inhibiting calcium influx in  vascular smooth muscle cells from rats 
[338]. It also decreases cytokine-induced surface expression of E-selectin, ICAM-1 and VCAM-1, 
therefore impairing monocytic adhesion [339-341].  
Lipooxygenase products are produced from all PUFAs. They form mono-, di- or tri-hydroxyl derivatives. 
The platelet 12-LOX pathway represents about one third of AA metabolism. Although 12-HpETE has 
been shown to activate COX, LOX and PLA2 and is implicated in essential hypertension [61, 342, 343], the 
lipooxygenase, particularly the mono-hydroxy derivatives of 12-LOX [12(S)-OH-20:3, 12(S)-OH-20:4, 
12(S)-OH-20:5, 14(S)-OH-22:6, 5(S),12(S)-diHETE have been shown to have inhibitory effects on platelets 
by possibly interfering with the TP receptor [343, 344]. Some of the lipoxygenases are capable of 
inhibiting COX-1 directly [343]. The products of DHA metabolism, 11-HDoHE and 14 HDoHE, are more 
active than 12-HETE and have been shown to prevent vasoconstriction [343].  
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Figure 1-11: The inhibitory effect of omega-3 PUFAs on platelet function 
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1.6.1.1 Lyprinol® – The New Zealand’s green lipped mussel (Perna Canaliculus) extract 
supplementation 
Green-lipped mussel Perna Canaliculus is native to New Zealand and its beneficial effects were 
postulated upon realisation that coastal Maori population had lower incidence of arthritis compared to 
their inland or European relatives [345]. This gained attention since rheumatoid disorders including 
osteoarthritis were as common as CVD and the treatment included use of NSAIDs which are associated 
with side effects [345]. The most bioactive Lyprinol© (Pharmalink Marketing Services Pty.Ltd, Burleigh 
Heads, Queensland, Australia) components are n-3 PUFAs, hence it is not surprising that the extract 
modulated platelet function (described in Chapters 3 and 4) in a similar manner to aspirin and better 
than fish oil. Lyprinol is commercially available dietary supplement that contains 50 mg of the Perna 
Canaliculus extract and 200 mg of olive oil [346]. Extract is prepared from supercritical CO2 lipid extract 
(CO2-SFE) of tartaric acid stabilised freeze-dried Perna Canaliculus.  The SFE process utilises liquefied CO2 
to avoid the use of any chemical solvents that could create health concerns for humans [347, 348].  
Lyprinol contains n-3 PUFAs including EPA and DHA [349-351]. The CO2-SFE oil contains some novel and 
rare n-3 PUFAs that carry anti-inflammatory activities [352, 353]. This anti-inflammatory potential is 
associated with PUFAs with 4, 5 and 6 double bonds, which represents around 40% of the total PUFA 
found in CO2-SFE oil [351, 352]. Those are structurally related n-3  PUFAs, C18:4, C19:4, C20:4, C21:5 
C20:3, C22:3, C18:3, C28:8 n-3  [321, 347, 351, 352], with the C20:4, a rare structural isomer of n-6 AA, 
possibly represent the most bioactive anti-inflammatory compound in the oil [347]. These rare n-3 fatty 
acids make Lyprinol different to fish oil that contains 13% EPA and 12% DHA in triglyceride form [321]. 
The treatment of chronic inflammatory conditions consists of the use of NSAIDs that can lead to various 
side effects including CVD complications (due to imbalance of COX-1/COX-2), gastro-intestinal problems 
and osteoporosis/joint degeneration [303]. Research data shows that Lyprinol could potentially be used 
as a natural agent in treatment of chronic inflammatory conditions. Doses of up to 300 mg/kg in arthritic 
rats were well tolerated, while the same dose of aspirin caused gastric hemorrhage [321, 346]. A phase I 
clinical trial in patients with advanced breast and prostate cancer was conducted to determine the 
safety and tolerability on Lyprinol with doses up to 4160 mg/day.  Lyprinol was well tolerated in this 
group of patients with most common reported side effects being dyspepsia and anaemia due to 
unrelated causes [354].  
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1.6.1.1.1 In vitro Lyprinol studies 
There is now strong evidence demonstrating the ability of mussel oil to inhibit COX and LOX enzymes. 
Literature also shows that the activity of mussel oil is beyond EPA and DHA, making it more effective 
than fish oil or the combination of EPA and DHA. Lyprinol supplementation may therefore resemble 
NSAIDs such as aspirin, which is still, despite its side-effects and resistance in some patients, the most 
commonly used anti-platelet agent. 
Since early 1980s it was known that Perna Canaliculus extract inhibits inflammation and prostaglandin 
synthesis and it was demonstrated that the rare n-3 PUFAs may act as competitive substrate inhibitors 
of n-6 AA for COX and LOX. Anti-histaminic substance lysolecithin was firstly isolated by Kosuge et.al. in 
the mussel extract, but the range of other biologically active components were largely unknown [355].   
The Tween-20 extracts of Perna Canaliculus inhibited IgG production, TNF-α, IL-12, IL-2 and IL-6 in 
various cell lines as well as ovine COX-1 and COX-2 activity in dose-dependent manner [356]. The 
inflammation was also decreased when LPS stimulated monocytic cell line was treated with Tween-20 
extract of Perna Canaliculus, while phenol mussel extract dose dependently inhibited PMA stimulated 
superoxide production of rat neutrophils [357]. Since it was believed that the bioactive component of 
the extract was glycogen, its inhibitory effects towards both COX-1 and COX-2 were compared to and 
shown to be better than that of glycogen extract alone. Since the treatment of extract with protease 
abolished some of the positive effects, it was postulated that the active component of Perna Canaliculus 
may be a protein [356].  
Some experiments suggested that the free fatty acids found in the extract may be responsible for the 
beneficial effect of mussel oil. Consequently the free fatty acids were fractionated from the tartaric-acid 
stabilised freeze-dried mussel powder. An in vitro anti-inflammatory assay measuring the release of 
leukotrienes by stimulated neutrophils was used to identify the most bioactive fractions. Separation of 
the free fatty acids in the CO2-SFE showed that apart from well-known bioactive n-3 PUFAs (like EPA and 
DHA), the extract contains rare and novel PUFAs including n-3 AA [347].  The n-3 AA found in the extract, 
on the contrary to n-6 AA which has 20 carbons and 4 unsaturated double bonds on positions 5,8,11 and 
14, has double bonds at positions 7, 11, 14 and 17, suggesting that this rare isomer of AA may be able to 
act as a competitive substrate inhibitor of n-6 AA, therefore decreasing the production of leukotrienes 
and prostanoids [347].  The unfractionated extract is also able to inhibit PGE2 production in AA 
stimulated monocytes while fractionated oil containing PUFAs with 4,5 and 6 double bonds inhibits the 
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formation of LTB-4 and 5-HETE in A23187 stimulated human PMN, postulating that free fatty acids may 
inhibit COX and LOX enzymes and consequent production of prostanoids and leukotrienes [346]. 
The lipid extract of Perna Canaliculus (1 µg/mL) only mildly inhibits COX-1 and COX-2 (12% and 25% 
respectively) until saponification, which increases inhibition of COX-1 to 38% and COX-2 to 57% 
confirming that the free fatty acid fraction is responsible for the COX inhibition [321]. Protease and 
protease lipase treated Perna Canaliculus was also capable of inhibiting both COX-1 (57% and 67% 
respectively) and COX-2 (47% and 62% respectively) [321]. The CO2-SFE lipid extract also inhibited both 
COX enzymes dose-dependently and the inhibition was better than that of indomethacin at equivalent 
concentrations. Hydrolysis again improved inhibitory potential up to 10 times, providing another 
supporting argument that the free fatty acids may be the most anti-COX component found in the extract 
[321]. The free fatty acid Lyprinol fraction was the most potent COX-1 (78%) and COX-2 (70%) inhibitor 
while sterol ester, sterol and phospholipid fraction inhibited COX-2 only (22-32%).  The inhibition of 
COX-1 and COX-2 is found to be non-selective. This suggests that the use of Lyprinol as an anti-
inflammatory supplement may have an advantage over use of various selective NSAIDs; aspirin that 
preferentially binds to COX-1, indomethacin that has preference for COX-2 or coxibs that specifically 
inhibit COX-2, therefore creating imbalance between the two enzymes and potentially increasing the 
risk of CVD complications [321, 350]. An important role of n-3 AA was identified in experiments which 
showed that incubation of AA and Lyprinol with COX-1 and COX-2 decreases AA metabolism while 
incubation of COX enzymes with Lyprinol only results in the production of alternative prostaglandin 
metabolites. Some n-3 fatty acids, including n-3 AA and EPA also directly inhibited both COX isoforms 
[321]. This suggests that the n-3 PUFAs found in Lyprinol act as competitive substrate inhibitors of n-6 
AA, and produce less active metabolites than series 2 prostaglandins are [321]. 
Apart from direct inhibition of prostaglandin and leukotriene synthesis by rare n-3 PUFAs, it was recently 
identified that the extract contains Furman fatty acid (F-acid), another possible anti-inflammatory 
component [358]. Furan fatty acids are naturally occurring antioxidant fatty acids found in plants and 
marine organisms but are relatively unstable and difficult to isolate [358]. They are potent antioxidants 
due to the electron-rich furan ring [358]. Wakimoto et.al. identified F4 (1.87 mg/g) and F6 (2.17 mg/g) F-
acids in the Perna Canaliculus extract, although small amounts of F2, F3 and F5 were also present [358]. 
Presence of F-acids in the extract further strengthens the anti-inflammatory potential of the supplement 
and suggests that the extract may also act as potent antioxidant. 
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1.6.1.1.2 In vivo Lyprinol studies 
Almost all in vivo Lyprinol studies examined its effect on chronic inflammatory conditions like 
rheumatoid and osteo-arthritis, asthma and inflammatory bowel disease in both animals and humans.  A 
number of studies compared the beneficial effects of Lyprinol to those of fish oil and various NSAIDs. 
There were proposals to even use a combination of pentoxiphylline and Lyprinol as a standard 
therapeutic regime for chronic inflammatory disorders [359]. 
Several lines of evidence support that Lyprinol supplementation is useful for both prophylactic and 
therapeutic treatment of rheumatoid arthritis and osteoarthritis. The extraction process influences the 
beneficial effect of Lyprinol since some activity of n-3 fatty acids may be lost due to processing [350].  
Earlier Lyprinol preparation that did not utilise the CO2-SFE extraction showed weaker beneficial effect 
in the treatment of those conditions. In 1993, a supplementation with isolated mussel protein moiety 
associated with glycogen was able to reduce carrageenin induced oedema by 51% in rats  and it also 
prevented mobilisation of neutrophils and fluid into subcutaneously implanted sponges [360].  The 
onset of collagen induced arthritis, an animal model of rheumatoid arthritis, was reduced in rats treated 
prophylactically with the extract of Perna Canaliculus  (100 mg/kg/day) with only 3/18 rats developing 
arthritic joints (14/24 in control group) [357]. Perna Canaliculus extract supplementation for 110 days 
reduced the joint inflammation in mice with established disease and in this group the arthritic score 
decreased from 2.2 to 1.42 which was significantly different to control group (2.0 to 2.63) [357]. 
The mussel oil was originally believed to be a slow –acting rather than acute anti-inflammatory agent by 
inhibiting COX and 5-LOX [346]. The SFE extract reduced rear and front paw swelling from 1.19 and 2.5 
mm respectively to 0.23 and 1.3 mm when used prophylactically in adjuvant arthritis rat model for 16 
days, while Lyprinol (20 mg/kg) reduced swelling from 1.21 and 2.8 mm to 0.23 and 1.4 mm [346].  The 
prophylactic effects were better than with fish oil, flaxseed, olive oil and evening primrose oil. 
Importantly, while the extract was similarly efficient to naproxen, it was more potent than ibuprofen 
and aspirin [346].  When Lyprinol was used as therapeutic regime in this model (given to rats from day 
10 to day 13 at 20 mg/kg), it reduced swelling from 1.09 and 1.8 mm to 0.02 and 0.5 mm, being more 
effective than ibuprofen, plant and fish oils [346]. Since the n-3 PUFAs contained in fish oil are EPA and 
DHA, this study confirmed that the anti-inflammatory potential of mussel oil is not totally attributed to 
their presence.  
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The acute and chronic effects of mussel extract preparations on rats with induced adjuvant arthritis 
were examined by Singh et.al. [348]. The CO2-SFE crude lipid (50 and 100 mg/kg) or the free fatty acids 
(30 mg/kg) of tartaric stabilised Perna Canaliculus powder were given to rats with adjuvant arthritis from 
day 10 to day 14 and the short term effects were compared to groups of rats given olive oil (850 mg/kg) 
as placebo and piroxicam (2 mg/kg) a positive control [348]. Olive oil and crude mussel lipid were also 
given to rats for all 15 days starting from the day of adjuvant inoculation. While administration of crude 
lipid material for 5 days did not reduce the rear paw swelling in comparison to placebo, administration 
for 15 days reduced swelling by 34%, which was equivalent to the group of rats that received piroxicam 
for 5 days [348]. Crude lipid administration also reduced front paw inflammation and deterioration of 
total body condition by 60% and 52% respectively following 15 day administration only [348]. The 
neutrophilic infiltration and fibrin deposition in the red pulp of the spleen was also reduced following 
crude lipid treatment for 15 days in comparison to placebo [348].  However, administration of enriched-
fraction containing novel n-3 PUFAs (containing C18:4, C19:4 and C20:4) improved total body condition 
by 52% and had almost normal spleen histology after only 5 days administration, suggesting that the 
anti-inflammatory component of Perna Canaliculus are mainly the free fatty acids and they are faster 
acting than crude oil [348]. The administration of both of those was well tolerated and there were no 
side effects [348].  In a different study of adjuvant arthritis model, rats were given Lyprinol (25 mg/kg), 
Olive oil (300 µL) or Naproxen (20 mg/kg) for 28 days while another group was supplemented for one 
year. Arthritic rats fed with Lyprinol for 1 year had no visible deformations of joints or lesions and also 
had lower levels of pro-inflammatory cytokines [361]. These results suggest that if Lyprinol is used in 
early phases of arthritis, it can reduce inflammation, symptoms and disease progression as effectively as 
NSAIDs by inhibiting levels of proinflammatory while increasing the levels of anti-inflammatory 
cytokines. Similar results were obtained in arthritic dogs where addition of mussel oil to food for 6 
weeks improved arthritic score, joint pain and swelling in comparison to control group (p<0.05) [362]. 
A 12 week trial was conducted on 49 inflammatory rheumatoid arthritis/arthrosis patients with 
moderate amount of pain and morning stiffness. Patients were given 2 Sanhelios Mussel Lyprinol Lipid 
Complex capsules per days that contain 458 mg of fish oil concentrate (50% EPA; 50% DHA) and 35 mg 
Lyprinol for the first 2 days and the dosage was increased to 2 capsules twice daily for the remainder of 
the study [363]. The duration of morning stiffness, joint pain and swelling were all reduced after 6 weeks 
supplementation and remained low after 12 weeks [363]. The tolerability to high fish/mussel oil was 
assessed as ‘very good’ and ‘good’ by 98% of participants and apart from mild nausea no severe side 
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effects were reported [363]. 34 patients required other therapy to treat the symptoms of arthritis 
before and during the trial, which was, at the end of the trial reduced in 21 and eliminated in 13 of those 
patients [363]. Considering that these patients were taking only 35 mg of Lyprinol in combination with 
EPA and DHA, higher doses of Lyprinol may prove to be more beneficial in this setting, potentially 
replacing the standard therapy. 
A current osteoarthritis therapy consists of NSAIDs in the absence of beneficial response of 
acetoaminophen and this is associated with gastric and peptic ulcers and IBS in some patients [364]. 
Knee pain, stiffness and physical knee function in 21 osteoarthritis patients improved after 
supplementing their diet with 3000 mg/day of freeze-dried mussel meat (GlycOmega TM PLUS, Aroma 
NZ Ltd) for 8 weeks [364]. The supplementation also improved gastrointestinal dysfunction and despite 
a very high dose, the supplements were well tolerated [364]. 
46 steroid-naïve patients with mild-moderate atopic asthma, another chronic inflammatory disease, 
mediated by leukotrienes, received 4 Lyprinol capsules per day or Olive oil placebo for 8 weeks [365].  
Lyprinol reduced a daytime wheezing and H2O2 exhalation in comparison to placebo [365]. Since 
leukotrienes increase microvascular permeability and allow infiltration of eosinophils and neutrophils 
that produce H2O2, the reduction of H2O2 reported suggests that Lyprinol could have inhibited leukocyte 
migration [365]. Lyprinol reduces the influx of eosinophils into bronchoalveolar lavage fluid therefore 
decreasing the allergic inflammation in mouse model of ovalbumin induced allergic airway disease [366]. 
Despite potential of Lyprinol to decrease platelet activation by inhibiting AA metabolism, there was only 
one small study performed examining platelet aggregation in humans and mice.  Lyprinol (150 mg/day) 
was given to 2 healthy volunteers for 7 days and rats (50 mg/kg) for 16 days. It had no effect on AA and 
ADP induced LTA [346]. The authors of the study postulated that Lyprinol may in fact be a more selective 
COX-2 inhibitor; however the study was small to draw any firm conclusions.  Similarly, a study of Mrphy 
et.al. [367] supplemented healthy volunteers with 2 mL/day of Green Lipped Mussel oil preparation and 
compared the effect with fish oil supplementation. While EPA and DHA increased in  mussel oil group, 
there was no difference in inflammatory markers. The optimal dose of Lyprinol, particularly in human 
volunteers may not have been achieved. Our studies (Chapter 3 and 4) demonstrate that the CO2-SFE 
inhibits platelet function in healthy human volunteers by interfering with AA metabolism, while Lyprinol 
acts as reversible inhibition of AA induced platelet aggregation. 
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1.6.2 Vitamin E supplementation 
Due to the role of oxidative stress on CVD development, use of antioxidant supplements has long been 
investigated. Platelet hyperactivity has been reported in patients with CVD and diabetes. Although 
various mechanisms have been implicated in platelet hyperactivity, these patient populations are shown 
to have decreased activity of glutathione peroxidise, owing to its age-related decrease and possibly 
glycation [67]. Antioxidant supplementation may, therefore, be advantageous for these patients. 
Antioxidant supplementation have been implicated as protective for CVD development [368]. 
Antioxidants protect cells against oxidative stress which can damage endothelium, activate platelets and 
promote monocytic adhesion [368]. 
Vitamin E is a lipid soluble vitamin found in membranes that consists of at least 8 isoforms: 4 
tocopherols and 4 tocotrienols [369]. Humans and animals obtain tocopherols from the diet since they 
are unable to synthesise them [370]. Alpha tocopherol is the main tocopherol found in mammalian 
tissues and believed to be most biologically active compound [371]. Gamma tocopherol is the most 
prevalent form of vitamin E found in plant seeds and their products. Due to the widespread use of those 
products, γ-tocopherol represents 70% of the vitamin E consumed in the typical US diet [372] while α 
tocopherol is the primary form of vitamin E found in supplements [373]. The lipid composition of human 
platelets contains 1.12 pmol/10
6 
cells of α and 0.21 pmol/10
6
 cells of γ tocopherol making their α/γ ratio 
lower than arterial endothelial cells (45.7 and 4.5 pmol/10
6 
cells for α and γ tocopherol respectively) and 
venous endothelial cells (28.8 and 2.8 pmol/10
6
 cells for α and γ tocopherol respectively) [374] . 
Tocopherols are free radical scavengers that protect PUFAs against oxidative stress [369, 371]. They are 
the only hydrophobic antioxidant found in phospholipid bilayer whose levels could be increased by 
dietary intake [375]. Tocopherols donate phenolic hydrogens to lipid radicals [210, 376]. All of them 
have a chromanol ring with a phytyl side chain that is that is saturated for tocopherols and unsaturated 
for tocotrienols, and the  α, β, γ and δ differ in the number and position of methyl groups substituted on 
the ring (Figure 4.11) [370].  Even though both isoforms are protective against reactive oxygen species, γ 
tocopherol seems to be more superior in protection against reactive nitrogen species [373]. Gamma 
tocopherol, unlike α tocopherol is not methylated on the 5 position of the chromanol ring, and can 
therefore be nitrated on that position to form 5-nitro-γ-tocopherol making it potentially a better 
antioxidant for RNS together with its physiological metabolite 2, 7, 8-trimethyl-2-(β-carboxyethyl)-6-
hydroxychroman (γ-CEHC)  [371, 372, 377].  Metabolites of α and γ  tocopherol, α and γ –CEHC are a 
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result of truncation of the phytyl tail [378]. Alpha tocopherol supplementation decreases plasma γ 
tocopherol concentrations due to competition for hepatic tocopherol transport protein, which 
preferentially binds to α tocopherol and increases metabolism of γ tocopherol in humans [378, 379] and 
mice [368]. Vitamin E is an antioxidant whose levels are significantly decreased in patients with diabetes 
compared with healthy volunteers [380]. Similarly, an inverse relationship between γ tocopherol levels 
and CVD morbidity and mortality has also been established [372], and patients with CHD have lower γ 
tocopherol and higher α/γ tocopherol ratio [381]. 
1.6.2.1 In vitro Vitamin E studies 
Most of in vitro studies concentrated on investigating the protective effects of α tocopherol. 
Neutralisation of ROS has been identified as one of the most important mechanisms by which α 
tocopherol defends the cells and reduces platelet activation. Collagen induced TxA2 formation, calcium 
mobilisation and inositol 1,4,5-triphosphate were inhibited by direct effect of vitamin E on hydrogen 
peroxide produced after collagen stimulation [382]. Alpha tocopherol increases the synthesis of NO and 
cGMP [383]. Incubation of cells with 100 µM α tocopherol  for 24 hours increased eNOS activity, but not 
the expression, and increased ionomycin induced eNOS phosphorylation at serine 1177, while 10-200 
µM concentrations increased cGMP production 1.4 times in comparison to control [383]. The enhanced 
eNOS phosphorylation observed was equivalently high if cells were treated with 100 µM of γ tocopherol 
[383].  
However, the ability of α tocopherol to directly inhibit platelet activation regardless of its antioxidative 
potential has also been proven. Alpha tocopherol analogues RRR-α-tocopherol acetate and RRR-α- 
tocopherol quinone, that possess no antioxidant properties, are able to inhibit platelet aggregation, 
although to a lesser extent than natural vitamin E [384]. This further strengthens the theory that the 
antioxidative properties of vitamin E are not solely responsible for inhibition of platelet function and 
may in fact act synergistically to produce more pronounced effects. The inhibition of platelet 
aggregation using various agonists was demonstrated by several authors. Thrombin, collagen and ADP 
induced platelet aggregation, adhesion of thrombin activated platelets to collagen and monocytic 
adhesion to plastic and endothelial cells were all diminished after treating cells with 100 or 200 µM of α 
tocopherol [385]. Pretreatment of platelets with 0.001 M DL-α – tocopherol inhibits AA induced 
aggregation completely, but the conversion of AA to TxB2 and hydroxyl-fatty acids is reduced by only 
20% [386]. The inhibition of AA conversion is modest but it still postulates that vitamin E affects platelet 
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COX and LOX enzymes [386]. Hydrophilic analogue of α tocopherol, 2, 2, 5, 7, 8, -pentamethyl-6-
hydroxychromane (PMC), which has a phytyl chain replaced by a methyl group, was used in some 
studies to further explore the inhibitory mechanism of α tocopherol on platelets. PMC dose dependently 
(5-25 µM) inhibits collagen and ADP induced platelet aggregation and ATP release. Collagen induced 
TxA2 formation and AA induced PGE2 formation were inhibited, without affecting cAMP and cGMP levels 
suggesting that the analogue may in fact inhibit COX-1 activity [387] . Activity of α tocopherol beyond 
COX-1 inhibition was postulated after observing that the compound causes significant decrease in AA 
induced platelet aggregation without affecting U-46619 and collagen induced aggregation, while 
reducing AA metabolites after thrombin stimulation [388]. Apart from inhibition of COX-1, α tocopherol 
inhibits PLA2 activity in platelets from both vitamin E deficient and sufficient rats [389]. Importantly, this 
group also demonstrated that that purified rat’s PLA2 is inhibited with d-α – tocopherol (natural vitamin 
E) and DL- α – tocopherol (synthetic vitamin E), while DL-α – tocopherol acetate (hydroxyl group in 
chromanol ring is replaced by acetate) demonstrates less inhibition [389]. Considering that some clinical 
trials used this synthetic product, it is not surprising that they did not show strong beneficial effects of 
vitamin E supplementation. On the contrary to those finding, Tran at. al. [375] used human umbilical 
vein endothelial cells due to their ability to synthesise  PGI2, and  showed that the PGI2 release and the 
PLA2 activity were both enhanced by α tocopherol in time and concentration dependent manner. The 
PGI2 release was also equivalently potentiated by the same concentration of γ tocopherol [375]. 
Hydroxyl moiety on the chromanol ring and phytyl chain of both molecules were required for this effect 
[375].  The discrepant finding may be attributable to the different cells used in the studies and 
measurement of different prostaglandins. Tocopherols may in fact promote PGI2 in endothelial cells but 
due to inhibition of COX-1 activity inhibit TxA2 formation in platelets, therefore decreasing overall 
platelet activation. 
Freedman et.al. [390] showed that 500 µM of α tocopherol inhibits phorbol ester (PMA), which activates 
platelets by activating PKC, induced platelet aggregation, suggesting that α tocopherol may be a direct 
PKC inhibitor. Arachidonic acid induced platelet aggregation, which is also PKC dependent was also 
reduced, while PKC independent, ADP induced aggregation, was inhibited to a lesser extent [390]. 
Further proof that α tocopherol inhibits PKC mediated platelet activation was shown in a study of 
Murohara et.al. which showed that thrombin and PMA induced P-selectin expression and PLA formation 
were inhibited after treating platelets with α tocopherol, an effect that was mimicked by a 
staurosporine a selective PKC inhibitor [391]. 
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Figure 1-12: The structure of Vitamin E isoforms. 
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1.6.2.2 In vivo Vitamin E studies 
Even though some clinical trials or epidemiological studies demonstrated the benefits of vitamin E 
supplementation on CVD risk factors [392-394], many failed to establish the relationship [317, 395, 396] 
possibly due to the use of mainly α-tocopherol, sometimes synthetic products and sometimes in 
extremely high concentrations. The degree of beneficial effects of Vitamin E in human volunteers can 
also depend on the initial Vitamin E status of volunteer, those with lower original levels having higher 
benefits.  
After a number of clinical trials using vitamin E supplementation, including the CHAOS study [396], 
which concluded that α tocopherol supplementation reduced the risk of primary trial endpoints, death 
and non-fatal AMI by 47% and risk of non-fatal AMI by 77%, but showed greater, although non- 
significant, mortality rate amongst α tocopherol group, yielded inconsistent results. Treatment of CVD 
patients with Vitamin E (400 IU) for a mean of 4.5 years had no beneficial or adverse effects on 
cardiovascular outcomes [395]. In the ‘Simvastatin and Niacin, antioxidant vitamins, or the combination 
for the prevention of coronary disease’ study, 800 IU d-α-tocopherol  with vitamin C, beta carotene and 
selenium supplementation showed no beneficial effect on patients with CAD in regards to progression of 
stenosis and minimal reduction in the rate of clinical events [397]. Importantly, the clinical benefits of 
niacin and simvastatin, which were able to lead to regression of stenosis, were diminished when 
administered together with antioxidants [397]. A meta-analysis concluded that α-tocopherol 
supplementation was not beneficial in improving all-cause mortality in either primary prevention trials 
that included 9240 patients or secondary prevention trials that included 72 536 patients [398]. The 
analysis included the results of the Secondary Prevention with Antioxidants of  Cardiovascular Disease in 
End stage Renal Disease (SPACE) trial and the Women’s Angiographic Vitamin and Estrogen (WAVE) 
study, two randomised trials with small sample sizes and found no beneficial effects of Vitamin E 
supplementation on all-cause mortality, cardiovascular death  or risk of stroke [398]. Yusuf et.al. showed 
no benefits of 400 IU vitamin E in high risk patients [395], while supplementation of type 1 diabetics 
with only a 100 IU of α tocopherol inhibited serum TxB2 levels and lipid peroxidation [399]. 
Supplementation of type 2 diabetics with 500 IU of α tocopherol, not only increased platelet NO 
production, but decreased plasma ICAM and VCAM-1 [400], while Beckman et.al. concluded that there 
are no benefits of α tocopherol supplementation on endothelial function in type 2 diabetics [401]. 
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Whole blood collagen (2 µg/mL) induced platelet aggregation, PT and APTT, and bleeding time assessed 
by PFA-100, did not change after supplementation with 800 IU of dl-α-tocopherol acetate for 14 days 
[402]. However thrombin and PMA induced platelet P-selectin expression and LPA formation were 
inhibited after supplementation with 300 mg/day of α tocopherol for 3 weeks [391]. Importantly, when 
a range of oral doses of α tocopherol starting from 75 IU/day to 200 IU/day to 400 IU/day (2 weeks 
each) for 6 weeks were investigated it was shown that lower α tocopherol levels were more beneficial 
[403]. Vitamin E did not alter lipid profile of volunteers after 6 weeks supplementation, but significantly 
inhibited ex vivo LDL oxidation [403]. ADP induced LTA was inhibited after supplementation and the 
greatest effect was seen after 2 weeks supplementation with 75 IU/day [403]. Platelet response to PGI2 
was also increased mainly in 75 IU/day of α tocopherol group after 2 weeks supplementation. Similarly, 
supplementation with lower doses (50 mg/day) decreased the incidence of major coronary event by 4% 
and fatal CHD by 8%, although supplementation had no effect on the incidence of myocardial infarctions 
[404].  
One of possible explanation for inconsistencies of those trials is selection of volunteers that may have 
sufficient vitamin E levels. Since pyruvate kinase activity, and the PLA2 activity in vitamin E deficient rats 
were 2 times higher than in vitamin E sufficient rats [389], it is possible that the beneficial effects of 
vitamin E supplementation may be more prominent in vitamin E deficient individuals, or in those 
exposed to higher oxidative stress. Importantly, these studies also show that the supplementation with 
lower α tocopherol doses was more beneficial. One of the possible explanations would be that γ 
tocopherol may in fact be a more active and beneficial Vitamin E form, and its levels are reduced by high 
α tocopherol supplementation, hereby increasing α/γ ratio. American Heart Association in fact 
recommended to increase vitamin E intake from food rather than supplements due to lack of proof for 
beneficial effects of supplemental vitamin E [405]. While supplemental vitamin E is mainly in the form of 
α tocopherol, dietary vitamin E contains mainly γ tocopherol [372]. While plasma and tissue γ 
tocopherol levels are suppressed by α tocopherol, γ tocopherol supplementation increases the 
concentration of both tocopherols [377, 406]. Further proof in favour of γ tocopherol was created when 
an inverse relationship between γ tocopherol levels and CVD morbidity and mortality has been 
established [372] and γ tocopherol,  but not α tocopherol, was found to be reduced, and α/γ ratio 
increased in CHD patients in comparison to healthy volunteers [407]. Gamma tocopherol 
supplementation improves lipid profile, decreases inflammation, platelet activity and other biomarkers 
of oxidative stress in studies of normal healthy subjects and in rat models, to a greater extent than α 
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tocopherol alone [210, 368, 379, 406, 408]. Saldeen at. al. [368] used 33 male Sprague Dawley rats and 
enhanced their diet with 100 mg/kg/day of either α or γ tocopherol or placebo for 10 days. They 
examined the effect of α and γ tocopherol supplementation on time taken for arterial thrombus 
formation in FeCl3 induced thrombosis model. While supplementation with α tocopherol increased time 
taken for thrombus formation by 25% in comparison to placebo, γ tocopherol supplementation 
prolonged the occlusion time by 58% in comparison to control and 60% of animals had unstable 
thrombus being formed.  Gamma tocopherol also inhibited ADP (20 µM) induced platelet aggregation 
(p<0.05 in comparison to α-tocopherol).  Apart from being a potent antioxidants, γ-tocopherol and γ-
CEHC have anti-inflammatory potential exerted by inhibiting PGE2 synthesis and formation of LTB4 and 
attenuating inflammation mediated damage in male Wistar rats [409]. Gamma-tocopherol and its main 
metabolite are capable of decreasing the COX-2 activity, possibly by competing with AA for the COX-2 
active site [410]. 
In the study of Liu et.al. [411] human volunteers were supplemented with a diet containing α 
tocopherol,  mixed tocopherol preparation or placebo for 8 weeks. Tocopherol supplementation 
increased SOD activity in plasma and protein expression in leukocytes and ecNOS activity in leukocytes 
without changing its protein expression, and decreased the PKC activation in leukocytes [411]. Vitamin E 
may inhibit lipid peroxidation and radical formation by inhibiting the activation of PKC by ox-LDL and 
prolonging the NO half-life by increasing the SOD activity [411]. In a follow up study Liu et.al showed 
that ADP induced platelet aggregation only decreased in volunteers taking mixed tocopherol 
preparation that contained 100 mg of γ , 40 mg δ and 20 mg α tocopherol for 8 weeks but not in 
volunteers taking 100 mg of all-rac-α – tocopherol acetate [210]. Mixed tocopherol supplementation 
increased NO release and ecNOS phosphorylation better than α tocopherol, while the inhibition of PKC 
activation and SOD protein content were affected similarly [210]. A recent study demonstrated that 
supplementation with 100 mg of pure γ-tocopherol inhibits platelet aggregation, P-selectin expression 
and lowers LDL-cholesterol in healthy volunteers [408]. 
Combination of γ tocopherol and aspirin is more potent than aspirin, or aspirin and α tocopherol in 
exerting anti-inflammatory potential and attenuation of aspirin induced side-effects in rats [412]. 
Devaraj et.al. [379] supplemented metabolic syndrome patients with placebo, 800 mg of α tocopherol, 
800 mg of γ tocopherol or 800 mg of α and γ tocopherol for 6 weeks. Only γ tocopherol 
supplementation, either alone or in combination with α tocopherol, decreased nitrotyrosine levels, 
while both α and γ tocopherol supplementation reduced markers of oxidative stress.  
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These results highlight that vitamin E supplementation rich in γ tocopherol may prevent CVD 
development by protecting cells against oxidative stress and lipid peroxidation, inhibiting platelet and 
leukocyte activation and decreasing inflammation. Both healthy and volunteers with predisposition for 
CVD benefited more from mixed tocopherol supplementation that from α tocopherol supplementation 
alone. 
1.7 Platelet function testing 
The ex vivo measurements of platelet reactivity have been extensively used as there is no standardised 
diagnostic method that assesses platelet reactivity in vivo. Platelet aggregation is one of the most 
commonly used methods for assessment of platelet reactivity and is capable of identifying common 
bleeding disorders. Evaluation of the effectiveness of antiplatelet therapy and determination of 
resistance are not currently in routine diagnostic use due to difficulties in finding the appropriate 
methodology and its standardisation. The diagnostic importance of platelet function testing is 
highlighted in cases of aspirin resistance with reported prevalence ranging from 0% to 60% [413], 
depending on the platelet function test used [414, 415]. While clopidogrel therapy was proven to be 
superior to aspirin in prevention of CVD complication overall, the great variability in the response of 
patients to clopidogrel therapy means that some patients will exhibit therapeutic failures, many of 
which are associated with high on-treatment platelet reactivity [259]. In 2010 clopidogrel started to 
contain a warning about its ineffectiveness in patients with inability to convert the drug to its active 
metabolite [416]. The warning also states that alternative treatments may be available to poor 
responders [416]. Poor responders may be identified by testing for CYP2C19 polymorphisms or platelet 
function that identifies high on-clopidogrel platelet reactivity [416]. Higher clopidogrel doses in some of 
those patients may be more beneficial [416]. A value of creating individualised antiplatelet therapy is 
demonstrated in a study of 504 patients with CAD or ACS following PCI that were treated with a 500 mg 
LD and 100 mg MD of aspirin or a 600 mg LD and 75 mg MD of clopidogrel. Their resistance to aspirin 
(impedance > 0 Ohms; 0.5 mmol/L AA) or clopidogrel (impedance > 5 Ohms 5 µM ADP) was determined 
by WBA. The reported WBA variability was less than 10%. This group identified that 30.8% of patients 
were clopidogrel resistant and 19.4% were aspirin resistant using the above mentioned guidelines [276]. 
Patients with aspirin resistance were given 300 mg MD of aspirin, which reduced the proportion of 
patients with aspirin resistance by 94.6%, or 500 mg MD if 300 mg MD was not sufficient, which 
eliminated aspirin resistance completely. Patients with clopidogrel resistance were given 1200 mg LD 
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then 150 mg/day MD, which reduced the proportion of patients with clopidogrel resistance by 69%, 
whereas use of prasugrel and ticlopidine reduced the overall clopidogrel resistance by 86.6% [276]. This 
study suggests the possibility of individualised and improved antiplatelet therapy. 
Multiple assays have been used to demonstrate high on-treatment platelet reactivity, but it is currently 
not recommended to monitor antiplatelet therapy except in clinical trials [259, 413]. In addition to the 
definition of resistance and the cut-off values that determine resistance to antiplatelet therapy being 
poorly defined, the evaluation of drug responsiveness also depends on the anticoagulants used [260], 
the sample (whole blood versus platelet rich plasma) choice, the concentration of agonist used and the 
platelet function test of choice [259, 417-420]. The difficulties in finding appropriate methods for 
assessing antiplatelet therapy can also be attributed to the existence of various platelet activating 
pathways, only some of which are targeted by antiplatelet therapy and only some of which can be 
measured by current methods [421]. There is no one test that assesses platelet activation entirely and 
the presence of various platelet activating pathways creates the possibility for patients to respond 
biochemically but not clinically to antiplatelet therapy [421]. 
1.7.1 Methodology for platelet function testing 
Platelet aggregometry is a method that was developed in the 1960s and since then, has been one the 
most commonly used platelet function tests [422].  The turbidimetric method or Light transmittance 
aggregometry (LTA), considered to be the ‘gold standard’ of platelet function tests, assesses the change 
in light transmittance due to platelet aggregation in platelet rich plasma after the addition of an agonist 
at low shear rates. These methods also evaluate the platelets ability to aggregate in an integrin αIIbβ3 
dependent manner [413, 423]. Some aggregometers are able to measure the luminescence, which 
represents the release of the ATP from dense granules during secondary aggregation [413]. The 
impedance (WBA) method uses whole blood and measures the change in resistance after platelet 
aggregation due to agonist exposure. Sample preparation is minimal and, therefore, the probability of 
artifactual platelet activation is lower than that in the turbidimetric method [422]. However, the 
impedance method is based on assumption that only platelets binding to electrodes are changing the 
resistance, which may not always be the case due to platelets ability to bind to larger cells like 
monocytes and neutrophils making the WBA platelet non-specific. 
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Both serum TxB2 and urinary 11-dehydro TxB2 directly reflect the maximal production of TxA2. Both are 
markers of in vivo thromboxane generation and could therefore be specific for TXA2 production by COX-
1 and aspirin therapy [424].  However, TxA2 can be produced by cells other than platelets and WBCs, and 
may be produced by platelet-derived COX-2, therefore questioning the specificity of serum TxB2 and 
urinary 11-dehydro TxB2. Serum TxB2 is considered to be more specific to platelet thromboxane sources; 
however, aspirin resistance identified by measuring sTxB2 levels poorly correlated with other methods 
like urinary TxB2, AA, and ADP-induced platelet aggregation and aspirin VerifyNow [420, 425]. 
VerifyNow and The Platelet Function Analyser-100 (PFA-100) are considered to be point-of care 
analysers, which highlights their simplicity. VerifyNow can potentially be used to monitor the three most 
common antiplatelet therapies as it uses ADP, AA or TRAP as agonists [421]. The principle behind 
VerifyNow is the assessment of integrin αIIbβ3 dependent platelet aggregation, highlighting its similarity 
to, and, therefore, its good correlation, with LTA [423]. The ADP induced LTA is considered to be the 
gold standard for assessing the ability of clopidogrel to inhibit platelet activation. However, ADP also 
binds to the P2Y1 receptor, which is not a target of clopidogrel, and this contributes to overall platelet 
activation. The VerifyNow P2Y12 POC analyser uses the LTA principle but contains PGE1, which 
eliminates the effect of the P2Y1 receptor, therefore, allowing for higher clopidogrel inhibition [426]. A 
correlation study comparing the P2Y12 VerifyNow with LTA was performed in 211 patients treated with 
clopidogrel undergoing PCI that received at least 80 mg of aspirin for 7 days. Results from this study 
showed a strong correlation between the two methods without any systemic bias, and that both the 
peak and late aggregation in LTA after clopidogrel treatment was correlated with the VerifyNow system 
[426]. 
The Platelet Function Analyser-100 assesses platelet function based on the time taken for platelet 
related occlusion of an aperture to occur in a membrane coated with collagen and either ADP or 
adrenalin under high-shear stress [422]. Results from the PFA-100 can be used as a negative predictor 
for bleeding diathesis if normal closure times are obtained; however, results have no correlation with 
high bleeding risk in patients when closure times are prolonged [427]. Shortened closure times obtained 
using the collagen-adrenalin PFA-100 are found among patients with CAD with a recent AMI, and these 
results can be associated with the stability of CAD [428]. The disadvantages of the PFA-100 are its 
imprecision, its poor correlation with other functional tests and its dependence on vWF levels and 
activity, platelet count and haematocrit levels [413, 421]. 
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The VASP phosphorylation flow cytometric method measures activation-dependent platelet signaling  
using of ADP and PGE1 [423]. VASP is an intracellular actin regulatory protein that is phosphorylated into 
its P-VASP form by cAMP-dependent kinases, and phosphorylation leads to inhibition of platelet 
aggregation and integrin αIIbβ3 activation [252]. The amount of phosphorylation is directly proportional 
to the extent by which the P2Y12 receptor is blocked. The results are expressed as the platelet reactivity 
index (PRI). As phosphorylation is dependent on the P2Y12 receptor, the method therefore potentially 
enables monitoring of thienopyridines [252]. However, some researchers have highlighted that the 
limitation of VASP phosphorylation is its inability to distinguish among patients whose response to 
clopidogrel is low, average or high, when the P2Y12 receptor occupancy was used as a reference 
method and levels of receptor occupancy were low [429]. 
Flow cytometry is an instrument that can accurately and rapidly measure specific characteristics of many 
cell types.  Cells can be identified based on their forward and side scatter and fluorescently conjugated 
monoclonal antibodies that attach to the cells. In platelet function testing, flow cytometry enables 
evaluation of various platelet activation pathways simultaneously and interaction of platelets with each 
other and other cell types [430]. In addition to the ability to measure the platelets’ responses to various 
agonists, flow cytometry can determine the basal activation state of platelets without exposure to 
agonists in vitro [431]. 
Homozygous and heterozygous bleeding disorders like Bernard-Soulier syndrome (GPIb/IX/V deficiency) 
and  Glanzmann thrombasthenia (integrin αIIbβ3 deficiency) can be diagnosed using flow cytometry by 
selecting appropriate monoclonal antibodies (CD42a, CD42b and CD42d for Bernard Soulier syndrome 
and CD41 and CD61 for Glanzmann thrombasthenia) [432]. Inherited and acquired dense granule 
storage pool deficiency can also be diagnosed by flow cytometry using mepacrine or 5-
hydroxytryptamine and the protocol also exists for rapid diagnosis of heparin induced thrombotic 
thrombocytopenia [430]. P-selectin is the alpha component of platelet granule that is displaced to the 
platelet membrane only after platelet activation [431]. P-selectin is considered to be the ‘gold standard’ 
for measuring platelet activation despite the fact that platelets rapidly lose P-selectin but still continue 
to circulate and function, thereby decreasing the overall sensitivity of the assay [431]. Platelets release 
the content of their granules after exposure to agonists. These agonists include ADP and TxA2 that bind 
to their G-coupled receptors and start a signaling cascade that activates integrin αIIbβ3 and promotes 
fibrinogen binding. The conformational change in integrin αIIbβ3 can be assessed by flow cytometry, 
and is a marker of platelet activation (PAC-1)[431]. 
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Studies in baboons and humans have demonstrated that MPAs are more sensitive markers of platelet 
activation in vivo than P-selectin. They detected no changes in P-selectin expression in patients after PCI 
and after AMI, whereas levels of MPA were significantly increased [153]. Monocyte-platelet aggregate 
formation after AMI precedes the increase of cardiac troponins and CK isoenzymes [433], therefore 
measuring MPAs instead of Troponins may lead to earlier diagnosis of AMI and less blood tests for the 
patients. Although the formation of MPAs occurs through the interaction of P-selectin and PSGL-1, 
formation is independent of the rapid loss of P-selectin from the platelet surface, which decreases 
sensitivity of the P-selectin assay [153]. In addition to measuring MPA and NPA levels, more 
sophisticated methods have been developed that assess the amount of TF, fibrinogen and FXa on 
leukocytes with or without bound platelets which can potentially be used to investigate the effect of 
antiplatelet therapies from a wider perspective [434]. 
The disadvantages of flow cytometry include the need for rapid sample processing, which is usually not 
applicable in routine diagnostic laboratories, complex sample preparation, poor reproducibility, the lack 
of consistency among different flow cytometry models, expensive instrumentation and reagents, and 
complex maintenance [435]. 
1.7.2 Performance and correlation of platelet function analysers 
LTA is widely used for inherited and acquired bleeding disorders, however methodologies  used in this 
testing show great inter-laboratory variability world-wide and need standardisation [436]. The Platelet 
Physiology Subcommittee of the Scientific and Standardisation Committee of the International Society 
on Thrombosis and Haemostasis conducted a global survey of LTA practices and found high variability in 
LTA practices and the need for standardisation [436]. There is a great variability in agonists and 
concentrations used, recorded parameters such as maximal aggregation, shape change, disaggregation 
and lag phase. Most laboratories do not have a reference material [436]. Although LTA demonstrates 
large inter- and intra-laboratory variability (up to 50%) because of the complex sample preparation and 
a lack of standardisation, it enables monitoring of all common antiplatelet therapies [422]. High on-
treatment (residual) platelet reactivity (HRPR) in patients leads to increased risk of ischaemic 
cardiovascular complications and poor clinical outcomes and can be used as a predictor of MACE [252, 
423, 437]. Laboratory resistance to aspirin has been shown to increase the risk of recurrent CV events 
[248]; however, when the effectiveness of therapy was measured by sTxB2 levels in both healthy 
patients and patients with CAD the levels of platelet activation were almost always suppressed by 
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aspirin while assessment with the LTA identified low responders [415]. The poor correlation among the 
tests used to evaluate aspirin responsiveness in healthy individuals and patients with CAD is also 
highlighted in a study by Grove and colleagues that also demonstrated a high coefficient of variation for 
duplicate measurements for each test used, and high day-to-day variability [438]. In a study where the 
residual activity of platelets after aspirin administration was measured by AA induced platelet 
aggregation and VerifyNow, the results obtained, unlike the measurement of sTxB2 levels, correlated 
with clinical outcomes. However, Kidson-Gerber and colleagues claim that a moderate correlation exists 
among sTxB2 levels, PFA-100 closure times and WBA even though the participants were not consistently 
classified as aspirin resistant on all the tests used [439]. The poor reproducibility of these assays and the 
inter-individual variability may be responsible for such results as well as the fact that samples from some 
patients showed inhibition of platelet aggregation with WBA and the VerifyNow, but not PFA-100, 
before aspirin intake [440]. 
The most commonly used method for monitoring thienopyridine responsiveness is ADP induced LTA. 
Different research groups will however disagree on the LTA protocol and measured indices of platelet 
aggregation. Need for the adjustment of platelet count and the anticoagulant of choice are discrepant in 
the literature.  The assessment of clopidogrel inhibition using ADP as an agonist does not reflect the 
amount of P2Y12 receptor, required for initiation of platelet stabilisation, as ADP also binds to the P2Y1 
receptor and initiates platelet aggregation [413]. Maximal platelet aggregation has been most widely 
used parameter; however, platelets may disaggregate after the action of clopidogrel and maximal 
platelet aggregation may not fully reflect the amount of inhibition. Gurbel and colleagues therefore 
investigated if final platelet aggregation, rather than maximal platelet aggregation reported after 6 
minutes, may be a better estimate of clopidogrel inhibition in a 100 patients with a stent, before and 
after clopidogrel treatment. The P2Y12 reactivity ratio (PRR) was also determined by the VASP 
phosphorylation assay and was used to determine the extent of receptor blockage in non-responsive 
patients. Non-responsiveness to therapy was defined as less than a 10% difference in either the full or 
maximal aggregation before and after treatment. The PRR correlated well with the maximal and final 
platelet aggregation, even though the final platelet aggregation estimation revealed greater 
responsiveness.  The prevalence of non-responsiveness was the same in all three methods used [441]. 
Some authors measured residual platelet aggregation that corresponds to the level of aggregation curve 
measured at 6 minutes after agonist addition [442], while some claim that examining the stabilisation of 
aggregation, measured by disaggregation and late aggregation (mainly driven by P2Y12 rather than 
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P2Y1) in combination with platelet secretion and activation (P-selectin and PAC-1) is more superior 
measure of clopidogrel responsiveness [260]. Using hirudin/PPACK instead of sodium citrate as 
anticoagulant reduced the number of clopidogrel non-responders from 35% to 12% and further to 6% 
when late aggregation was used as a measure of responsiveness rather than maximal aggregation. 
Those authors concluded that platelet disaggregation should be used as a measure of clopidogrel 
responsiveness [260] but there was no reported follow up on the number of patients that had adverse 
events and therefore lack of correlation between clinical and chemical resistance. Maximal and final 
aggregations were however found to correlate well in determination the prevalence of non-
responsiveness to clopidogrel by some authors [441]. 
Platelet count was long believed to be a major determinant of platelet aggregation and should be 
adjusted using patients own platelet poor plasma. Correction of PRP platelet count became a 
controversy since a study reported that adjustment of platelet count introduced variability of the assay 
and reduced overall platelet aggregation when lower agonist concentrations were used [443].  They 
showed that platelet count is not the main determinant of platelet aggregation for platelet counts 
between 200 and 600x10
9
/L. The decrease in platelet aggregation observed in adjusted samples was due 
to inhibitory effect of PPP rather than decreased platelet count [443]. During centrifugation to obtain 
PPP cells can break down and release various substances such as ADP that could desensitise platelet 
ADP receptor impairing platelets response to the added ADP [443]. 
LTA however does not always correlate with other methods used to identify platelet activity. An 
agreement between the results from WBA and LTA is not always achieved when evaluating the effect of 
antiplatelet therapy. Results from a study of the inhibition of platelet activation after clopidogrel intake 
showed that WBA, compared with LTA, overestimated inhibition by 13% when 5 µM ADP was used and 
underestimated inhibition by 11% when 20 µM ADP was used, indicating poor correlation between the 
assays [419]. Another interesting finding from this study relates to the current guidelines for adjusting 
the dose of clopidogrel if there is less than 50% inhibition of platelet aggregation after therapy. 
Clopidogrel resistance was identified in 55% of patients using LTA with 5 µM ADP, 66% using LTA with 20 
µM ADP, 71% using WBA with 5 µM ADP, 47% using WBA with 20 µM ADP and 61% using P2Y12 
VerifyNow [419]. The patients identified as resistant to clopidogrel by WBA were not the same as those 
identified as resistant by LTA or VerifyNow [419]. These results highlight that although all methods were 
sensitive to clopidogrel, they were not able to determine the cut-off value that differentiate patients 
who were resistant to clopidogrel from patients who were responsive or non-compliant. 
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In a study that evaluated different clopidogrel doses there was a discrepancy in results showing 
suboptimal response between LTA and VerifyNow P2Y12 (15.3% by LTA and 17% by VerifyNow at 
baseline) [442].  If LTA is used to determine HRPR 16/23 patients with recurrent ischaemic events were 
identified while Thrombelastography (thrombin induced clot strength) identified 20/23 [437]. After 30 
and 60 mg loading dose of prasugrel  in patients scheduled for coronary angioplasty and possible PCI 
there was no high platelet residual activity when measured by LTA (5 and 20 µM ADP), VerifyNow and 
Multiplate [444]. Larger study of 300 patients undergoing PCI for ACS reported that post-treatment 
platelet reactivity was observed in 25% of patients as determined by VASP index, linking high post 
treatment PR to occurrence of thrombotic events [445]. Despite its poor reproducibility and high 
variability, ADP-induced LTA can correlate well with VASP-phosphorylation and P2Y12 receptor 
occupancy in volunteers treated with clopidogrel [429].  However, the randomised, international, 
placebo-controlled GRAVITAS clinical trial enrolled patients with stable angina/ischaemia or non-ST 
elevation AMI undergoing PCI and assessed platelet reactivity after clopidogrel treatment 12–24 hours 
post PCI. Those patients with high residual reactivity (PRU = 280) were randomised to receive either 75 
mg or an additional 600 mg LD followed by 150 mg MD of clopidogrel for 6 months. Patients without 
high residual platelet reactivity received 75 mg clopidogrel for 6 months. Platelet activity was measured 
after 30 days, and at 3 and 6 months. The primary endpoints were the time to the first occurrence of CV 
death, nonfatal MI or stent thrombosis. Positive results from this trial could have created a possibility of 
using results from the VerifyNow analyser to create effective and individualised antiplatelet therapy for 
high-risk patients [446].  More than 5000 patients were enrolled, with 2214 having high residual platelet 
activity. The 6-month follow up results showed no benefits of increased clopidogrel dose in patients who 
were not responsive to clopidogrel. The PRU decreased from 280 to 200 in patients receiving 150 mg 
MD of clopidogrel and from 280 to 240 in patients receiving 75 mg of clopidogrel [447]. The study 
authors concluded that platelet function testing did not correlate with clinical events, thereby possibly 
eliminating the use of VerifyNow in the follow up of patients in clinical practice. 
Gum and colleagues determined the prevalence of aspirin resistance in 325 patients with stable CVD 
who were given 325 mg/day of aspirin for 7 days or more and compared the detection of aspirin 
resistance between LTA and PFA-100. 5.5% of patients were found to be aspirin resistant and 23.8% 
were aspirin semi responders by LTA, while 9.5% of patients were found to be aspirin resistant by PFA-
100. Of the 18 patients who were found to be aspirin resistant using LTA, only 4 were also found to be 
aspirin resistant using the PFA-100, therefore showing poor correlation between these two methods 
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[448]. One of the reasons for the poor correlation is that the PFA-100 assesses aspirin response using 
collagen- and adrenalin-coated cartridges, neither one of which is specific for COX or TxA2 production 
[421]. 
In addition to analysing platelet function after antiplatelet therapy to predict the clinical outcome and 
define potential resistance to therapy, analysis of platelet function would also identify those patients 
with a high risk for major bleeds, which can occur after antiplatelet therapy, particularly dual 
antiplatelet therapy. Up to 27% of patients that require coronary revascularisation may undergo CABG, 
and the use of clopidogrel has been shown to increase the risk of major bleeds [449]. The 2007 ACC/AHA 
guidelines state that cessation of clopidogrel therapy is necessary 5 to 7 days before CABG [450]. 
Recovery of platelet function occurs between 3 to 7 days after clopidogrel administration and 7 to 9 
days after prasugrel administration depending on the baseline platelet activity, highlighting that the 
recovery of platelet function varies amongst individuals [444] and patients may need individual 
estimation of platelet recovery. Alstrom and colleagues tried to correlate the amount of preoperative 
platelet inhibition by dual antiplatelet therapy with the risk of bleeding related to surgical procedures. 
Platelet inhibition, as determined by the P2Y12 VerifyNow,  before surgery was significantly correlated 
with total blood loss and the amount of packed cells transfusion but only when all patients were 
analysed. There was a lack of correlation when the analysis was applied to individual patients [451]. 
Although results from the P2Y12 VerifyNow failed to predict bleeding outcome, it correlated well with 
VASP phosphorylation when the platelet inhibition before surgery was measured [451]. 
The results of all these studies demonstrate that currently used methodologies for evaluation of platelet 
function are highly variable, not reproducible and show poor correlation with one another. No currently 
available method correlates well with clinical outcomes even though some may be able to identify 
deficiency in certain platelet activation pathway – inherited, or acquired due to antiplatelet therapy. The 
most comprehensive method for evaluation of platelet activity, flow cytometry, is not routinely used 
due to need for immediate sample processing and highly trained operators.  
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1.8 Summary and Aims  
This introduction has highlighted the complexity of platelet involvement in atherogenesis and 
atherothrombosis. This relationship is multifactorial and, while current therapies focus exclusively on 
targeting platelet activation and aggregation to prevent late stage thrombotic complications of 
atherogenesis, this approach is limited and requires careful monitoring. The assessment of platelet 
function however lacks standardisation and demontrates poor correlation amongst currently used 
methods. The issue is partially created due to the lack of a methodology that is capable of examining a 
complete and complex platelet activation pathway. Despite its complexity and related expense, flow 
cytometric analysis offers the most encompassing assessment of platelet function and the relationship 
between platelets and other blood elements, such as monocytes and neutrophils. However, for flow 
cytometric analysis to be introduced into the routine laboratory setting, the developments of methods 
that prolong the current processing time are necessary.  Due to high chemical and clinical resistance to 
current antiplatelet therapies as well as high incidence of reported side effects, an alternative approach 
of targeting the interaction of platelets and inflammation, such as with antioxidants, novel prostanoid 
modulating lipids, may provide a novel, alternative approach to antiplatelet therapy. Addressing these 
problems the aims of this thesis were: 
1. To explore ability of natural products, namely gamma tocopherol and Lyprinol supplementation, to 
decrease platelet activation and potentially delay the onset of cardiovascular disease. Chapter 2 of this 
thesis provides an insight into ability of gamma tocopherol to decrease platelet activation in an 
increased oxidative stress setting caused by strenous exercise. It also demonstrates superiority of 
gamma tocopherol over the most commonly investigated Vitamin E supplement, alpha tocopherol. 
Chapter 4 of this thesis shows that Lyprinol supplementation acts as short-lasting modulator of platelet 
prostanoid pathway. We only performed 7 day supplementation trial, and suggest that longer 
supplementation with this, currently regarded anti-inflammatory supplement, may be cardioprotective 
supplement that attenuated both platelet and inflammation.   
2. To investigate the mechanism by which gamma tocopherol and the extract from the New Zealand 
Greeen Lipped Mussel Perna Canaliculus, inhibit platelet function. Chapter 3 of this thesis shows that 
both compounds inhibit the platelet arachidonic acid pathway. While gamma tocopherol appears to 
inhibit COX-1, novel marine lipids demonstrate multiple inhibitory targets, by possibly modulating 
platelet prostanoid receptors.  
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3. To design a simple point of care test for examination of platelet function using flow cytometry. 
Chapter 5 of this thesis describes a novel, simple and reproducible flow cytometric point of care test 
which uses capillary blood to assess platelet function. The method allows assessment of various platelet 
activating pathways and platelet interaction with monocytes with and without exogenously added 
agonist and without the need for immediate processing. 
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2 CHAPTER 2: THE EFFECTS OF GAMMA TOCOPHEROL ON PLATELET 
FUNCTION – AN IN VIVO STUDY 
2.1 Introduction 
American Heart Association recommended to increase vitamin E intake from food rather than 
supplements due to lack of proof for beneficial effects of supplemental vitamin E [405]. While 
supplemental vitamin E is mainly in the form of α tocopherol, dietary vitamin E contains mainly γ 
tocopherol [372].  The hypothesis that α and γ tocopherol, the two main vitamin E forms, may have 
different biological effects, and γ tocopherol may in fact be a more potent antioxidant, was created 
when an inverse relationship between γ tocopherol levels and CVD morbidity and mortality has been 
established [372] and γ tocopherol,  but not α tocopherol, was found to be reduced, and α/γ ratio 
increased in coronary heart disease patients in comparison to healthy volunteers [407].  Gamma 
tocopherol improves lipid profile, decreases inflammation, platelet activity and other biomarkers of 
oxidative stress in studies of normal healthy subjects and in rat models, to a greater extent than α-
tocopherol alone [210, 368, 379, 406, 408]. 
Given the known potential of γ tocopherol to decrease CVD risk factors in healthy volunteers (Chapter 1) 
this study aimed to investigate its ability to counteract some of those risk factors induced by strenuous 
aerobic exercise, at 70% of the VO2 max for 30 minutes up to 1 hour in healthy but sedentary volunteers. 
The exercise was used to increase the overall inflammation, platelet activity, coagulation and oxidative 
stress (Chapter 1). This study used high γ tocopherol preparation and compared its effects with α-
tocopherol supplementation. It was impracticable to use pure γ tocopherol supplements, but at the 
same time, α and γ tocopherol together may have synergistic effect on platelet cNOS activity, inhibition 
of free radical generation and platelet aggregation [452]. 
Based on a study of Clarke et. al. [453], 6 weeks supplementation with 300 mg of γ tocopherol is 
sufficient to increase serum and cell γ tocopherol levels. We believe that supplementation with high γ 
tocopherol would be able to attenuate platelet activity induced by strenuous exercise since the changes 
in platelet γ tocopherol levels would be more pronounced than in any other cell type [454].  
Supplementation with 500 mg (749 IU) of α tocopherol per day, increased serum and cell α tocopherol 
levels, but also resulted in increased γ-CEHC excretion, and decreased plasma and erythrocyte γ 
tocopherol [453]. This is in line with previous reports highlighting that high α tocopherol intake reduces 
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γ tocopherol levels [406, 455]. It is due to competition for hepatic α tocopherol transport protein, which 
preferentially transports α tocopherol to VLDL, having only 9% affinity for γ tocopherol [456]. In a 
randomised placebo controlled trial, supplementation with 400 IU of α tocopherol per day for 2 months 
decreased serum γ tocopherol levels by 60% [406]. Relative affinity of the protein is linearly related to 
biological activity of each vitamin E subtype [456] which dependents on its delivery to tissues and 
explains the decrease of γ tocopherol after α tocopherol supplementation. 
We measured platelet count and activity, coagulation and fibrinolysis, lipid profile and inflammation 
markers before and immediately after strenuous exercise in a placebo controlled trial, before and after 
supplementation with either high (300 mg/day) or low (150 mg/day) γ tocopherol, high (400 IU/day) or 
low (200 IU/day) α tocopherol, or mixed (150 mg/day γ and 200 IU/day α) tocopherol and hypothesised 
that supplementation with γ but not α tocopherol for 6 weeks would attenuate the negative effects of 
strenuous exercise on CVD risk factors. 
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2.2 Materials and Methods 
2.2.1 Volunteer recruitment and study outline 
Thirty seven healthy and sedentary volunteers, with an age range of 18-55 years gave informed consent 
to participate in the study. Thirty six subjects, 16 males and 20 females, completed the treatment 
regimen and the full complement of testing was performed. Institutional Human Research Ethics 
Committee approval was obtained (HREC Application 12/07) and Clinical Trial Notification to the 
Therapeutic Goods Administration was submitted as registration was not required. The TGA notification 
number was 20070551. 
All participants were apparently healthy, non-smokers with no history of ingestion of medications or 
dietary supplements for at least 2 weeks prior to and for the duration of the study, based on the filled 
questionnaire. Only sedentary volunteers were included in the study and this was confirmed by VO2 max 
of less than 40 mL/kg/min [457, 458].  A determination of VO2 max was performed 7 days before the 
trial, and consisted of exercise on a bicycle ergometer with constant increase of the workload until 
exhaustion. A flow chart for subject screening, enrolment and study participation is outlined in Figure 
2.1. Subjects were randomised to one of 6 single-blind oral 6-week supplement regimens, outlined in 
Figure 2.2. Compliance was verified by leftover capsules count and verbal question. 
2.2.2 Supplements 
The placebo capsule was obtained from Schiff Nutrition International, Salt Lake City, UT and contained 
1.36 g of soy lecithin per capsule. Jarrow Formulas, Los Angeles, CA produced both Gamma E and d- α 
tocopherol capsules. The gamma-E capsule was labeled to contain 300 mg of γ tocopherol per capsule, 
34 mg (50 IU) of α tocopherol, 100 mg δ tocopherol and 7 mg β tocopherol. Alpha tocopherol 
supplements were labeled to contain 400 IU of d-alpha-tocopherol. The doses were selected as the 
study  of Singh et.al. [408] showed that supplementation with 100mg and 200mg of pure gamma 
tocopherol suppressed platelet activation in healthy volunteers. Our supplements were not pure gamma 
tocopherol and authors anticipated that some bioactivity would be lost due to presence of alpha 
tocopherol and hence higher doses would be able to counteract such effect.  
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2.2.3 Outline of the protocol 
Briefly, volunteers reported to the laboratory between 06.00 and 10.00 and a fasting blood sample was 
obtained for Full blood examination (FBE) including the total platelet count (Plt), mean platelet volume 
(MPV) and haematocrit (Hct); Whole Blood Platelet aggregation using 2 µg/mL collagen as agonist; 
Coagulation studies including PT, APTT and quantitative D-Dimers; Lipid profile that revealed total 
cholesterol, high density lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL) and 
triacylglycerols and inflammation markers: C-reactive protein (CRP) and creatine kinase (CK). 
Participants were asked to take an overnight fast. 
After collection of fasting baseline samples, participants were asked to perform exercise on a bicycle 
ergometer at a constant workload corresponding to 70% of their VO2 max for a maximum of one hour or 
until exhaustion providing they exercised for at least 30 minutes. Volunteers were allowed to drink 
water only, during and after exercise. Fasting blood samples were collected immediately after exercise 
for the same test profile as performed on the fasting samples. After 6 weeks oral supplementation the 
entire testing procedure was repeated (fasting blood sampling, exercise and post-exercise blood 
sampling). Participants performed the same exercise as in the pre-supplementation period. A total of 22 
mL of venous blood was collected at each time point using a vacutainer adapter and 21 gauge needle. 
Blood was collected into 2 mL di-potassium ethylene-diamine-tetra acetic acid (EDTA 1.8 mg/mL), 4 mL 
tri-sodium citrate (3.8% w/v) and 8 mL serum separator tubes (VACUETTE® Serum Tubes with Gel). Care 
was taken to ensure minimal specimen handling and agitation. 
2.2.4 Full Blood Examination 
Whole blood collected in EDTA tube was used to obtain full blood examination parameters using a 
Beckman Coulter Ac.T 5diff analyser (Coulter Corporation, Miami, FL). The satisfactory performance of 
the analyser was confirmed using Coulter ® Calibrators and Coulter ® A
c
.T
TM
 5diff Controls Plus, Beckman 
Coulter®, Miami, FL . 
Platelet counts after exercise before and after supplementation were corrected for haemoconcentration 
using haematocrits obtained. Formula for correction was as follows: 
(Post exercise platelet count X Pre exercise haematocrit) / Post exercise haematocrit 
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2.2.5 Whole blood platelet aggregation 
Whole blood platelet aggregation was assessed with an impedance aggregometer (Chrono-Log 
Corporation, Havertown, PA) equipped with MacLab software (AD Instruments PTY, LTD, Castle Hill, 
NSW) for data quantification and analysis. 
Whole blood was collected into 3.2% (w/v) sodium citrate in 9:1 ratio. Within 15 minutes of collection, 
450 µL blood was diluted with 450 µL pre-warmed saline (37
o
C) and was incubated at 37
o
C for 5 
minutes.  Collagen was added to the sample (2 µg/ml final concentration) and the change in impedance 
was monitored for 6 minutes. Maximal impedance at 6 minutes was recorded as a measure of collagen 
induced platelet aggregation [459]. Testing was completed within 1 hour after venesection. 
2.2.6 Coagulation studies 
Samples for coagulation studies were separated and stored at -80˚C for batch analysis (maximum 3 
months). All coagulation studies were performed using the ACL Futura and Hemosil PT, APTT and D-
dimer reagents (Instrumentation Laboratory, IL Company, Lexington). Results for PT (s) and APTT (s) 
were validated using appropriate controls (either Hemosil or Citrol from Dade Behring, Marburg, 
Germany) and D-dimer results using Hemosil DD- calibrators and controls. 
Prothrombin time and APTT testing were performed in duplicate and the average result was recorded. 
2.2.7 Lipid profile and inflammation markers 
Serum samples for lipid profile and inflammation markers were centrifuged for 10 minutes, 3000 rpm, 
separated and stored at -80˚C for batch analysis (maximum storage time 3 months). The lipid profile and 
inflammation markers were tested at Gribbles Pathology using the Dimension XL (Dade Behring, 
Deerfield, Illinois) biochemistry analyser. All reagents including controls and calibrators were specific for 
Dimension instrument and are produced by Dade Behring. 
2.2.8 Results analysis 
The results were analysed using GraphPad Prism 5.01 (GraphPad Software, Inc. La Jolla, CA). Exercise-
induced changes before and after supplementation were expressed as the percentage deviation from 
the pre-exercise level for each parameter. The group mean changes before and after supplementation 
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were compared using Student’s two tailed paired t-test. The baseline levels between groups, or any 
other analysis that required a comparison between more than two different groups were analysed using 
1-way ANOVA with Newman-Keuls multiple comparison post test comparing all groups. Significant 
change was indicated by p < 0.05 for the null hypothesis. 
StatMate 2.0 (GraphPad Software, Inc. La Jolla, CA) was used to calculate the power of already 
completed experiments where significant results were obtained. The power calculations were not 
performed prior to trial commencment.  
  
 Figure 2-1: Outline of the study 
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Figure 2-2:  Supplementation Scheme 
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2.3 Results 
Only participants whose VO2 max was less than 40 mL/kg/min were recruited for the study.  Thirty six 
volunteers completed the study. 3 participants complained of feeling nauseous on some days, if 
supplements were taken in the morning, but were able to complete the trial. One participant withdrew 
during the supplementation period due to illness of an unrelated nature. Nine enrolled participants 
were excluded from the study on day 8 since they were unable to perform the first exercise test for 30 
minutes. Exclusion of participants made group sizes unequal and smaller. It was anticipated that each 
group would consist of 8 participants. 
2.3.1 Pre-supplementation, pre-exercise parameters 
Participants were randomised to one of the 6 supplementation groups. For all parameters measured, 
there should be no difference between each supplementation group. In order to test this possibility all 
parameters were compared before exercise and before supplementation for each supplementation 
group to ensure no differences are found. As shown in Table 2.1, the baseline levels of all the 
parameters measured. Means and standard errors of the mean are reported and results were analysed 
using 1-way ANOVA with Newman-Keuls post test. There were no significant differences between 
groups for any parameter measured. 
2.3.2 Exercise-induced changes before supplementation 
Strenuous exercise increases platelet count and activity, inflammation and hypercoagulability and 
fibrinolysis in sedentary population. It was important to ensure, exercise in this experimental design 
produced expected changes. In order to confirm this possibility, pre and post exercise levels for all 
parameters measured for all volunteers were compared using Student's paired t-test. Parameters 
unaffected by strenuous exercise before supplementation were excluded from further analysis. The 
exercise-induced change in the measured parameters were analysed using Student’s paired t-test. The 
platelet count increased from 252 x 10
9
/L ± 8.3 to 282 x 10
9
/L ± 8.4 before the correction for 
haemoconcentration (p<0.001, n=36), shown on Figure 2.3A and 2.3B and 273.1 x 10
9
/L ± 7.7 after the 
correction for haemoconcentration (p<0.001; n=36; Figure 2.3C and 2.3D). In contrast, exercise however 
did not affect the mean platelet volume (8.4 ± 0.8 to 8.4 ± 0.7) (Figure 2.3E), (p>0.05, n=36), thus no 
further analysis of this parameter was performed. 
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Collagen-induced whole blood platelet aggregation increased slightly after exercise from 25.5 Ohms ± 
1.1 to 27.9 Ohms ± 1.3 (p<0.01) (Figure 2.4). In contrast, shortening of the APTT (Figure 2.5A) from 33.4 
s ± 4.0 to 30.8 s ± 4.2 (p<0.0001; n=28) was noted but the PT was unaffected (Figure 2.5B; 13.9 s ± 1.0 to 
13.8 s ± 1.3, p>0.05, n=28). D-dimer levels (Figure 2.5C) increased significantly from 361.6 ng/mL ± 189.8 
to 503.8 ng/mL ± 304 (p<0.01; n=26). 
From inflammation markers, only creatine kinase (CK) levels (Figure 2.6 A and 2.6 B) were increased by 
exercise from 110.9 U/L ± 62.6 to 125.9 U/L ± 69.5, p<0.0001,n =35,  while CRP remained unchanged 
(2.6B; 4.1 mg/L ±3.8 to 4.2 mg/L ± 3.9, p>0.05, n=36). 
  
 Table 2-1: Baseline Characteristics. 
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Figure 2-3: Exercise induced changes in circulating platelet count and mean platelet volume before supplementation. 
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Figure 2-4: Exercise induced changes in collagen induced platelet aggregation before supplementation. 
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Figure 2-5: Exercise induced changes in coagulation parameters before supplementation. 
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Figure 2-6: Exercise induced changes in inflammation markers before supplementation. 
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2.3.3 The effect of Vitamin E supplementation on exercise induced circulating platelet 
count increase 
Strenuous exercise increases platelet count due to increased haemoconcentration and stimulation of 
platelet release from bone marrow, spleen and lungs, possibly due to increase in adrenaline levels. 
Newer platelets are more metabolically active and may be more responsive to agonist stimulation. 
Vitamin E may suppress platelet release. Therefore, platelet count before and after exercise and before 
and after supplementation was measured and results for each supplementation group compared. The 
platelet count was expressed as the post exercise percentage change from the pre-exercise baseline, 
before and after supplementation with different vitamin E forms and changes for each supplementation 
group were analysed using 1-way ANOVA with Newman-Keuls multiple comparison test. Results for 
individual supplementation group were compared using Student’s paired t-test. In all groups, the 
circulating platelet count, after correction for haemoconcentration, increased after exercise by 10% on 
average before and after supplementation (Figure 2.7). Supplementation with either α or γ tocopherol 
was not capable of attenuating exercise induced increase in platelet counts (p>0.05, n=6 for all except 
high γ tocopherol, where n = 7 and mixed tocopherol where n = 5). 
2.3.4 The effect of vitamin E supplementation on exercise induced changes on collagen-
induced platelet aggregation 
Platelet activity increases after strenuous exercise. Increased activity is caused by multiple mechanisms 
including increase in the ROS production, NO hyporesponsiveness, adrenaline release and increase in 
α2-adrenoreceptor density on platelets. Both vitamin E forms can quench ROS and RNS and inhibit 
platelet hyperactivity. Gamma tocopherol can reduces platelet activation in healthy volunteers better 
than α tocopherol. In order to test the effect of vitamin E supplementation on exercise induced changes, 
collagen induced whole blood platelet aggregation was measured before and after exercise and before 
and after supplementation and compared for each supplementation group to see if vitamin E prevents 
exercise induced platelet hyperactivity. As shown in Figure 2.8 the effect of Vitamin E supplementation 
on collagen induced platelet aggregation was expressed as the percentage change in the maximum 
aggregation after exercise compared to that determined pre-exercise, both before and after 
supplementation. Results for each supplementation group were compared using Student’s two tailed 
paired t-test, while results for all groups were compared using 1-way ANOVA with Newman-Keuls post 
test. 
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In placebo group before supplementation collagen-induced maximal platelet aggregation after exercise 
increased to 116.8% ± 14.1 (24.17 Ohms ±4.2 to 28.30 Ohms ±5.9) and remained elevated after 6 weeks 
supplementation 24.08 Ohms ±6.2 to 26.08 Ohms ± 6.13 (109.6% ±18.33), n=6. Similar trend of results 
was observed in high (26.04 Ohms ± 5.5 and 27.95 ± 5.8 before supplementation and 25.54 Ohms ±1.5 
and 29.84 Ohms ±4.3) n= 5 and low (26.8 Ohms ± 1.6 and 30.96 ± 1.6 before supplementation and 24.05 
Ohms ± 4.3 and 24.58 Ohms ± 2.5 after supplementation) n=6,  α tocopherol supplementation groups. 
However, supplementation with high γ tocopherol (n=7) ameliorated exercise induced increase in 
collagen induced platelet aggregation (Figure 2.8D).  Collagen induced platelet aggregation increased 
from 24.6 Ohms ± 1.8 to 28.6 Ohms ± 1.4 before supplementation with 300 mg/day γ tocopherol. After 
6 weeks supplementation, the collagen-induced maximal aggregation after exercise did not increase, but 
showed a significant decrease to 89.5%±4.4, p<0.01, n=7. The aggregation after supplementation 
decreased from 24.5 Ohms ± 1.2 before exercise to 21.8 Ohms ±1.2 after exercise.  Lower doses of γ-
tocopherol supplementation (150 mg/day) showed a similar trend with aggregation decreasing from 
109.2% ±13.3 (28.4 Ohms ± 4.0 at baseline and 29.3 Ohms ±3.4 after exercise) before supplementation 
to 95.16% ±12.7 (25.9 Ohms ±3.3 at baseline to 23.8 Ohms ± 2.8 after exercise) after supplementation, 
but results were not statistically significant (Figure 2.8E; p>0.05, n=6). 
This experiment was adequately powered (80%) to detect the difference in collagen induced platelet 
aggregation in high γ tocopherol group, where n=7 and standard deviation of the difference was 20 with 
alpha 0.05 (two-tailed). However it was not adequately powered for other supplementation groups 
(power < 70%). 
2.3.5 The effect of Vitamin E supplementation on exercise induced changes to the APTT 
Exercise increased both coagulation and fibrinolysis. While fibrinolysis returns to normal soon after 
exercise, hypercoagulable state remains. It is mainly due to increased shear stress which induces platelet 
procoagulant activity, promoting FV and FVIII binding to platelets and platelet-derived microparticles 
and triggering thrombin generation. There is also an increase in vWF antigen and activity which allows 
vWF to bind to platelets and enhance their binding to fibrinogen, thereby stabilising platelet-platelet 
aggregates. While supplementation with α tocopherol did not improve haemostasis parameters in 
healthy volunteers, no studies have examined the effect of γ tocopherol. In order to test whether γ 
tocopherol affected haemostasis, coagulation parameters were measured before and after 
supplementation with vitamin E forms before and after exercise and results for each group compared. 
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Considering that strenuous exercise did not have an effect on PT before supplementation, that 
parameter was excluded from further analysis. As shown on Figure 2.9, Vitamin E supplementation had 
mild effect on exercise-induced changes to the APTT. Results are analysed using 1-way ANOVA with 
Newman-Keuls post-test. Only low γ tocopherol supplementation (Figure 2.9E) prevented exercise-
induced shortening of the APTT time. A significant decrease of the APTT was induced by exercise 
(decreased from 32.64 s ± 1.46 to 28.80 s ± 1.87, p<0.05, n=6). After 6 weeks supplementation with low 
γ tocopherol, the APTT did not decrease significantly (36.38 s ± 1.098 at baseline and 30.98 s ± 1.180 
after exercise, p>0.05, n=6). Supplementation with other Vitamin E forms had no effect on exercise-
induced shortening of the APTT. 
Experiment was adequately powered (>80%) to detect the difference in the APTT result of 3, with 
standard deviation of the difference 2 (before supplementation) and n=6, alpha = 0.05 (two-tailed).  
2.3.6 The Effect of Vitamin E supplementation on D-dimer levels 
Strenuous exercise increases both coagulation, fibrinolysis and platelet activity. If vitamin E has ability to 
attenuate platelet activation and hypercoagulability, it may have an indirect inhibitory effect on 
fibrinolysis due to decreased coagulation. In order to test this possibility, D-Dimer levels were measured 
before and after exercise, before and after supplementation and compared for each supplementation 
group. Even though strenuous exercise leads to increased D-dimer levels (Figure 2.5), Vitamin E 
supplementation did not significantly affect the results (Table 2.2). Results were analysed using 1-way 
ANOVA with Newman-Keuls multiple comparison test. Even though all groups showed a trend of 
increased D-Dimer levels after exercise, the increase for individual groups was not significant. As shown 
in Table 2.2, the volunteers showed great variation in the D-dimer levels after exercise for both time 
points as demonstrated by very high standard errors in some groups (placebo 550.9 ± 230.5 at baseline; 
400 IU α tocopherol 577.9 ± 227.8; 200 IU α tocopherol ± 121.2), which could explain the lack of any 
significant results. 
2.3.7 The effect of Vitamin E supplementation on exercise induced changes to Creatinine 
Kinase 
Strenuous exercise increases inflammatory response. Vitamin E forms have been shown to decrease 
release of cytokines and interleukins and may have an effect on the markers of inflammation. In order to 
see if vitamin E supplementation with exercise affected inflammation, CK levels were measure before 
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and after exercise, before and after supplementation and results compared for each supplementation 
group. Since CRP levels were unaffected immediately after strenuous exercise in sedentary volunteers, 
the parameter was excluded from further analysis. As shown in Table 2.3, the effect of supplementation 
with Vitamin E on exercise-induced changes to CK level. Results were compared using 1-way ANOVA 
with Newman-Keuls multiple comparison test. Neither form of Vitamin E or placebo had effect on CK 
levels (p>0.05 n=6 for placebo, high and low α , n= 7 for high γ and n=5 for low γ and mixed tocopherol 
supplementation). 
2.3.8 The effect of Vitamin E supplementation on lipid profile 
Pure γ tocopherol supplementation was shown to improve lipid profile in healthy volunteers. Since pure 
γ tocopherol is not found in nature and is difficult to isolate, we tested if high γ, low α tocopherol 
preparation has the same effect. Full lipid profile was tested before and after supplementation with 
vitamin E forms and results for each group compared. Lipid profile results are shown in Table 2.4. They 
are expressed as the mean ± SEM and analysed using 1-way ANOVA with Neman-Keuls multiple 
comparison test.  Despite previous reports showing the ability of γ-tocopherol to improve lipid profile, 
there were no significant differences in any supplementation group. The results of all parameters 
measured are within the reference range. 
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Figure 2-7: The effect of vitamin E supplementation on exercise induced circulating platelet count increase. 
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Figure 2-8: The effect of vitamin E supplementation on exercise induced changes in collagen induced platelet aggregation. 
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Figure 2-9: The effect of vitamin E supplementation on exercise induced changes in activated partial thromboplastin time. 
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able 2-2: The effect of vitamin E supplementation on D-dimer levels (ng/mL). 
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 Table 2-3: The effect of vitamin E supplementation on exercise induced changes in CK levels
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 Table 2-4: The effect of Vitamin E supplementation on lipid profile
 
  
T
a
b
le
 2
.4
: 
T
h
e
 e
ff
e
ct
 o
f 
V
it
a
m
in
 E
 s
u
p
p
le
m
e
n
ta
ti
o
n
 o
n
 l
ip
id
 p
ro
fi
le
. 
. 
109 
110 
 
2.4 Discussion 
Six weeks oral supplementation with 300 mg γ tocopherol, but not 400 IU or 200 IU α tocopherol or a 
mixture of the two Vitamin E forms (150 mg γ and 200 IU α tocopherol) prevented exercise-induced 
platelet activation and hypercoagulability as assessed by the APTT. Furthermore, supplementation with 
300 mg γ tocopherol per day in combination with exercise reduced collagen-induced platelet 
aggregation below the baseline level. Low γ tocopherol supplementation produced similar trend but the 
results were not significant. Therefore γ tocopherol in the absence of high dose α tocopherol may 
enhance the beneficial effects of exercise on haemostatic and cardiovascular function. 
Supplements used in this study were not pure γ tocopherol preparation, but contained small α 
tocopherol amounts.  There are currently no supplements that contain pure γ tocopherol available in 
supermarkets, as such nutritional supplements are designed to emulate dietary intake, which does 
contain some α- in addition to the predominant γ tocopherol. Intake of high γ and low α tocopherol 
supplementation leads to increase of both isoforms in blood plasma [460] and increase in γ but not α 
tocopherol in platelets [456]. A combination of γ tocopherol with low α tocopherol may act 
synergistically to counteract oxidative stress produced by exercise and reduce platelet activation [452]. 
This study confirmed that exercise at 70% VO2 max in sedentary individuals increases the postulated CV 
risk factors [457] by increasing the circulating platelet count [461] and activity [462], promoting 
hypercoagulability demonstrated by shortening of the APTT [463, 464] and increasing fibrinolysis, 
demonstrated by the increase in D-dimer [463, 464]. The increased circulating platelet count, even after 
correction for haemoconcentration, is in agreement with previous studies claiming the release of 
platelets from bone marrow, spleen and lungs [461]. The decrease in the APTT is mainly postulated to 
be due to an increase in the factor VIII:c [463] which remained elevated 2 hours after recovery [464].  
The increase in the D-dimer level is consistent with the literature reports, however it has also been 
reported that the fibrinolysis decreases quickly during recovery while hypercoagulability remains [463, 
464]. This study was not designed to examine the duration of the hypercoagulable state, but focused on 
the immediate period after exercise, which represents the peak risk for exercise related cardiovascular 
events [206]. While this study has showed that 300 mg of γ tocopherol supplementation per day for 6 
weeks was capable of ameliorating the undesirable thromboinflammatory response to exercise 
immediately after cessation of exercise, it was not designed to assess the duration of this protection and 
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it is possible that thromboinflammatory risk was merely delayed. Further studies are necessary to 
examine this. 
Vitamin E supplementation had no effect on platelet count. The analysis of each supplementation group 
before supplementation showed that there was a trend towards an increase in platelet count after 
exercise, but the increase was not significant. That could be a result of small group sizes and large 
variation in baseline counts and response to exercise amongst volunteers. Considering that there was no 
significant exercise-induced increase in platelet counts when each supplementation group was analysed 
separately, it may not be possible to see any effect due to Vitamin E. 
While this study was inadequately powered to compare the ability of individual tocopherol treatment 
regimens to attenuate exercised induced hypercoagulable state, a trend for improved APTT following γ 
tocopherol supplementation was observed, but only achieved statistical significance in the low dose 
(150 mg/day) group. Further, adequately powered studies are required to confirm this effect. No 
tocopherol supplementation influenced D-dimer levels. 
The mechanism by which γ tocopherol supplementation exerts its effect on exercise induced platelet 
function is not clear, in part because the exact mechanism by which strenuous exercise in sedentary 
people induces platelet activation is not clear. Increased platelet counts after exercise may be partially 
responsible, since those newly released platelets are more metabolically active and may have higher 
aggregating potential [465]. Some studies have suggested that increased shear stress may contribute to 
elevated platelet activation during and following exercise, while others have suggested catecholamine 
release as the mechanism of activation [221, 222]. Gamma tocopherol may decrease catecholamine 
release. This could therefore inhibit splenic platelet release after exercise, since epinephrine infusions 
lead to splenic contractions, which can result in platelet release [217]. 
Exercise increases oxygen radicals production, lipid peroxidation and production of oxidatively modified 
LDL which decreases platelets ability to generate NO [466]. One possible mechanism by which γ 
tocopherol might have reduced collagen-induced platelet aggregation after exercise below the baseline 
levels could be related to upregulation of NO production since NO has been shown to inhibit platelet 
activation by influencing calcium mobilisation, secretion, shape change and integrin activation [467]. 
Nitric oxide inhibits dense granule ADP release and phosphorylates the TP receptor inhibiting TxA2 
induced platelet aggregation [467]. Gamma tocopherol was shown to increase NO and NOS activity as 
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well as increase eNOS protein expression [468-470]. Both tocopherols have been shown to increase NO 
generation and cNOS activity with γ tocopherol being more potent, but only γ tocopherol increases 
cNOS protein expression [368]. A combination of tocopherols containing 63% y tocopherol, 25% δ 
tocopherol and 12% α tocopherol attenuated platelet aggregation through a decrease in free radical 
generation and an increase in platelet cNOS activity better than each compound alone [452]. 
Supplementation with mixed tocopherol preparation  with high γ tocopherol content inhibits ADP 
induced platelet aggregation, increases NO release from platelets and eNOS activation better than  α 
tocopherol [210]. Nitric oxide levels increase after acute exercise [471], however platelet activation 
increases simultaneously.  On the other hand, repeated bouts of moderate exercise enhance the long 
term biosynthesis of eNOS and give higher plasma NO concentration that is maintained between 
sessions [471-473]. The synergistic NO production from γ tocopherol supplementation and repeated 
bouts of exercise in these groups can potentially explain the results obtained. 
Physiological concentrations of γ tocopherol and its main metabolite γ-CEHC are also more capable than 
α tocopherol in inhibiting COX-2 activity in macrophages and epithelial cells and consequent generation 
of PGE2 synthesised via the COX-2 [410]. Decreased PGE2 and LTB4 synthesis was also demonstrated in 
rats, induced by γ tocopherol and its main metabolite [409]. The authors suggest that this effect is 
achieved by competition of γ tocopherol and γ-CEHC with AA at the active site of COX-2 [410]. These 
results suggest that this Vitamin E form may in fact be capable of reducing platelet COX-1 activity and 
consequent TxA2 generation. This alone is not sufficient to fully prevent exercise induced platelet 
activation, since aspirin therapy has limited benefits in this setting [213], however a potential decrease 
in TxA2 formation together with concomitant increase in platelet NO can decrease platelet activation. 
In contrast to other studies that provided strong evidence of anti-inflammatory properties of γ 
tocopherol and improvement in lipid profile after supplementation [379, 408], this study demonstrated 
no influence of any tocopherol on improving lipid profile or inflammation markers. Fatouros et al 
showed, after a completion of their study, that CRP levels increase 1 hour post-exercise and peak (200% 
rise, p<0.0001) at 24 hours post-exercise [474]. 300 mg of γ enriched tocopherol preparation (60% γ 
tocopherol) was also reported to decrease the CRP levels in haemodialysis patients after 14 days 
supplementation [475]. This suggests that the effect of γ tocopherol supplementation on CRP levels may 
have been missed since the samples were taken immediately after exercise, at a point where they did 
not significantly differ from baseline levels. Creatinine kinase levels increase immediately after exercise 
[474] but CK is a marker of muscle damage and Vitamin E supplementation had no effect on its levels. A 
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previous study that demonstrated improved lipid profile after 100 mg/day γ tocopherol 
supplementation for 5 weeks used pure γ tocopherol supplements [408], while this current study used 
high γ/low α tocopherol preparation which could potentially explain the difference observed. Volunteers 
in this study also had lipid profile within reference ranges (Table 2.1) and the effect of vitamin E 
supplementation may be more prominent in the abnormal lipid profile setting. 
The major limitations of this study were small group sizes where parameters had large inter-individual 
variation in baseline. It has recently been shown that the effect of at least EPA and DHA enriched 
supplementation on platelet function is influenced by gender, possibly due to sex hormone differences 
[476]. This finding explains the lack of beneficial effect of fish oils in some clinical trials which included 
both male and female participants. Due to small group sizes in this study, we were not able to sub-
analyse results for males and females separately. Even though gamma tocopherol is strucuraly different 
to omega-3 fatty acids and influences platelets function via different mechanisms, as shown in Chapter 
3, it still targets platelet COX-1 pathway and the mixed study population could influence the conclusions 
drawn. Future studies need to be conducted in males and females participants to elucidate this further. 
Furthermore, while VO2 max was standardised between groups, interindividual differences in fitness 
level and catecholamine / stress responses may have reduced the ability to demonstrate small effects 
resulting from tocopherol treatments.  
Plasma tocopherol levels before and after supplementation were not measured, and even though γ 
tocopherol exhibits faster clearance than α tocopherol [378], a number of previous studies [210, 371, 
379, 408] reported that chronic dietary supplementation with γ tocopherol increases both plasma and 
tissue γ tocopherol concentration [371], the assumption was made that the effects seen are mainly 
attributable to γ tocopherol. The beneficial results are only seen in enriched γ tocopherol 
supplementation group, but not in α tocopherol, which is in line with previous studies reporting that 
supplementation with 800 mg/day α tocopherol for 6 weeks decreases γ tocopherol levels and even 
though both forms increase in blood plasma after mixed supplementation (400 mg α and 400 mg γ 
tocopherol) the increase of γ is much less than with high γ tocopherol preparations [379]. 
While platelet aggregometry remains the gold standard for measuring platelet function, it is not clear 
whether the inhibition of exercise-induced platelet aggregation with 300 mg of γ tocopherol per day for 
6 weeks was a result of decreased platelet-fibrinogen binding, platelet degranulation or platelet 
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activation per-se. Molecular and flow cytometric studies may be effective in determining the 
biochemical mechanism of this potentially beneficial effect. 
This study measured surrogate laboratory markers which may contribute to exercise related 
cardiovascular risk. Further studies with a much larger sample size are required to confirm that 
tocopherol has the potential to inhibit clinical endpoints, such as major adverse cardiovascular events, 
immediately following exercise. However, due to the large sample size, and the ethical considerations of 
inducing cardiovascular outcomes with strenuous exercise, such a study is unlikely to be performed. 
Therefore, in the absence of stronger clinical data, the results of our study may inform dietary 
supplementation regimens to safely enhance the beneficial effects of low to moderate exercise in 
sedentary people. Further studies are necessary to determine if this strategy may be applied to disease 
paradigms and other populations. 
2.5 Conclusion 
This is the first study to assess the effect of supplementation of different isoforms of tocopherol on 
exercise induced thromboinflammatory parameters. The findings suggest that supplementation with 
300 mg of γ tocopherol per day for 6 weeks prevents exercise-induced platelet and coagulation 
hyperactivity through as yet undetermined mechanisms, and results in inhibition of platelet function 
following exercise in sedentary individuals. Therefore γ tocopherol supplementation may enhance the 
beneficial effects of exercise in this population and prevent adverse effects of strenuous exercise in 
sedentary individuals. 
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3 CHAPTER 3: THE EFFECTS OF PERNA CANALICULUS EXTRACT AND 
GAMMA TOCOPHEROL ON PLATELET FUNCTION – AN IN VITRO 
STUDY 
3.1 Introduction 
Lyprinol is a commercially available dietary supplement prepared from supercritical CO2 lipid extract 
(CO2-SFE) of tartaric acid stabilised freeze-dried New Zealand green lipped mussel (Perna canaliculus) 
powder with olive oil and α tocopherol excipients [477]. It is widely used for its anti-inflammatory 
properties, particularly in arthritis and degenerative joint disease [326, 478-485], and generally better 
tolerance and safety profile than NSAIDs [326, 346, 486].  
The CO2-SFE in Lyprinol contains a complex profile of free fatty acids including novel and rare n-3 and n-
6 PUFAs (C18:4, C19:4, C20:4, C21:5, 28:8 n-3) that are responsible for its potent anti-inflammatory 
activities [352, 353, 487]. These novel n-3 PUFAs, as well as EPA (20:5 n-3) and DHA (22:6 n-3) have 
potential to inhibit platelet function by several mechanisms, described in literature review. Despite the 
potential for antiplatelet activity with this supplement, only one study [346] has examined the effect of 
Lyprinol on platelet activation. No significant effect was seen, however this study only examined a single 
low dose in humans (n = 2; 150 mg/day) and rats [346]. Considering proven efficacy of n-3 PUFAs in 
downgrading AA metabolism and inflammation (as described in literature review), there is a possibility 
that the lack of effect was missed due to a small sample size, or inappropriate dose used. We therefore 
aimed to systematically determine whether CO2-SFE dose dependently inhibits human platelet 
activation induced by a range of chemical agonists in vitro and compare the effect to standard fish oil 
formulations. If CO2-SFE inhibits platelet activation and aggregation, we wanted to determine the 
mechanism by which platelet function is inhibited. The results of this study were used to design an in 
vivo clinical trial that assesses the effect of Lyprinol supplementation on CVD risk factors (Chapter 4). 
In previous chapter we determined that supplementation with γ tocopherol, the most prevalent form of 
vitamin E found in plant seeds and their products [372], prevented exercise induced platelet and 
coagulation hyperactivity through as yet undetermined mechanisms. As described in literature review 
most studies concentrated on determining the mechanism by which α tocopherol ameliorates CVD risk 
factors, with very few describing the mechanism of action of γ tocopherol. Most studies concentrated 
on describing the anti-oxidative properties of both isoforms. However, apart from being potent 
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antioxidants, γ tocopherol and γ-CEHC, show anti-inflammatory potential exerted by inhibiting PGE2 
synthesis, formation of LTB4 and attenuating inflammation mediated damage in male Wistar rats [409]. 
Gamma-tocopherol and its main metabolite are capable of decreasing the COX-2 activity, possibly by 
competing with AA for the enzyme’s active site [488]. These finding led to our hypothesis that γ 
tocopherol may be able to decrease platelet COX-1 activity and interfere with AA induced platelet 
activation.  
Both CO2-SFE and γ tocopherol may therefore exhibit similarity in the way they modulate platelet 
function, since both have potential to inhibit AA induced platelet activation. We also aimed to 
determine if γ tocopherol may interfere with the platelets' AA metabolism and attenuate platelet 
activation in vitro. 
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3.2 Materials and Methods 
3.2.1 Study Population 
After obtaining institutional human research ethics approvals (19/09 and 79/11) we recruited healthy 
human volunteers. Participants were allowed to enroll if they were 18 – 60 years old, healthy and not on 
any medication known to affect platelet function for 14 days prior to enrolment. All together 6 females 
33.5 ± 10.5 years old and 6 males 32.1 ±  8.2 years old were recruited. Up to 10 mL of blood was 
collected in 3.2% (w/v) sodium citrate tubes (Vacuettes) with a ratio of 9 parts blood to 1 part 
anticoagulant on one occasion for platelet function testing. 2 mL of blood was used for flow cytometry 
testing, while 8 mL was used for platelet aggregometry.  Blood for flow cytometry was processed within 
30 minutes of collection and analysed immediately, while blood for platelet aggregation was processed 
and analysed within 3 hours of collection.  
3.2.2 Sample preparation 
CO2-SFE and standard fish oil were donated by Associate Professor Theo Macrides and Natural Products 
Research Group RMIT University. Both CO2-SFE and fish oil were dissolved in ethanol to final 
concentration of 50 mg/mL (50mg of either CO2-SFE or fish oil in 1mL of ethanol), while CO2-SFE was 
also prepared in 10 mg/mL concentration (10 mg of CO2-SFE in 1 mL of ethanol). Final concentrations of 
CO2-SFE in blood samples were 0.5 mg/mL and 0.1 mg/mL while fish oil was used at final concentration 
of 0.5 mg/mL. Those final concentrations were obtained by adding 5 µl of CO2-SFE and fish oil dissolved 
in ethanol to 500 µl PRP for platelet aggregation and 5 µl of either CO2-SFE or fish oil to 500 µl of whole 
blood for flow cytometry samples. The mixtures were incubated for 5 minutes.  (+)-γ-Tocopherol was 
purchased from Sigma –Aldrich (St. Louis, MO, USA) and dissolved in ethanol to concentration of 30 and 
60 mM. Final concentration of γ tocopherol in blood samples was 300 µM (1 in a 100 dilution with whole 
blood). Acetylsalicylic acid was purchased from Sigma-Aldrich and dissolved in ethanol giving final 
concentration in blood samples of 10 µg/mL (1 in 100 dilution in both PRP and whole blood).  Final 
concentration of ethanol in blood samples (whole blood and PRP) never exceeded 1 %. The effect of 1% 
(v/v) ethanol on LTA was compared to untreated samples in response to AA. 
Since the exact composition and molecular weight of CO2-SFE and fish oil were not known, the 
concentration of both compounds was expressed as mg/mL. Gamma tocopherol was purchased from 
Sigma - Aldrich and it had a molecular weight and density, therefore molarity was used to express 
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concentration. We believed that different expression of concentration would not influence the results or 
conclusions made as the aim of the experiment was to examine the effect of each compound on 
platelets rather than compare the strength of the effect of gamma-tocopherol to marine oils.  
3.2.3 Light Transmittance Aggregometry 
Platelet rich plasma was obtained by centrifuging samples at 250g for 10 minutes at room temperature 
without brake. Supernatant was removed, while the remainder was centrifuged at 2000g for 10 minutes 
at room temperature with brake to obtain PPP. Platelet count in PRP was measured on AcT5 Diff 
haematology analyser and was adjusted to 250x10
9
/L using Ringer citrate/dextrose buffer (108 mM 
NaCl, 38 mM KCl, 1.7 mM NaHCO3, 21.2 mM sodium citrate, 27.8 mM glucose, and 1.1 mM MgCl2),  pH 
7.4. Platelet aggregation studies were performed on 2 channel Whole Blood/Optical Lumi-Aggregometer 
(Chrono-Log Corporation, Havertown, PA) connected to AGGRO/LINK (8) software.  
3.2.3.1 CO2-SFE and agonist dose response curves 
Arachidonic acid, U-46619 and ADP dose response curves were obtained by activating 250x10
9
/L PRP 
with increasing concentrations of agonists and recording percentage of aggregation on 3 volunteers. 
PRP samples from 3 volunteers were incubated with increasing concentrations of CO2-SFE (0.01, 0.05, 
0.06, 0.08, 0.1, 0.15, 0.25, 0.5 and 1 mg/mL) or 1% (v/v) ethanol for 10 minutes at room temperature to 
obtain dose-response curves. PRP samples were allowed to stand in the aggregometer for 2 minutes at 
37°C. Instrument was calibrated to 0% and 100% absorbance as per manufacturer instruction before 
addition of 2 µM U-46619 to constantly stirred samples. Aggregation was recorded for 6 minutes and 
maximal aggregation, expressed as percentage, recorded. 
Platelets aggregation was chosen instrument to obtain marine oil dose response curves. The inhibition 
of platelet function was more prominent than if using flow cytometry due to lower variability of results. 
Dose response curves were not performed for gamma tocopherol as the effect of gamma tocopherol on 
platelet function was tested only by flow cytometry. Chapter 1 and 2 of this thesis summarise studies 
that investigated the effect of gamma tocopherol on platelet aggregation. 
3.2.3.2 The effect of supplements on light transmission aggregometry (LTA) 
After obtaining dose response curves, PRP samples from 6 volunteers were incubated with final 
concentrations of 1% ethanol, 0.5 mg/mL and 0.1 mg/mL CO2-SFE, 0.5 mg/mL fish oil and 10 µg/mLASA 
119 
 
for 10 minutes. LTA was performed on treated PRP samples in response to stimulation with 0.5 mM AA, 
10 µM ADP and 2 μM U-46619. Maximum amplitude at 6 minutes versus PPP control was recorded. For 
this part of the study 3 female and 3 male volunteers participated. 
3.2.3.3 Labile aggregation-stimulating substance (LASS) test on CO2-SFE treated samples 
LASS test was performed to test the ability of TxA2 to induce platelet aggregation after incubation with 
CO2-SFE. 900 µL of control PRP that contained 1% (v/v) ethanol and 400 µL of test PRP were used for the 
experiment. Control PRP was activated with 0.5 mM AA and aggregation recorded. When 50% 
aggregation was achieved in control plasma, 200 µL of it was transferred to the test plasma. Test plasma 
was treated with 10 µg/mL ASA, 0.5 mg/mL CO2-SFE or a combination of 10 µg ASA/0.5 mg/mL CO2-SFE. 
Aggregation was started and measured for 6 minutes, with maximal aggregation being recorded.  
3.2.4 Flow Cytometry 
The effect of CO2-SFE and γ tocopherol on platelet activation was investigated.  Whole blood samples 
were incubated with final concentration of 1% (v/v) ethanol, 10 µg/mL ASA, 0.5 mg/mL and 0.1 mg/mL 
CO2-SFE, 0.5 mg/mL fish oil and 300 μM γ tocopherol for 10 minutes at 37°C.  
Whole blood flow cytometric analysis of platelet surface P-selectin expression and integrin αIIbβ3 
receptor activation, as reported by PAC-1 binding, was performed as previously described [435]. Briefly, 
treated whole blood was labeled with phycoerythrin/cyanin 5 (PC5) conjugated CD42b (BD Pharmingen, 
Becton, Dickinson and Company, California, USA; clone HIP1) and either phycoerythrin (PE) conjugated 
P-selectin (CD62P, BD Pharmingen, Becton, Dickinson and Company, Franklin Lakes, New Jersey; clone 
AK4) and fluorescein isothiocyanate (FITC) conjugated PAC-1 (Becton, Dickinson and Company, 
California, USA) or PE conjugated mouse IgG1κ isotypic control (BD Pharmingen; Becton, Dickinson and 
Company, Franklin Lakes, New Jersey) with FITC PAC-1 blocked by 2.5 μg/mL eptifibatide (Millennium 
Pharmaceuticals, Cambridge, MA). Final antibody concentrations were 0.5 µg/mL.  Simultaneously, 
aliquots were incubated with 0.3 mM AA (Chrono-Log Corporation, Havertown, PA), 5 μM ADP (Chrono-
Log Corporation, Havertown, PA), 0.5 and 5 μM U-46619 (Cayman Chemical Company, Michigan), 10μM 
calcium ionophore (A23187; Sigma-Aldrich, St. Louis, MO). In addition, CO2-SFE treated samples were 
also incubated with 5 and 20 μM thrombin receptor activator peptide 6 (TRAP; Sigma-Aldrich, St. Louis, 
MO) and 20 µg/mL collagen (Chrono-Log Corporation, Havertown, PA). Incubation with antibodies and 
agonists was performed for 15 minutes at 37°C. The reaction was stopped by addition of 25:1 volume of 
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1% (v/v) formaldehyde in HEPES buffered saline, pH 7.4. Samples were analysed on BD FACSCanto II flow 
cytometer, equipped with a solid state blue laser operating at 488 nm connected to a BD FACSdiva 
acquisition and analysis software. Platelets were identified by characteristic forward and side light 
scatter (log scale) and an expression of CD42b and then for PAC1 and P-selectin expression, recorded as 
mean fluorescence intensity (MFI).  For this part of the study 5 male and 5 female volunteers were 
recruited. 10 volunteers were tested for all agonists except calcium ionophore, where n=8 and TRAP and 
collagen where n=6.  
3.2.5 Kinetic assay of calcium mobilisation in platelets treated with CO2-SFE and γ 
tocopherol 
The method for measurement of rise in platelet cytosolic calcium in whole blood samples treated with 
either 0.5 mg/mL CO2-SFE, 300 μM γ tocopherol or 1% ethanol was adapted from Ceu Monteiro et.al. 
[489]. 
Briefly, whole blood collected in 3.2% (w/v) sodium citrate was incubated with 1% (v/v) ethanol, 0.5 
mg/mL CO2-SFE and 300 μM γ tocopherol for 10 minutes at 37°C. Samples were then diluted 1 in 10 with 
modified Tyrode’s buffer (MTB; 137 mM NaCl, 2.8 mM KCl, 1 mM MgCl2, 12 mM NaHCO3, 0.4 mM 
Na2HPO4, 0.35% BSA, 10 mM HEPES, 5.5 mM glucose, pH 7.4). Diluted blood was incubated at 37°C for 
15 minutes with 10 μM Fluo-3 AM from 1 mM stock solution in DMSO purchased from Molecular Probes 
®.  Fluo-3 AM concentration was optimised by incubating samples with 1, 2, 5, 10 and 20 μM Fluo-3 AM 
(n=3). Incubation times were optimised by incubating samples for 5, 10, 15 and 20 minutes with Fluo-3 
AM (n=3).  Blood loaded with calcium probe was incubated with 2 µg/mL CD42a PE (BD Pharmingen; 
Becton, Dickinson and Company, Franklin Lakes, New Jersey) for 15 minutes at room temperature. 
Samples were diluted 1 in 30 with MTB and analysed on BD FACS Canto II flow cytometer (Becton 
Dickinson, Sydney, NSW). Platelets were identified by characteristic forward and side scatter 
(logarithmic scale) and CD42a positivity. All samples were analysed using low acquisition speed counting 
10000 platelets.  
In order to obtain agonist dose response curves and test for leakage of the dye, a scatter plot of time 
versus FL-1 was created and regions, each representing approximately 30 second interval, were drawn 
on the time axis. Mean fluorescence intensity of FL1 for each time region was recorded. BD FACS Canto 
II and analysis software only contains an arbitrary time axis, and the 30 second interval regions created 
were not identical with some slightly overlapping.  Consequently, after verifying conditions of the 
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protocol and determining the agonist concentrations required for further experiments, FITC positivity of 
double gated platelet population was recorded as MFI. Total FITC MFI (labeled as total calcium flux) was 
recorded as well as MFI of the FITC positive population (labeled later as maximal flux).  
Samples were run for the first 30 seconds to obtain baseline Fluo-3 AM fluorescence. Acquisition was 
then stopped.  Agonist was added and acquisition resumed. Dose response curves were obtained for AA, 
ADP and U-46619 (n=3). The leakage of calcium was tested by running the sample loaded with 10 μM 
Fluo-3AM for 15 minutes (n=3).Agonists used in calcium mobilisation experiments were 20 μM ADP, 0.6 
mM AA, 0.5 μM U-46619, 10 μM calcium ionophore and 10 μM TRAP and tested for additional 150 
seconds (total recording time was 3 minutes) on flow cytometer. 
After performing the first set of experiments, 10 µg/mL ASA was used to block platelet COX-1, CAY10449 
(Cayman Chemical Company, Ann Arbour, Michigan) was used to antagonise platelets’ IP receptor and 
SQ 29,548 (Cayman Chemical Company, Ann Arbor, Michigan) was used to antagonise platelets’ TP 
receptor. Whole blood was incubated for 10 minutes at 37°C with blocking agents. Ethanol (1% (v/v)), γ 
tocopherol (300 μM) and CO2-SFE (0.5 mg/mL) were added and samples incubated for further 15 
minutes at 37°C. Platelets were then loaded with Fluo-3AM as previously described and platelet calcium 
mobilisation in response to AA, U-46619, A-23187, TRAP and/or ADP measured (same concentrations as 
previously described). Samples were kept in the dark at all times. 
3.2.6 Statistical analysis 
GraphPad Prism 5 was used for all data analysis. Student’s paired t-test was used to compare two sets of 
results while repeated measures ANOVA was used for in vitro study comparing more than 2 groups. 
Bonferroni multiple comparison test was used to compare all sets of data while Dunnett’s multiple 
comparison test was used to compare sets of data to the control sample. Power calculations before and 
after experiments were performed using GraphPad StatMate 2.00. 
Sample size was determined before the experiment. For platelet aggregation, it was estimated that a 
standard deviation of the difference was 10. Standard deviation of the difference was estimated was 10 
based on previously done platelet aggregation experiments in out laboratory. Sample size of 3 was 
required to see the difference of at least 30 with 99% power between CO2-SFE treated and untreated 
samples; alpha (0.05, two tailed). 
122 
 
Flow cytometric data, it was estimated that the standard deviation of the difference would be 400, 
measured in MFI.  In order for experiment to detect the difference of 400 MFI with 90% power, 10 
volunteers needed to be recruited (alpha 0.05). 
Power calculations were performed after the experiments examining calcium influx were completed 
using Graph Pad StatMate. The difference of the means was compared (AA induced flux was used as 
example), and while study was adequately powered to detect the difference between CO2-SFE treated 
samples and vehicle control, we had 75% - 80% power to detect difference between γ tocopherol and 
vehicle control.   
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3.3 Results 
Oils, γ tocopherol and ASA were all dissolved in ethanol, which can have both pro-aggregatory and 
inhibitory effect on platelets. Consequently, platelet rich plasma samples were treated with 1% (v/v) 
ethanol and the LTA induced by AA compared to untreated samples.  As shown in Figure 3.1, 1% (v/v) 
ethanol had no significant effect on 0.5 mM AA induced LTA in comparison to untreated PRP samples 
(p>0.05; n=4). 
3.3.1 Dose response curves of AA, ADP and U-46619 mediated platelet aggregation and the 
effect of different CO2-SFE concentrations on platelet aggregation  
We aimed to find the optimal concentrations of agonists used in this study. Optimal agoniost 
concentrations were those that were the lowest for each agonist, but sufficient to induce full platelet 
aggregation.  We also aimed to determine the concentration of CO2-SFE that inhibits platelets. 
250x10
9
/L PRP samples were activated with 0.1 - 1.0 mM AA, 2.5 - 20 µM ADP and 0.5 - 4 µM U-46619.  
After agonist concentrations were selected, 250 x 10
9
/L PRP was treated with CO2-SFE concentration 
ranging from 0.01 to 1 mg/mL and activated with 2 µM U-46619. Percentage of aggregation and 
inhibition were recorded. As shown in Figure 3.2A  when 250x10
9
/L PRP was stimulated with 0.1 - 1.0 
mM AA, there was a dose-dependent increase in slope and amplitude of platelet aggregation that 
plateaued at 0.5 mM AA. In contrast, 250x10
9
/L PRP  stimulated with 2.5 - 10 µM ADP mediated 
aggregation, displayed a dose dependent increase in slope and amplitude of platelet aggregation that 
plateaued at 10 µM ADP (Figure 3.2B).  250x10
9
/L PRP  stimulated with  0.5 - 4.0 µM U-46619 mediated 
aggregation, induced a potent increase in platelet aggregation that plateaued at 2 µM U-46619. Based 
upon these results  0.5 mM AA, 10 µM ADP and 2 µM U-46619 were used for further studies.  As shown 
in Figure 3.3, incubation of PRP with CO2-SFE inhibited 2 μM U-46619 induced LTA in dose dependent 
manner.  Incubation of PRP with 0.5 mg/mL CO2-SFE inhibited aggregation by more than 50% (Figure 
3.3A), while incubation with 0.1 mg/mL caused 25% inhibition (Figure 3.3B). The two doses were 
selected for further studies. 
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Figure 3-1: The effect of 1% (v/v) ethanol on platelet rich plasma aggregation in 0.5 mM arachidonic acid induced samples. 
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Figure 3-2: Agonist dose response curves for light transmission aggregometry. 
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Figure 3-3: The effect of 0.01 – 1 mg/mL CO2-SFE  concentration on 2 µM U-46619 platelet aggregation. 
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3.3.2 The effect of CO2-SFE on Light Transmittance Aggregometry 
Since CO2-SFE dose dependently inhibited platelet aggregation, we aimed to determine the pathways 
that are affected as well as to compare its effect with fish oil and aspirin in order to elucidate 
mechanism of inhibition. In order to test the effect of CO2-SFE on LTA, 250x10
9
/L PRP was treated with 
1% (v/v) ethanol, 0.5 and 0.1 mg/mL CO2-SFE, 0.5 mg/mL fish oil and 10 µg/mL ASA. Platelet aggregation 
was induced with 0.5 mM AA, 2 µM U-46619 and 10 µM ADP. As shown in Figure 3.4 treatment of 
250x10
9
/L PRP with CO2-SFE  dose dependently inhibited LTA induced by 0.5 mM AA (A), 2 μM U-46619 
(B) and 10 μM ADP (C) better than the equivalent concentration of fish oil. AA induced LTA was 
completely inhibited by 0.5 mg/mL CO2-SFE (mean aggregation 4.5% ± 4.5 for CO2-SFE treated samples 
while 1% (v/v) ethanol treated samples showed 89.8% ± 3.5, p<0.001; n=6). 0.5 mg/mL fish oil treated 
samples had mean aggregation of 45.3% ± 3.5, which was not statistically different to samples treated 
with 0.1 mg/mL CO2-SFE that showed aggregation of 58.3% ± 12.4 (n=6). The inhibition of AA induced 
platelet aggregation by 0.5 mg/mL CO2-SFE was not statistically different to the inhibition caused by ASA 
(p>0.05; n=6).  
As shown in Figure 3.4B, 0.5 mg/mL CO2-SFE showed less 2 μM U-46619 induced aggregation (10.7% ± 
4.8) than vehicle control (92.0% ± 3.9; p<0.001; n=6), fish oil (44.5% ± 4.6; p<0.001; n=6) and ASA (85.7% 
±3.2; p<0.001; n=6). There was no statistically significant difference (p>0.05; n=6) between inhibition 
caused by fish oil and 0.1 mg/mL CO2-SFE (62.7% ± 5.4). 
As shown in Figure 3.4C, a similar pattern of results was observed in 10 μM ADP induced LTA, where 
vehicle control showed 80.8% ± 4.6 aggregation. 0.5 mg/mL CO2-SFE (21.2% ± 3.1) inhibited aggregation 
better than 0.5 mg/mL fish oil (44.0% ± 3.1; p<0.01; n=6), ASA (62.0% ± 6.8; p<0.001; n=6) and 0.1 
mg/mL CO2-SFE (62.8% ± 3.8). Inhibition of aggregation by 0.1 mg/mL CO2-SFE was equivalent to that of 
ASA (p>0.05; n=6) and less than fish oil (p<0.05; n=6).   
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Figure 3-4: : The effect of CO2-SFE on light transmission aggregometry. 
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3.3.3 The effect of CO2-SFE and γ tocopherol on P-selectin and PAC-1 expression 
 
The inhibitory effect of CO2-SFE on platelet function was further investigated by estimation of platelet 
degranulation and activation and compared to fish oil and aspirin. The effect of γ tocopherol on platelet 
activation and degranulation was also investigated. A range of agonists activating platelets' different 
pathways was used to determine the inhibitory mechanism of both compunds.  In order to examine the 
effect of CO2-SFE and γ tocopherol on P-selectin expression and PAC-1 binding whole blood was treated 
with 1% (v/v) ethanol, 10 µg/mL ASA, 0.5 mg/mL and 0.1 mg/mL CO2-SFE, 0.5 mg/mL fish oil and 300 µM 
γ tocopherol. Samples were activated with 0.3mM AA, 5 µM ADP, 0.5 and 5 µM U-46619. Platelet 
degranulation was measured by the expression of P-selectin, while PAC-1 binding represented platelet 
activation.  As shown on Figures 3.5 A-F representing  agonist dose response curves for P-selectin and 
PAC-1 expression, increasing concentrations of each agonist produced dose-dependent P-selectin 
exposure and PAC-1 binding. Based on the dose response curves, selected agonists concentrations were 
0.3 mM AA, 5 μM ADP and 0.5 μM U-46619 (low U-46619) as they produced saturable P-selectin 
exposure and PAC-1 binding. 5 μM U-46619 (high U-46619) was also included in the analysis as positive 
control. As shown in Figure 3.6D, treatment of whole blood with 0.5 mg/mL CO2-SFE inhibited 0.5 µM U-
46619 PAC-1 and P-selectin (Figure 3.7D) expression while 300 μM γ tocopherol inhibited 0.3 mM AA 
induced platelet activation (Figure 3.6B) and degranulation (Figure 3.7D). 0.1 mg/mL CO2-SFE and 0.5 
mg/mL fish oil had no inhibitory effect on any parameters measured (p>0.05; n=10).  The results for the 
expression PAC-1 and P-selectin of aspirinated samples were expected, with strong inhibition (p<0.001; 
n=10) of AA induced activation and degranulation.  
Specifically, 0.5 mg/mL CO2-SFE decreased 0.5 μM U-46619 induced PAC-1 expression from 4593 ± 630 
MFI to 2939 ± 485 MFI as shown on Figure 3.6D and P-selectin expression from 17697 ± 2719 MFI to 
7976 ± 1608 MFI as shown on Figure 3.7D (p< 0.001 when analysed using repeated measures ANOVA 
with Dunnett’s multiple comparison test; n=10). 300 μM γ tocopherol was a weak inhibitor of 0.3 mM 
AA induced PAC-1 expression, decreasing MFI from 1582 ± 266 to 1095 ± 162 as shown on Figure 3.6B 
and P-selectin expression decreasing MFI from 6117 ± 1083 to 3358 ± 528 as shown on Figure 3.7B, 
p<0.05; n=10. 
Higher resting platelet P-selectin expression was observed in 0.5 mg/mL CO2-SFE (801 ± 134 MFI) than in 
vehicle control (538 ± 63 MFI); however upon addition of agonists the hyperactivity was ameliorated. 
0.5 mg/mL fish oil treated samples showed the same pattern of results with P-selectin expression 
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increasing to 755 ± 93 MFI and PAC-1 expression increasing from 624 ± 90 MFI in vehicle control to 965 ± 
134 MFI (p<0.05; n=10) and the hyperactivity was ameliorated in 5 μM U-46619 and 10 μM ADP induced 
samples, while it remained higher than vehicle control in 0.3 mM AA and 0.5 μM U-46619 activated 
platelets.  
3.3.4 Mechanism of inhibition of platelet function by CO2-SFE and γ tocopherol 
In order to decipher the mechanism by which CO2-SFE and γ tocopherol inhibit platelet function, further 
experiments were performed using only those two supplements. 
3.3.4.1 The effect of CO2-SFE and γ tocopherol on P-selectin exposure and PAC-1 expression 
To ensure both CO2-SFE and γ tocopherol interact only with AA pathway, whole blood was also activated 
with A23187 and tested for PAC-1 (Figure 3.8A) and P-selectin (Figure 3.8B) expression (n=8). 0.5 mg/mL 
CO2-SFE decreased 10 μM A23187 induced PAC-1 expression from 2654 ± 489 MFI to 1943 ± 330 MFI 
(p<0.01; n=8) and P-selectin expression from 12348 ± 2184 MFI to 5269 ± 1109 MFI (p<0.001; n=8) when 
results were analysed using repeated measures ANOVA with Dunnett’s multiple comparison test.        
300 μM γ tocopherol showed tendency for decreased PAC-1, with MFI decreasing to 2129 ± 418 and P-
selectin, with decreasing MFI to 9242 ± 1766 expression, but difference did not reach statistical 
significance when results were analysed using repeated measures ANOVA with Dunnett’s multiple 
comparison test. Due to non-Gaussian distribution of data for PAC-1 expression, significance of results 
was checked by reanalysing data using non-parametric Friedmann method with Dunn’s multiple 
comparison test. Results were in agreement with previous analysis, where 0.5 mg/mL CO2-SFE inhibited 
platelet activation and degranulation (p<0.01; n=8), while γ tocopherol showed tendency for inhibition. 
CO2-SFE however had no inhibitory effect on TRAP or collagen induced activation and degranulation as 
shown on Figure 3.9. 
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Figure 3-5: Agonist dose response curves (PAC-1 and P-selectin). 
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Figure 3-6: PAC-1 expression in samples treated with CO2-SFE, fish oil, ASA and γ tocopherol. 
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Figure 3-7: P-selectin expression in samples treated with CO2-SFE, fish oil, ASA and γ tocopherol. 
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Figure 3-8: PAC-1 and P-selectin expression in samples treated with CO2-SFE and γ tocopherol, activated with 10 µM A23187. 
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Figure 3-9: The effect of CO2-SFE on TRAP and collagen induced platelet activation and degranulation. 
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3.3.4.2 The effect of CO2-SFE on Labile Aggregation Stimulating Substance test 
The following experiment was performed after analysing flow cytometric and LTA data with hypothesis 
that CO2-SFE may inhibit platelet function due to production of TxA2-like compounds with help of COX-1 
that occupy platelets’ TP receptor as shown on Figure 3.10. LASS test was performed to further examine 
the direct effect of TxA2 induced aggregation on CO2-SFE treated PRP. U-46619 has high affinity for 
platelets’ TP receptor but it is a PGH2  analogue that may or may not require TxAS for its action. 
Aggregation of control PRP in response to AA suggests that sufficient TxA2 has been produced to activate 
platelets. Transfer of an aliquot of aggregating control PRP into the test PRP transfers formed TxA2. Any 
aggregation observed in the test sample is attributable to the effect of TxA2. An aliquot of control 
sample was, after activation with AA transferred to ASA, CO2-SFE and ASA and CO2-SFE treated samples. 
As shown in Figure 3.11, CO2-SFE inhibits TxA2 induced platelet aggregation (n=3) equivalently with or 
without blocking platelets’ COX-1 by 10 µg/mL ASA. Aggregation was reduced from 69% in untreated 
and aspirinated samples by 50% in 0.5 mg/mL CO2-SFE treated samples (Table 3.1). 
  
 Figure 3-10: Proposed mechanism for CO2-SFE inhibition of platelet function. 
 
 
Figure 3.10: Proposed mechanism for CO2-SFE inhibition of platelet function 
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 Figure 3-11:  Labile aggregation stimulating substance testing in CO2-SFE treated samples.  
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Table 3-1: Labile aggregation stimulating substance testing in CO2-SFE treated samples. 
 
 
 AA induced control PRP (n=3)  
% aggregation in CO2-SFE treated samples  29% ± 2.5  
% aggregation in CO2-SFE +ASA treated samples  25% ± 0.0  
% aggregation in ASA treated samples  65% ± 4.0  
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3.3.5 Calcium flux in CO2-SFE and γ-tocopherol treated samples 
 
Both CO2-SFE and γ tocopherol inhibit platelet activation by acting on arachidonic acid pathway. Since 
calcium mobilisation is an important event in platelet activation process and can be inhibited by cAMP 
level, the effect of those two compounds on calcium flux was evaluated. The method for measurement 
of rise in platelet cytosolic calcium in whole blood samples was adapted from Ceu Monteiro et.al. [489]. 
Whole blood samples were treated with either 0.5 mg/mL CO2-SFE, 300 μM γ tocopherol or 1% (v/v) 
ethanol. Additional experiments were performed where ASA was used to block platelet COX-1, 
CAY10449 to antagonise platelets’ IP receptor  and SQ 29,548 to antagonise platelets’ TP receptor 
before treating whole blood with CO2-SFE and γ tocopherol. 
3.3.5.1 Method optimisation 
Experimental procedure was optimised by firstly performing a dose response curve for Fluo-3 AM 
concentration in whole blood. As shown on Figure 3.12, loading platelets with 10 μM Fluo-3 AM 
produced the highest difference in fluorescence between resting and activated platelets and highest 
increase in MFI ratio, with smallest SEM, and was therefore chosen for further experiments. While 2 µM 
Fluo-3 AM produced the highest ratios, the increase in MFI upon addition of ADP  was too small to be 
accurately determined.  As shown on Figure 3.13, this concentration on Fluo-3 AM demonstrated 
stability and no calcium leakage was observed over 15 minutes interval. Coefficients of variation for 
each volunteer are displayed on the table near the figure and they were 1.95%, 3.56% and 3.19%. 
In order to determine the optimal incubation time of Fluo-3 AM in whole blood, 10 µM Fluo-3 AM was 
incubated from 5 to 20 minutes at 37˚C and MFI and MFI ratios recorded. As shown in Figure 3.14, 15 
minutes incubation with 10 μM Fluo-3 AM showed the highest MFI (Figure 14A) and MFI ratios (Figure 
14B) after activation with 10μM ADP. Incubation for 5 minutes produced the highest ratios but the 
increase in MFI was minimal. 
In order to determine the optimal agonist concentrations for calcium kinetics experiments, whole blood 
was incubated with 10 µM Fluo-3 AM for 15 minutes at 37°C before being labeled with 2 µg/mL CD42a 
PE for 15 min at room temperature. After obtaining baseline fluorescence for 30 seconds, increasing 
ADP (5-20 µM), AA  (0.2 - 0.6 mM) and U-46619 (0.5-5 µM) were added to activate sample to obtain 
dose-response curves (Figure 3.15). U-46619 showed brief increase in cytosolic calcium over 
approximately 10 second period, and highest MFI and MFI ratios were observed with 0.5 μM. 0.4 mM 
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AA showed small increase in cytosolic calcium that quickly returned to normal, while 0.6 mM AA 
produced high increase that continues to rise after 180 seconds and was therefore chosen for further 
experiments. There was a small difference in cytosolic calcium increase between 5, 10 and 20 μM ADP; 
however 20 μM ADP was chosen as it showed highest increase at the beginning of activation. Due to 
variability of response to ADP induced platelet activation, highest dose was selected to decrease inter-
individual variability. 
In order to check for compartmentalisation of Fluo-3 AM in platelets, they were loaded with Fluo-3 AM 
at 37°C and at room temperature [490].  As shown in Figure 3.16, while 15 min was sufficient time for 
loading the probe at 37°C before labeling with antibody (additional 15 minutes), a stable baseline was 
not obtainable when platelets were loaded at room temperature for 15 minutes before being labeled 
with CD 42aPE for additional 15 minutes. In contrast, a stable baseline was obtained after at least 40 
minutes incubation at room temperature. Results from 2 volunteers were compared (Figure 3.16) after 
stimulation with AA and ADP. In addition, faster loading time of Fluo-3 AM at 37°C was observed with 
minimal difference in MFI. Therefore, this temperature was chosen for further experiments.  
3.3.5.2 The effect of CO2-SFE and γ - tocopherol on platelet calcium mobilisation 
Considering that flow cytometer is not capable of displaying the exact but rather arbitrary time – axis, 
calcium movement could not be measured in exact but rather approximate 30 second intervals, some of 
which were overlapping as shown on Figure 3.17. Average MFI of each 30 second interval was then 
recorded over 180 second interval (30 seconds before agonist addition and 150 seconds after agonist 
addition). This was used to optimise methodology, however, due to many approximations created with 
this analysis, total calcium flux and maximal calcium flux were analysed (Figure 3.18) to investigate the 
effect of CO2-SFE and γ tocopherol on calcium kinetics in platelets. An example of results obtained after 
treating whole blood with CO2-SFE and γ tocopherol is shown on Figure 3.19. 
In this set of experiments 0.6 mM AA, 10 µM A23187, 10 µM TRAP, 0.5 µM U-46619 and 20 µM ADP 
were used as agonists to investigate if either γ tocopherol or CO2-SFE interfere with platelet calcium flux 
and which platelet activating pathways may be affected. As shown on Figure 3.20, both CO2-SFE and γ 
tocopherol inhibited platelet calcium flux in 0.6 mM AA, 10 µM A23187 and 10 µM TRAP activated 
samples (Figure 3.20). Total calcium flux in AA activated samples (Figure 3.20A) decreased from 4310 ± 
566 MFI in vehicle control to 3032 ± 585 MFI in CO2-SFE treated samples (p<0.05, n=6) and 2871 ± 605 
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MFI (p<0.05; n=6) in γ tocopherol treated samples. Calcium ionophore induced flux (4364 ± 592 MFI in 
vehicle control) as shown on Figure 3.20C was also mildly reduced (p<0.05, n=6) in CO2-SFE (3651 ± 433 
MFI) and γ tocopherol (3490 ± 444 MFI) treated samples. 
CO2-SFE had higher inhibitory effect on total TRAP induced calcium flux (Figure 3.20E), decreasing it 
from 678± 56 MFI in Vehicle control to 588 ± 43 MFI (p<0.01; n=6) than γ tocopherol (602 ± 50; p<0.05; 
n=6). When calcium flux was measured in positive population only (Figure 3.20F), γ tocopherol (633 ± 50 
MFI) was not different to vehicle control (705 ± 55), p>0.05, n=6 while CO2-SFE still showed mild 
inhibitory effect (601± 41 MFI). 
Neither CO2-SFE, nor γ tocopherol influenced platelet calcium flux in response to ADP and U-46619 
(Figure 3.21). Lack of inhibition of calcium flux by CO2-SFE in 0.5 µM U-46619 (Figure 3.21C, D) activated 
samples was somewhat surprising as in all previous experiments CO2-SFE had inhibitory effect on U-
46619 induced activation.  Total calcium flux decreased from 565 ± 42 in vehicle control to 523 ± 36 in 
CO2-SFE treated platelets, but results were not statistically significant (p>0.05, n=6) when results were 
analysed using repeated measures ANOVA with Dunnett’s post test. 
3.3.5.3 The effect of COX-1, IP and TP receptors on calcium influx in CO2-SFE and γ-tocopherol 
treated platelets 
Considering that both γ tocopherol and CO2-SFE interfere with platelet calcium influx, further 
experiments were performed to elucidate the mechanism responsible for this response. Taking into 
account previous experiments (P-selectin and PAC-1 expression), both products mainly influenced AA 
pathway of platelets as well as A23187 activation, therefore COX-1, TP receptor and IP receptor were 
blocked in the following experiments before addition of either γ tocopherol or CO2-SFE, and calcium 
influx was measured. In parallel to that, experiments were performed in blood without blocked COX-1 or 
receptors. 
3.3.5.3.1 Arachidonic acid induced calcium influx  
Figure 3.22 shows calcium flux in 0.6 mM AA activated samples. Figures 3.22 A and B demonstrate that 
both CO2-SFE and γ  tocopherol inhibit total calcium flux after AA induced activation, similar to previous 
results. After blocking platelet IP receptor (Figure 3.22 C and D), the inhibitory effect of the CO2-SFE was 
ameliorated while γ tocopherol still retained inhibitory effect. Treatment of whole blood with γ 
tocopherol after blocking IP receptor inhibited calcium flux in response to AA from 6270 ± 945 MFI in 
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vehicle control to 4667 ± 794 MFI. Interestingly, there was statistically insignificant increase in CO2-SFE 
increase in calcium flux (6643 ± 954 MFI) after blocking IP receptor suggesting that production of cAMP 
by oil may decrease platelet activity. 
3.3.5.3.2 A23187 induced calcium flux 
In order to investigate the role of calcium channels, calcium ionophore was used to induce calcium flux 
as shown in Figure 3.23 A and B. CO2-SFE and γ tocopherol, similarly to previous results inhibited calcium 
flux upon activation with calcium ionophore. In addition, blockage of COX-1 ameliorated inhibitory 
potential of CO2-SFE and γ tocopherol, with total fluorescence changing from 4565 ± 652 MFI in vehicle 
control, 4662 ± 666 MFI in CO2-SFE treated sample and 4283 ± 608 MFI in γ tocopherol treated samples 
(Figures 3.23 C and D). In contrast,  while blockage of IP and TP receptors prevented inhibition of 
calcium flux upon A23187 stimulation in CO2-SFE treated samples (Figure 23 E-H), while it had no effect 
on γ tocopherol treated samples. γ tocopherol decreased total calcium flux from 5359 ± 345 MFI (vehicle 
control) to 4900 ± 250 (p<0.05; n=6) in platelets with antagonised TP receptor, and from 5043 ± 398 
(vehicle control) to  4242 ± 543 (p<0.01, n=6). 
3.3.5.3.3 TRAP induced calcium flux  
Both CO2-SFE (p<0.01) and γ-tocopherol (p<0.05, n=5) inhibited 10 µM TRAP induced platelet calcium 
flux in comparison to vehicle control (Figure 3.24). Inhibition of platelets’ COX-1 ameliorated the 
inhibitory effect of both compounds. Blocking of IP receptor, in this case prevented the ability of γ 
tocopherol to inhibit TRAP induced flux on the contrast to above described agonists, and the total MFI 
changed from  918 ± 66 MFI in vehicle control to 900 ± 84 in γ tocopherol, p>0.05, n=5 (900 ± 77 MFI in 
CO2 SFE treated samples). While blocking of platelets’ TP receptor inhibited the effect of CO2-SFE (966 ± 
91 MFI in vehicle control to 917 ± 86 MFI in CO2-SFE treated samples), it had no effect on γ tocopherol 
treated samples (903 ± 82; p<0.05; n=5). 
3.3.5.3.4 ADP and U-46619 induced calcium flux 
We investigated ADP and U-46619 induced calcium flux in platelets with blocked COX-1, IP and TP 
receptor as shown on Figures 3.25 and 3.26 respectively. This data was in agreement with previous, 
where neither compound had any effect on calcium changes induced by those two agonists. There as a 
small but significant (p>0.05; n=5) tendency of both compounds to  increase the response to U-46619 
induced activation in platelets with blocked COX-1. Total calcium flux was increased from 695 ± 79 MFI 
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to 751 ± 105 MFI in γ tocopherol treated samples, while the MFI of positive population increased from  
2066 ± 324 MFI to 2314 ± 334 MFI in CO2-SFE treated samples (Figure 3.26). 
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Figure 3-12: Optimisation of Fluo-3 AM concentration.  
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Figure 3-13: Stability of cytosolic calcium measurement in blood loaded with 10 µM Fluo-3 AM.  
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Figure 3-14: Optimal incubation time of blood with 10 µM Fluo-3 AM. 
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Figure 3-15: Agonist dose-response curves in calcium kinetics experiments.  
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Figure 3-16: Fluo-3AM loading temperature. 
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Figure 3-17: Determination of calcium kinetics in platelets. 
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Figure 3-18: Determination of calcium kinetics in platelets.  
 
Figure 3.18: Determination of calcium kinetics in platelets 
After loading platelets with Fluo-3 AM and labeling with CD42a PE, flow cytometric testing of calcium mobilisation was 
performed on flow cytometer.Platelets were gated  (gate P1) on logarithmic FS and SS (A). All events in that (P1) gate staining 
positive for CD42a PE (B) were gated (P2) and identified as platelets. Platelets (P1+P2) were tested for increased FITC 
fluorescence after agonist addition. Total FITC  fluorescence (red gate, graph C) was recorded as total calcium flux. Blue gate 
(graph C) was recorded as calcium flux of positive population only. Blue gate limits were created on platelet population before 
addition of agonists, and it was not changed during experiment.  This gate allowed for monitoring baseline variability between 
samples. While calcium flux of positive population only could be influenced and skewed by accidental highly positive peak from 
few cells, total flux is more stable and less prone to artifactual highly positive single cell. Total flux was also not influenced by 
small baseline variabilities between samples. FITC fluorescence of platelet population was also plotted against arbitrary time 
axis (D). This was used to determine the baseline fluorescence for 30 seconds and increase in fluorescence after agonist 
addition over 150 second interval.  
  
 Figure 3-19: Calcium kinetics in platelets. 
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Figure 3-20: The effect of CO2-SFE and γ tocopherol on platelet calcium flux  
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Figure 3-21: The effect of CO2-SFE and γ tocopherol on platelet calcium flux. 
Figure 3.21: The effect of CO2-SFE and γ tocopherol on platelet calcium flux. 
Whole blood was treated with 1% (v/v) ethanol, 0.5 mg/mL CO2-SFE and 300 µM γ tocopherol. After loading platelets with Fluo-
3 AM and labeling with CD42a PE, flow cytometric testing of calcium mobilisation was performed on flow cytometer. Samples 
were stimulated with 20 µM ADP (A,B) and 0.5 µM U-46619 (C, D) after obtaining baseline fluorescence for 30 seconds and 
tested for additional 150 seconds. Total FITC fluorescence (A and C) was recorded as well as the fluorescence of positive 
population only (B and D). Calcium flux was not inhibited by CO2-SFE or γ tocopherol in samples activated with ADP and U-
46619. 
Results were expressed as mean ± SEM and analysed using repeated measures ANOVA with Dunnett’s multiple comparison 
test.  
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Figure 3-22: The effect of CO2-SFE and γ tocopherol on AA induced calcium flux  in platelets with blocked IP receptor. 
 
Figure 3.22: The effect of CO2-SFE and γ tocopherol on AA induced calcium flux  in platelets with blocked IP receptor. 
Whole blood was treated with 1% (v/v) ethanol, 0.5 mg/mL CO2-SFE and 300 µM γ tocopherol before (A,B) and after (C,D) 
blocking IP receptor  with CAY10449. After loading platelets with Fluo-3 AM and labeling with CD42a PE, flow cytometric testing 
of calcium mobilisation was performed on flow cytometer.  
Samples were stimulated with 0.6 mM AA after obtaining baseline fluorescence for 30 seconds and tested for additional 150 
seconds. Total FITC fluorescence (A and C) was recorded as well as the fluorescence of positive population only (B and D).  
The inhibitory effect of CO2-SFE was ameliorated after blocking platelets’ IP receptor (p>0.05 in comparison to vehicle control; 
n=6), while γ tocopherol  continued to show mild inhibition (p<0.05 in comparison to vehicle control; n=6).  
Results were expressed as mean ± SEM and analysed using repeated measures ANOVA with Dunnett’s multiple comparison 
test. * indicates p<0.05.  
  
156 
 
Figure 3-23: The effect of CO2-SFE and γ tocopherol on A23187 induced calcium flux  in platelets with blocked COX-1, TP or IP receptor. 
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Figure 3-24: The effect of CO2-SFE and γ tocopherol on TRAP induced calcium flux  in platelets with blocked COX-1, TP or IP receptor. 
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Figure 3-25: The effect of CO2-SFE and γ tocopherol on ADP induced calcium flux  in platelets with blocked COX-1, TP or IP receptor. 
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Figure 3-26: The effect of CO2-SFE and γ tocopherol on U-46619 induced calcium flux  in platelets with blocked COX-1 or IP receptor. 
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3.4 Discussion 
3.4.1 The effect of CO2-SFE on platelet function 
This study provides the first report of the inhibition of platelet activation with lipid extract of New 
Zealand green-lipped mussel (Perna Canaliculus) in a dose dependent manner. The magnitude of 
inhibition of AA, U-46619 and ADP induced platelet aggregation by CO2-SFE was significantly greater 
than that obtained by standard fish oil formulation of equivalent concentration (Figure 3.4). The 
inhibitory effect exerted on AA induced aggregation by CO2-SFE was comparable to aspirin. However, 
unlike aspirin, CO2-SFE inhibited U-46619 induced activation, demonstrating that the mechanism of 
action is at least partially achieved by inhibition of thromboxane synthesis downstream of COX-1 (Figure 
3.4). The magnitude of inhibition of U-46619 induced flow cytometric parameters of platelet activation 
and exocytosis was statistically different between CO2-SFE and standard fish oil formulation again 
suggesting that inhibition by thromboxane dependent pathways is different between those two oils and 
some effects are specific to CO2-SFE (Figures 3.6 and 3.7). Amelioration of inhibitory effect of CO2-SFE on 
AA, A23187 and TRAP induced increase in intracellular calcium by blocked COX-1, IP and TP receptor 
suggests that all three of them are to some extent targets of CO2-SFE (Figures 3.22, 3.23 and 3.24). 
However, significant inhibition by CO2-SFE of thromboxane independent platelet aggregation induced by 
ADP, and A23187 induced platelet activation and degranulation confirms that multiple mechanisms may 
be in place (Figures 3.4 and 3.8). 
The dose response curve demonstrated volunteers’ variability in sensitivity to CO2-SFE, which interferes 
with AA metabolism and TxA2 induced platelet activation. Arachidonic acid is always bound to 
phospholipids and the free AA levels are minimal. Free AA levels may be present in people with high 
dietary intake or in disease state, and such will lead to increased risk of CVD due to an imbalance 
between TXA2 and PGI2.  Considering that this is a in-vitro study, high amounts of free CO2-SFE n-3PUFAs 
were present in plasma and were unlikely to be incorporated into membranes during short incubation 
and were therefore more efficient in the competition for COX-1 particularly in those volunteers with 
lower free n-6 AA amounts. Some authors showed that the inhibition of eicosanoid synthesis is not 
determined by the quantity of n-3 present, but by the n-3 to n-6 ratio [491, 492]. Volunteers that were 
more sensitive to CO2-SFE may have therefore have higher amounts of n-3 PUFAs obtained through their 
diet, incorporated in the cell membranes. 
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Considering that both fish oil and CO2-SFE inhibited platelet aggregation suggests that the inhibitory 
effect of CO2-SFE is at least partially caused by the presence of EPA and DHA shared by both compounds, 
where they actively compete for COX-1 metabolism with AA, and decrease TxA2 production by 
concomitant increase in TxA3 and inactivating prostaglandin and thromboxane synthase.The inhibition 
of ADP induced aggregation by CO2-SFE significantly higher than that of aspirin implicates that the 
mechanism of inhibition may involve increase in cAMP or decrease in cytosolic calcium. Series 3 
prostanoids are a likely explanation for increased cAMP levels that were produced in vitro, or have 
already been present in the extract. Series 3 prostanoids already present in the extract or produced 
from n-3 PUFAs found in mussel oil with help of human COX-1 may have ability to occupy and 
desensitise platelets’ TP receptor, and prevent/decrease TxA2 induced platelet aggregation upon agonist 
addition by increasing cAMP levels. Platelets whose TP receptor is desensitised with U-46619 (PGH2 
analogue with high affinity for the TP receptor) respond more to prostacyclin analogue iloprost and 
amplify cAMP signal [493].  
In order to elucidate if the TP receptor occupancy due to production of series 3 compounds through 
competition for COX-1 with n-6 AA are responsible for platelet inhibition we performed LASS testing on 
CO2-SFE and ASA and CO2-SFE treated samples (Figure 3.11). With or without inhibition of COX-1 by 
aspirin, CO2-SFE was capable of abolishing TxA2 induced platelet aggregation, suggesting that the 
inhibitory effect observed is to some extent independent of COX-1 and that it, at least partially, acts 
below COX-1 level. That could include the inhibition of TxS or occupancy of the TP receptor.  Sole 
inhibition of TxS in unlikely as it leads to accumulation of PGH2 which can activate platelets by binding to 
TP receptor [75].Prostaglandin like products, may have already been present in the sample, without the 
requirement for human COX-1.   
Platelet aggregation data in this experiment needs to be interpreted with some caution. We have 
performed light transmittance aggregometry, which is still regarded as ‘gold standard’ for platelet 
function testing, however the addition of both fish oil and CO2-SFE increases lipaemia in samples. A 
degree of inhibition is therefore likely to be caused by decreased sample absorbance. Performing LTA on 
washed platelets would solve this problem, however it was not feasible in our experiments due to 
requirement for addition of PGE1, which could have interfered with the inhibitory pathways of marine 
oil. 
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Inhibition of platelet degranulation and activation as shown in PAC-1 and P-selectin expression data 
again demonstrates that the inhibitory effect of CO2-SFE exceeds that of fish oil and could at least 
partially be caused by a unique and rare set of n-3 PUFA, one of which is the n-3 AA, not found in fish oil, 
which may act synergistically or alone. Omega- 3 AA has been shown to inhibit PGHS activity and unlike 
EPA, forces n-6 AA to be metabolised by the 12-LOX pathway therefore reducing overall platelet activity. 
Calcium ionophore induced platelet activation and degranulation was also inhibited by the mussel oil 
extract, suggesting that the extract could increase cAMP production in platelets. Inhibition of calcium 
ionophore induced platelet activation together with the fact that both marine oils showed tendency to 
increase resting platelet parameters of activation, which was ameliorated in some cases upon addition 
of agonists could potentially be explained by the formation or presence of various isoprostanes in 
treated samples. F2-Isoprostanes are prostaglandin-like oxidation products of AA and they modify 
platelet function by binding to the TP receptor (aggregatory) and increasing cAMP level (inhibitory) 
[494].   F3-isoprostanes are formed from EPA and F4-neuroprostanes are formed from DHA [495]. While 
F2 and F3 isoprostanes possess vasoconstrictive properties, DHA oxidation products lack them [495].15-
F2t-Isoprostane causes reversible platelet aggregation on its own, but it also inhibits U-46619 induced 
aggregation. EPA derived 15-F3t-isoprostane has similar but weaker action as F2t-isoprostane, and 
inhibits U-46619 induced platelet aggregation [495]. Stimulation of platelets with calcium ionophore 
releases 15-F2t  and 8-F2-t isoprostanes, probably due to increased oxidative stress caused directly by 
calcium ionophore or indirectly due to stimulation of COX-1 [495]. The authors identifying the role of n-3 
PUFAs isoprostanes on platelet function have used mainly U-46619 and A23187 as agonists, but other 
platelet agonists may induce high oxidative stress. Overproduction of isoprostanes derived from AA that 
can induce platelet aggregation may explain the lack of significant inhibition of AA induced platelet 
degranulation and activation. 
The increase in platelet cytosolic calcium upon stimulation with calcium ionophore, AA and TRAP was 
ameliorated with CO2-SFE.  It is not surprising that TRAP induced calcium flux was inhibited as the oil 
interferes with AA metabolism in platelets.  TRAP stimulates the release of AA, and the combination of 
granule release and platelet aggregation can be inhibited by COX/LOX inhibitors [496]. A23187 induced 
platelet activation does not require synthesis of prostaglandins for its action but can be prevented by 
substances that increase cAMP levels in the platelets [497]. Blockade of either COX-1, TP or IP receptor 
in platelets ameliorated the effect of CO2-SFE on calcium flux (Figures 3.22-3.24).  
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These experiments suggests that all three components are targeted by oil. One possible mechanism by 
which CO2-SFE could exert its action is that during incubation, 1 or more series 3 prostanoids contained 
in oil desensitise platelet TP receptor (and other prostanoid receptors due to high homology). Upon 
agonist stimulation,  their precursors like n-3AA competes with n-6 AA for human COX-1 and decreases 
n-6 AA release, which produces more series 3 compounds. Due to the TP receptor desensitisation there 
is an extensive accumulation of cAMP upon stimulation of platelet IP receptor by homologous series 3 
compounds, which in turn inhibit calcium increase and consequent platelet activation. The amount of 
cAMP produced during process is sufficient to inhibit the pro-aggregatory effect of isoprostanes formed 
from PUFAs. Blockade of platelet COX-1 inhibits production of series 3 prostanoids, and those present 
are inadequate to continuously stimulate IP and TP receptors. On the other hand, blockade of the TP or 
IP receptors prevents increase in cAMP level caused by CO2-SFE. Despite TxA3 being regarded as less 
potent platelet agonist than TxA2, it is still capable of activating platelets that can then release content 
of their granules including ADP and continue the cycle. However prior interaction of prostanoids with 
the TP induces is anti-aggregatory potential in combination with prostacyclin like compounds. While this 
represents a possible mechanism behind the activity of CO2-SFE, the role of other platelet prostanoid 
receptors was not accounted for. It is possible that apart from binding to the TP and IP receptor, 
interaction with other prostanoid receptors takes place and may contribute to the inhibitory effect of 
mussel oil. Further studies are required to elucidate this mechanism. 
The limitations of this study include the relatively few volunteers with a high degree of inter-individual 
variability, especially in flow cytometric analysis of samples. Even though the effect of the extract was 
demonstrated in both platelet aggregation and flow cytometry, the effect of lipaemia on PRP 
aggregation was not controlled for. The data obtained in this study allows for some elucidation of 
mechanisms by which the CO2-SFE inhibits platelet function; however relative contribution of each 
mechanism to the overall antiplatelet potential of CO2-SFE has not been demonstrated. The exact 
composition of the n-3PUFA found in the CO2-SFE has already been determined in previous studies as 
described in Chapter 1. Apart from classical EPA and DHA whose function is well defined, the CO2-SFE 
also contains unique and rare n-3 PUFAs. This study demonstrates that the action of the extract is not 
solely attributable to the presence of EPA and DHA but those rare n-3 PUFAs as well, however it is not 
known if those PUFAs present, act synergistically or alone in inhibition of platelet function, and which 
composite is responsible for which mechanism of platelet inhibition. While this study has provided the 
first evidence of inhibition of platelet activation, through multiple and novel mechanisms, the dose of 
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CO2-SFE used in this experiment is 0.5 mg/mL which is higher than could be reasonably achieved 
through dietary supplementation in healthy volunteers, particularly because the n-3 PUFA in vivo would 
be acting on other cells and not exclusively on platelets therefore assessment of the effectiveness in 
vivo, at a more clinically relevant dose is necessary (see Chapter 4). The discrepancy in the amount of 
inhibition of platelet activation observed in aggregation and flow cytometry could relate to the 
incubation of PRP and whole blood with the extract. 
Recent study of Phang et.al. [476] reported difference in response to EPA and DHA supplementation 
between male and female volunteers. The studies performed in this chapter were in vitro studies where 
for each volunteer, each treatment was compared to own control and results were analysed using 
repeated measures ANOVA, hence we believed that the gender will not influence the conclusions made.   
3.4.2 The effect of γ tocopherol on platelet function 
This study provides evidence that γ tocopherol inhibits platelet function by interfering with AA induced 
activation. Treatment of whole blood with γ tocopherol prevented increase in cytoplasmic calcium levels 
after stimulation with AA, TRAP and A23187 (Figure 3.20) , an effect that was not ameliorated by 
blocking platelets IP and TP receptors (Figures 3.22-3.24). Blockade of COX-1 however ameliorated the 
inhibition in response to all 3 agonists suggesting that γ tocopherol may be a direct inhibitor of platelet 
COX-1 (Figures 3.23 and 3.24). 
While AA induced platelet activation and degranulation, measured by PAC-1 and P-selectin respectively, 
were inhibited, U-46619 induced activation was comparable to vehicle control in γ tocopherol treated 
samples. In this respect, γ tocopherol resembles aspirin, although it was significantly less potent platelet 
inhibitor than aspirin. In conjunction, a lack of inhibitory effect on ADP and A23187 induced platelet 
activation suggested that AA pathway at or above COX-1 may be the target of γ tocopherol. γ tocopherol 
and its main metabolite y-CEHC have already been shown to inhibit PGE2 synthesis and COX-2 activity, 
the effect unrelated to its antioxidative properties [488]. Some studies reported possibility that γ 
tocopherol may inhibit platelet function by interfering with ADP induced activation [210], however in 
this study,  γ tocopherol did not have an effect on ADP induced P-selectin expression, platelet activation 
or ADP induced calcium flux. This group measured ADP induced LTA before and after supplementation 
with mixed tocopherols. Multiple effects, including the antioxidative potential of γ tocopherol may have 
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contributed to this effect. The group did not measure AA induced aggregation,  although mixed 
tocopherol supplementation had no effect on PMA induced LTA [210]. 
Incubation of whole blood with γ tocopherol resulted in decreased calcium flux upon stimulation with 
AA, A23187 and TRAP (Figure 3.20). Although the inhibitory effect was weak, it was not ameliorated 
upon inhibition of platelet IP and TP receptors suggesting that neither TxA2 nor PGI2 are crucial for its 
action. However, it was the blockade of COX-1 that prevented inhibition of A23187 and TRAP induced 
calcium flux. While TRAP induced calcium flux depends on AA release, as described above, A23187 
induced calcium flux could be prevented by higher cAMP levels. However, γ tocopherol did not influence 
A23187 induced P-selectin expression or conformational change in Integrin αIIb/βIII, suggesting that 
other mechanism may be in place. It is possible that γ tocopherol due to its direct anti-oxidative 
properties as well inhibition of COX-1 prevented radical damage and isoprostanes formation from AA. γ 
tocopherol is able to inhibit 8-isprostane formation through its anti-COX-2 mechanism in LPS stimulated 
macrophages [488], and it may have reduced platelet activation and calcium mobilisation due to 
reduction of isoprostanes formed upon agonist stimulation.  
Due to its likely COX-1 effect,  it is not surprising that γ tocopherol in combination with aspirin was more 
potent than aspirin, or aspirin and α-tocopherol in exerting anti-inflammatory potential and attenuation 
of aspirin induced side-effects in rats [412].  
This study provides evidence that γ tocopherol interferes with AA induced platelet activation by possibly 
interfering with COX-1, however it allows partial elucidation of the exact mechanism of action. Further 
studies are required to examine the extent and duration of COX-1 inhibition in platelets. It is also not 
known if the inhibition of COX-1 is due to anti-oxidative properties already described in literature 
review, interference with NO and possible cGMP elevation, or if γ tocopherol decreases enzyme activity 
by directly binding to it. In vivo studies are required to assess the length of inhibition of AA platelet 
activation and the dosing requirements. 
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4 CHAPTER 4: THE EFFECTS OF IN VIVO LYPRINOL SUPPLEMENTATION 
ON PLATELET FUNCTION 
4.1 Introduction 
The reported side-effects and contraindications of current NSAID drugs prompted further investigations 
of other agents, including natural products as alternatives for prevention and treatment of CVD [302, 
303]. Mussels, like other marine organisms are abundant in n-3 PUFA, particularly EPA and DHA. High 
dietary EPA and DHA have been postulated to alleviate the symptoms of inflammatory conditions and 
CVD [321, 351]. The research presented in the previous chapter (Chapter 3) demonstrated that the anti-
inflammatory lipid CO2 extract of Perna Canaliculus inhibits platelet function in vitro by regulating the AA 
metabolism.  Commercially available formulations of this extract exist and are reportedly used for their 
anti-inflammatory and anti-arthritic properties. The research presented in the current chapter therefore 
sought to build on the initial in vitro findings to investigate whether clinical administration of the extract 
formulation was capable of inhibiting agonist induced platelet function, and markers of in vivo 
subclinical platelet activation.  
Lyprinol© (Pharmalink Marketing Services Pty.Ltd, Burleigh Heads, Queensland, Australia) is a stabilised 
green lipped mussel extract (50 mg per capsule) containing concentrated n -3 PUFA including EPA and 
DHA, with removed salt and allergens [349-351, 498]. The SFE process utilises liquefied CO2 to avoid the 
use of any chemical solvents that could create health or acceptability concerns for human applications 
[347, 348].  Lyprinol also contains 100 mg of excipient olive oil and 0.255 mg d-α-tocopherol [499].  The 
analysis of n -3 PUFAs revealed that the tartaric acid-stabilised freeze dried powder of the mussel flesh 
subjected to supercritical-CO2 fluid treatment contains a structurally related family of n-3 PUFAs in the 
most bioactive fractions, which included C18:4, C19:4, C20:4, and C21:5 PUFA [347]. The C20:4 is a 
structural isomer of AA [347] which, as described in the previous chapter, may be partially responsible 
for anti-platelet activity of the CO2-SFE.  
Lyprinol administration is effective in the treatment of various inflammatory conditions such as 
osteoarthritis [349], asthma [365] and arthritis [345, 348, 357, 361-363] and in mouse inflammatory 
bowel disease [499] and unlike NSAIDs is not gastro toxic  [346]. Both Lyprinol and total lipid extract of 
Perna Canaliculus inhibit COX-1 and COX-2 enzymes and PGE2 production [321, 346] . The PUFAs found 
in Lyprinol act as competitive substrate inhibitors of AA, since in the absence of exogenous AA alternate 
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prostaglandins appear [321].  The active ingredients of Lyprinol inhibit the production of leukotriene 
metabolites [346, 348]. Apart from their role in inflammation, leukotrienes could influence the 
progression of atherosclerosis since the products of non-enzymatic lipid peroxidation serve as ligands 
for leukotriene receptors therefore contributing to lesion development [500].  
Lyprinol is well tolerated even at high doses. While doses shown to be most effective in direct inhibition 
of platelet function in the previous chapter are not achievable, clinically relevant doses may potentially 
have beneficial effects on the thromboinflammatory processes. No side effects of 35 mg of Lyprinol 
were observed in patients with rheumatoid joint disease given in combination with 458 mg of fish oil 
concentrate that contained 50% EPA and  50% DHA twice daily [363]. A phase I clinical trial in patients 
with advanced breast and prostate cancer, refractory to treatment, was conducted to determine the 
safety and tolerability of Lyprinol with doses up to 4160 mg/day.  The maximum tolerated dose levels 
were not reached in this group, and Lyprinol was well tolerated with the most common reported side 
effects being dyspepsia and normocytic anemia likely to be treatment/disease related [354]. The in vitro 
study demonstrated that the 0.5 mg/mL of the extract significantly inhibited platelet function. This dose 
was unachievable in in vivo setting and would require participants to ingest at least 50 Lyprinol capsules 
per day. One tenth of the dose (0.05 mg/mL) could be exceeded by 8 capsules (400 mg of the active 
ingredient) per day. Slightly higher dose was selected as we hypothesised that ingested Lyprinol would 
be acting on leukocytes as well as on platelets. 
In this study we aimed to elucidate if Lyprinol supplementation attenuates platelet function in healthy 
volunteers in vivo. This trial assesses the effect of 7 day Lyprinol supplementation, at one tenth of the 
dose used in in vitro study, on platelet activity and coagulation. We also conducted a post-study to 
determine if Lyprinol was a short-acting inhibitor of platelet function. 
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4.2 Materials and Methods 
4.2.1 Study population and design 
After obtaining RMIT University Human Research Ethics Committee Approval (HREC Numbers: 08/10 
and 79/11) and the informed consent of the participants, 26 healthy volunteers, 15 females and 11 
males, not on any medication or dietary supplements for at least 7 days prior to, or for the duration of,  
the study, were recruited. Volunteers were allowed to participate if they were between 18 and 60 years 
old. Exclusion criteria also included known medical conditions or known problems with phlebotomy. 
Volunteers were randomised to receive either 8 Lyprinol capsules per day (400 mg of the green lipped 
mussel extract and 800 mg of Olive oil in total) or 1 Seagate Extra Virgin Olive Oil (1000 mg) capsule per 
day for 7 days (Figure 4.1). Compliance was monitored by the leftover capsule count. Volunteers aged 
18-60 were allowed to participate. Blood samples were taken on day 1 before supplementation and 7 
days later. Total of 10 mL whole blood was collected in 3.2 (w/v) sodium citrate and 2 ml in dipotassium 
EDTA on each occasion.  
A pharmacodynamic sub-study was performed to determine the peak effect time point of Lyprinol 
supplementation (Figure 4.1).  Citrated blood samples (8 mL) were collected immediately prior to and 
then 2, 6 and 24 hours after a single dose of 8 Lyprinol capsules in 9 volunteers. Another sub-study was 
performed were 15 volunteers were bled before and 4 hours after 8 Lyprinol capsules. Inclusion criteria 
for volunteers were the same as previously described. This study did not include a control group as it 
was conducted after 7-day supplementation trial and the aim was only to see the effect of Lyprinol 
supplementation. 
4.2.2 Tests 
FBE, LTA, P-selectin and PAC-1 were measured as per protocols described in the in vitro study (Chapter 
3). Platelet aggregation using 0.3 mM AA, 6.4 µM U-46619 and 5 µM ADP to induce aggregation was 
performed at all time-points in both 7-day trial and pharmacodynamic studies. P-selectin expression and 
reactivity with PAC-1 (that recognises only the activated GPIIb/IIIa receptor)were also performed on all 
volunteers in the 7-day trial and time line study using 0.3 mM AA, 2 µM ADP, 0.3 µM and 20 µM U-
46619. Concentrations of agonists selected were adequate to induce platelets aggregation and 
activation in volunteers but were still at lower range as we aimed to look for the amount of inhibition by 
Lyprinol. 
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FBE and coagulation studies were performed on samples before and after 7 days supplementation. Full 
blood examination was performed as already described in Chapter 2 (Materials/Methods). 
500 µL of citrated plasma was aliquoted and stored at -80°C until coagulation tests were performed. 
Prothrombin time (PT) and Activated partial thromboplastin time (APTT) were measured manually. For 
PT, a 100 µL of aliquoted   plasma was pre-warmed for 2 minutes at 37°C and extrinsic coagulation 
triggered with addition of 200 µL of PT Fibrinogen HS Plus (HemosIL ®) and time until visually 
determined clot formation was recorded. The intrinsic coagulation pathway  was measured by 
incubating 100 µL of pre-warmed plasma with 100 µL of APTT reagent (APTT-SP HemosIL®) for 5 
minutes, then 100 µL of CaCl2 (0.025M) was added and time taken for clot formation was measured. 
Both tests were performed in duplicate and the average time recorded. Quality was controlled by 
performance of normal and abnormal (Citrol 1 and Citrol 2 from Dade Behring) reference plasmas in 
duplicate. 
4.2.3 Statistical analysis 
Results were analysed using Graph Pad Prism 5. Data was firstly analysed using parametric tests. The 2-
tailed Student’s t-test was used for comparison of two groups and a repeated measures or 1-way 
ANOVA was used for comparisons between more than 2 groups. Bonferroni multiple comparison test 
was used to compare all sets of results while Dunnett’s multiple comparison test to compare treatment 
groups to their pre-study data in the time line trial. 
If data did not have Gaussian distribution, a non-parametric analysis was performed to confirm the 
results. Mann-Whitney test was used for comparison of two sets of data while Kruskal-Wallis with 
Dunn’s multiple comparison test was used for more than 2 sets of data point. 
GraphPad StatMate 2.00 was used to calculate the power of experiments. Power calculations were 
performed before the 7 day trial for platelet aggregation. The assumption was made that the standard 
deviation of the groups is approximately 5 and alpha is 0.05 (two-tailed). In order to detect the 
difference of 7 (approximately 10% inhibition of platelet aggregation), we needed to recruit 12 
volunteers to have an experiment with 90% power.  Power calculations performed on already 
completed experiments, with standard deviation of 5 in each group were adequately powered (>85%) to 
detect 10% difference in the platelet aggregation results for both AA and U-46619 LTA. 
 Figure 4-1: Study Protocol. 
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4.3 Results 
4.3.1 In-vivo 7-day Lyprinol Supplementation 
In order to see the effect of Lyprinol supplementation on CVD risk factors volunteers needed to take 8 
Lyprinol capsules (approximating 1/10th of the dose used in in vitro study). Since capsules contain Olive 
oil, which is cardio protective as well, control group of volunteers was given approximately equivalent 
amount of Olive oil per day. 7-day supplementation may be adequate to inhibit already produced 
platelets, but is unlikely to provide an insight into more chronic effect of Lyprinol supplementation. 
Volunteers were randomised to receive either Olive oil or Lyprinol supplements for 7 days and were 
bled before and after supplementation period. Compliance was monitored by the left-over capsule 
count and verbal conversation. Side effect were reported verbally. All participants completed the trial. 
There were 16 females and 10 males, all aged 20 – 55. Side effect reported in Lyprinol supplementation 
group was unpleasant after-taste if capsules were taken before breakfast, while volunteers allocated to 
Olive oil group did not report any issues. Most volunteers started supplementing the diet immediately 
after the blood test. They were taking Lyprinol capsules in set of 4 (morning and night) and the last set 
of capsules was taken the night before the post-supplementation testing by 12  out of 13 volunteers.  
4.3.1.1 The effect of in vivo Lyprinol supplementation on Haematological parameters  
Full blood examination was performed as part of routine check up for volunteers. FBE parameters 
outside of reference range would be exclusion criteria for participants. Considering that Lyprinol acts as 
anti-inflammatory agent, it could have decreased total leukocyte count. We also questioned the 
possibility of Lyprinol to decreased platelet size. In order to see whether Lyprinol supplementation 
affected haematological parameters full blood examination was performed before and after 
supplementation with Lyprinol and Olive Oil and results compared. The FBE results (mean ± SEM) before 
and after supplementation are shown in Table 4.1. Hemoglobin (Hb), White Cell Count (WCC), Platelet 
count (Plt) and Mean Platelet Volume (MPV) were compared for both groups before and after 
supplementation using 1-way ANOVA with Bonferroni multiple comparison test. There were no 
statistically significant differences between groups for any parameter measured.  
4.3.1.2 The effect of in vivo Lyprinol supplementation on ex vivo platelet aggregation  
Light transmission aggregometry is still regarded as 'gold standard' for platelet function testing. Since in 
vitro Lyprinol inhibits platelet aggregation in response to AA, U-46619 and ADP, we aimed to see if 8 
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Lyprinol capsules per day for 7 days are adequate to inhibit ex-vivo platelet aggregation in response to 
those agonists. Platelet aggregation was tested in response to AA, U-46619 and ADP before and after 
supplementation with Olive oil and Lyprinol. Agonists selected were specifically inhibited by CO2-SFE in 
in vitro study. LTA results were recorded as percentage aggregation. The post-supplementation results 
(the effect of therapy) were expressed as the ratio of change of post-supplementation versus pre-
supplementation values, where the pre-supplementation result was regarded as 100%. Mean of change 
±SEM is presented.  Student’s paired t-test was used to compare results before and after 
supplementation and the Student’s unpaired t-test was used to compare the mean parameters from the 
Olive Oil and Lyprinol supplementation groups.  
As shown in Figure 4.2A, 7 day supplementation with Lyprinol decreased ex vivo platelet aggregation in 
response to stimulation with 0.3 mM AA. Even though we obtained statistically significant difference, 
the results are not clinically significant. The overall aggregation decreased from 89.5% ±1.3 at baseline 
to 86.3% ± 1.6 after 7 days supplementation (p<0.05, n=13). The mean of change in the Olive Oil 
supplementation group was 101% ± 3, while in Lyprinol supplementation group was 96 ± 1 (p>0.05, 
n=13).  
 Similar, but not statistically significant trends were seen when the PGH2 analogue U-46619 (6.4 µM), 
and 5 µM ADP were used as agonists. The maximum aggregation for the Lyprinol treated group 
decreased from 90.2% ± 1.6 to 86.1% ± 2.4 (p>0.05, n=13, Figure 4.2B) in U-46619 induced LTA and from 
81.1% ± 2.9 to 72.9% ± 7.9 (p>0.05, n=13; Figure 4.2C) in ADP activated samples. Olive oil 
supplementation did not have a significant effect on platelet aggregation.  
4.3.1.3 The effect of in vivo Lyprinol supplementation on platelet activation and 
degranulation measured by flow cytometry 
Several platelet activation pathways can be measured simultaneously by flow cytometry. Both resting 
and agonist induced platelet activation can be estimated. Since in vitro CO2-SFE inhibits platelet 
activation and degranulation, we aimed to see if in vivo Lyprinol supplementation shows similar 
inhibitory platelet function effect, and if so, whether it inhibits platelet activation measured by activated 
GPIIb/IIIa, or platelet degranulation, measured by P-selectin expression. Platelet activation and 
degranulation were measured before and after supplementation with Lyprinol and Olive oil. Resting and 
agonist induced changes were measured. Agonist used were AA, ADP and U-46619. Figure 4.3 
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represents data for GPIIb/IIIa activation, while Figure 4.4 shows data for P-selectin expression before 
and after supplementation with Olive Oil and Lyprinol. Results are expressed as mean ± SEM and 
analysed using 1-way ANOVA with Bonferroni multiple comparison test.  As shown in figures 4.3 A-E and 
4.4 A-E, 7 days supplementation with  Olive Oil or Lyprinol affected neither GPIIb/IIIa activation nor P-
selectin expression in resting or agonist induced platelets. Kruskal-Wallis, non-parametric analysis was 
performed with Dunns post-test to re-analyse unequally distributed data (p>0.05, n=13). 
4.3.1.4 The effect of in vivo Lyprinol supplementation on haemostasis 
No studies have examined the effect of Lyprinol supplementation on coagulation profile. SInce 
supplementation with fish oil and n-3 PUFA can decrease levels of coagulation factors, n-3 PUFAs from 
Lyprinol could also lead to prolongation of PT or APTT. Therefore both PT and APTT were measured 
before and after supplementation with Lyprinol and Olive oil. No significant differences in coagulation 
parameters PT (Figure 4.5A) or APTT (Figure 4.5B) were found. However, a mild and non-significant 
trend for prolongation of the APTT (Figure 4.5B) was observed in Lyprinol supplementation group. 
Overall, the post-supplementation APTT result expressed as a percentage change from a pre-
supplementation result in the Olive Oil supplementation group remained the same (99.8% ± 1.6), while 
it mildly increased in the Lyprinol supplementation group (103.5 ± 2.1), but the difference was not 
statistically significant (p>0.05, n=12).  APTT increased from 34.1s ±0.5 at pre-supplementation to 35.4s 
±0.7 post 7 days supplementation, p>0.05; n=12. 
  
 Table 4-1: Hematological parameters and volunteer demographics before and after supplementation with Lyprinol and Olive oil
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Figure 4-2: The effect of in vivo Lyprinol supplementation on ex vivo platelet aggregation. 
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Figure 4-3: The effect of in vivo Lyprinol supplementation on platelet activation, measured by the expression of activated GPIIb/IIIa receptor. 
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Figure 4-4: The effect of in vivo Lyprinol supplementation on platelet degranulation, measured by the expression of P-selectin. 
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Figure 4-5: The effect of in vivo Lyprinol supplementation on haemostasis. 
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4.3.2 The effects of Lyprinol supplementation of platelet activation markers at 2, 4, 6 and 
24 hour time points 
All volunteers completed the study. In the first part 5 females and 4 males were recruited, while in the 
second part 9 females and 6 males participated. Second time-line study was done after completion of 
the 7 day trial and the first-time line study in order to see if Lyprinol acts as short acting inhibitor of 
platelet function that peaks at 4 hours and returns to normal after 6-24 hours. 
4.3.2.1 The effect of a single in vivo Lyprinol dose on ex vivo platelet aggregation over 24 
hours 
Lyprinol may have both acute and chronic inhibitory effect on platelet function. In order to evaluate the 
acute effect of n-3 PUFAs from Lyprinol, volunteers were bled before and 2, 6 and 24 or only 4 hours 
after taking 8 Lyprinol supplements. Platelet aggregation induced by AA, U-46619 and ADP was 
performed on volunteers after a single dose of 8 Lyprinol capsules. Volunteers were bled at different 
time-points in order to evaluate and determine the peak effect. As shown on Figure 4.6, the greatest 
effect of 8 Lyprinol capsules was observed 2 and 4 hours after the supplementation in both 0.3 mM AA 
and 6.4 µM U-46619 induced LTA. However, the AA-induced aggregation at 2 hours was excessively 
affected by two volunteers. This may suggest that some people are more sensitive than others to the 
effect of Lyprinol. 
As shown in Figure 4.6A, AA induced aggregation decreased from 90.2% ± 2.5 to 65.7% ± 12.5 two hours 
later, with 2 volunteers showing no AA induced aggregation. After 6 hours, the mean aggregation 
returned to 79.6% ± 3.9 (p>0.05; n=9; in comparison to baseline). Importantly the AA induced 
aggregation returned to the original levels (87.9% ± 1.8) 24 hours after the supplementation, p>0.05; 
n=9 in comparison to 0 hours.  When results were analysed using repeated measures ANOVA with 
Dunnett’s multiple comparison test, pre-supplementation results were significantly higher than those 
obtained 2 hours later (p<0.05). However, when non-parametric test was used to confirm the results 
(Kruskal-Wallis with Dunn’s multiple comparison test), p>0.05, n=9 indicating that the significance was 
obtained due to 2 outliers that showed no aggregation in response to AA.  
In a separate pharmacodynamics study, AA induced aggregation decreased from 87.3% ±1.9 to 79.7% 
±1.7 at 4 hours, p<0.01, n=15, as shown on Figure 4.6B. In this cohort, the reduction in aggregation was 
more consistent across the whole group.  
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Baseline 6.4 µM U-46619 induced PRP aggregation (Figure 4.6C) was 87.9% ± 2.3, which decreased to 
76.5% ± 5.1 at 2 hours (p<0.05; n=9). After 6 hours, U-46619 induced aggregation was 77.8% ±2.1 
(p>0.05, n=9) and had returned to pre-supplementation levels by 24 hours to 82.8% ± 2 (p>0.05, n=9). A 
non-parametric test revealed that there was a weak inhibition of U-46619 induced aggregation at 6 hour 
time point, while the 2 hour time-point was affected by one outlier whose aggregation decreased from 
78% to 36%. 
In a separate study, baseline U-46619 induced aggregation (Figure 4.6D) was not significantly different 
at 4 hours in comparison to baseline (86.3% ± 1.7 at baseline and 81.3% ±3.1 at 4 hours; p>0.05, n=15).   
As shown on Figure 4.6E, ADP induced aggregation showed a similar trend, however volunteers’ 
response to ADP was more variable as demonstrated by the SEM, 73.9% ± 4.6 at baseline to 60.7% ± 
10.6 at 6 hours post dose, therefore the results were not statistically different. Lack of significant 
inhibition of ADP induced aggregation was confirmed using non-parametric test. In both cases, p>0.05, 
n=9. A significant decrease in ADP induced LTA was noted in a separate timeline study with aggregation 
decreasing from 78.4% ± 5.1 at baseline to 70.6 ± 5.5 after 4 hours, p<0.05, n=15 (Figure 4.6F). 
4.3.2.2 The effect of single Lyprinol dose on platelet activation and degranulation, measured 
by flow cytometry 
Resting and agonist induced platelet activation and degranulation parameters may be decreased by n-3 
PUFAs found in Lyprinol after a single dose. Lyprinol may act as short and reversible inhibitor of platelet 
function or may have more prolonged effect. In order to test this possibility, platelet activation, 
measured by PAC-1 binding and degranulation, measured by P-selectin expression were measured over 
24 hour interval after a single dose of 8 supplements in order to detect the peak effect. The analysis of 
platelet activation (PAC-1) and P-selectin expression demonstrated that the effect of Lyprinol had similar 
trend as observed in LTA study with the most prominent decrease in platelet activation occurring 
between 2 and 4 hours after supplementation. 
As shown on Figures 4.7 and 4.8, GPIIb/IIIa conformational change expressed as mean fluorescence 
intensity in resting and activated platelets is decreased by a single dose of 8 Lyprinol capsules.  2 µM 
ADP induced PAC-1 expression (MFI) decreased from 1950 ± 362 to 1327 ±234, while 0.3 mM AA 
induced activation decreased from 1784 ± 663 to 551 ±159, 0.3 µM U-46619 decreased from 1811 ± 277 
to 1173 ±232 and 20 µM U-46619 activation decreased from 6134 ±673 to 4710 ±750 at 2 hours post 
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supplementation with a single dose of 8 Lyprinol capsules (Figures 4.7 B, C, D and E respectively).  The 
decrease did not reach statistical significance for any agonist when results were analysed using repeated 
measures ANVOA with Bonferroni multiple comparison test. Non-Gaussian distributed data was re-
analysed using non-parametric Kruskal-Wills test with Dunn’s multiple comparison test. Similarly to LTA 
results, platelets PAC-1 expression expressed as MFI returned to baseline within 24 hours (1588 ± 445 
for ADP, 1218 ± 469 for AA , 2363 ± 617 for 0.3 µM U-46619 and 5450 ±987 for 20 µM U-46619). 
A statistically significant decrease in PAC-1 expression was observed in 0.3 mM AA activated samples, 4 
hours after Lyprinol supplementation, as shown on Figure 4.8C (MFI decreased from 1073 ±259 at 
baseline to 468.5 ±141 after 4 hours, p<0.01, n=15). PAC-1 binding induced with 20 µM U-46619, as 
shown on Figure 4.8E, was mildly inhibited by Lyprinol supplements (6005 MFI ± 437 at baseline to 5087 
MFI ± 589 at 4 hour time point) with P<0.05, n=15 when results were analysed using Student’s paired t-
test.  
Similarly to PAC-1, platelet P-selectin expression showed tendency to decrease 2 hours after 
supplementation with 8 Lyprinol capsules (Figure 4.9), but results reached statistical significance only 4 
hours after supplementation (Figure 4.10) in 0.3 mM AA, 0.3 µM and 20 µM U-46619 induced platelet 
activation.  0.3 mM AA induced P-selectin expression  (MFI) decreased from 1977 ± 355 at baseline to 
1156 ± 197 after 4 hours (p<0.01, n=15). 0.3 µM induced P-selectin expression decreased from 15525 ± 
4070 before supplementation to 5456 ± 1608, 4 hours later (p<0.05, n=15) and from 38779 ± 6296 at 
baseline to 25893 ± 3869 after 4 hours (p<0.05, n=15) in 20 µM U-46619 induced samples. Non – 
parametric Mann-Whitney test confirmed significant reduction in the P-selectin expression in the AA 
activated samples (p<0.05, n=15), while 0.3 µM U-46619 had borderline significance (p=0.05, n=15). 
  
182 
 
Figure 4-6: The effect of a single in vivo Lyprinol dose on ex vivo platelet aggregation over 24 hours. 
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Figure 4-7: The effect of single Lyprinol dose on platelet activation measured by PAC-1 binding, over 24 hours. 
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Figure 4-8: The effect of single Lyprinol dose on platelet activation measured by PAC-1 binding, over 4 hours. 
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Figure 4-9: The effect of single Lyprinol dose on platelet degranulation measured by P-selectin expression over 24 hours.  
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Figure 4-10: The effect of single Lyprinol dose on platelet degranulation measured by P-selectin expression over 4 hours. 
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4.4 Discussion 
We have shown, for the first time, that anti-inflammatory supplement Lyprinol inhibits platelet function. 
Similarly to finding in in vitro study (Chapter 3), active n-3 PUFAs found in this supplement, interfere 
with AA and U-46619 induced platelet activation, degranulation and aggregation. This study 
demonstrates that Lyprinol supplementation produces acute, short-acting inhibition of platelet function. 
While 7 day supplementation trial of 8 Lyprinol capsules per day was insufficient to produce clinically 
significant decrease of platelet aggregation, activation and degranulation, platelet function was 
abolished between 2-4 hours after a single dose of 8 Lyprinol capsules. The anti-platelet effect of 
Lyprinol peaked between 2 and 4 hours after supplementation but importantly, it was no longer 
apparent between 6 and 24 hours. This could explain the lack of stronger inhibition of platelet function 
by Lyprinol supplementation in the 7 day trial. Volunteers were retrospectively asked the time the final 
dose of Lyprinol was taken and all but 1 reported taking the last set of capsules on the evening before 
testing (approximately 12 hours). These results suggest that 8 Lyprinol capsules are sufficient to inhibit 
platelet function, however 7 day supplementation may not be adequate to see the cumulative effect of 
the supplement. Our findings are partially in line with the study of Von Schacky et.al. who reported that 
EPA appears in plasma free fatty acids and phospholipids 4 hours after ingestion, but it is only 
incorporated into platelet phosphatidylinositol or - serine after 6 day supplementation [501]. This study 
was however supplementing volunteers with 6 g/day of EPA, which is significantly higher concentration 
than in our study, hence longer supplementation may be required to achieve the inhibitory effects.  
Lyprinol, like other marine oils, contains high concentrations of EPA and DHA. McPhee et.al. [321] 
showed that fish oil, rich in EPA and DHA, inhibits COX-1 and COX-2 to a lesser extent than Lyprinol, 
while our in vitro study showed stronger inhibition of platelet function by CO2-SFE than by fish oil. This 
suggests that inhibitory effect of Lyprinol is partially caused by the presence of EPA and DHA. Those n-3 
PUFAs inhibit platelet function by several mechanisms, which are described in Chapter 1. They can 
increase the net negative surface charge of platelets, actively compete for COX metabolism and 
decrease TxA2 production by concomitant increase in TxA3, and inactivate prostaglandin and 
thromboxane synthase. However, stronger inhibition caused by Lyprinol/CO2-SFE than by fish oil 
suggests that that the inhibitory effect of Lyprinol is also caused by unique and rare set of n -3 PUFA not 
found in fish oil, which may act synergistically with EPA and DHA or alone. 
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The administration of a single dose of 8 Lyprinol capsules showed that the effect of Lyprinol peaked 
between 2 and 4 hours, which is not in line with recently published data showing the peak anti-
aggregatory effect of 1000 mg of EPA and DHA supplementation (collagen induced whole blood 
aggregation reduced for 13.3% with EPA and 11.9% with DHA) after 24 hours [502]. The differences 
observed could be due to higher doses of n -3 PUFAs used in the study. The authors investigated the 
effect of EPA and DHA using collagen induced whole blood aggregometry, while this study concentrated 
on AA pathway in both LTA and flow cytometry.  
The membrane phospholipids of inflammatory cells taken from humans consuming Western-type diets 
contain approximately 20% of n -6 AA while EPA is typically about <1% of fatty acids, which makes AA 
the main substrate for eicosanoid synthesis [312]. n-3 PUFA from the diet replace the AA of cellular 
membranes and modulate the production of AA-derived eicosanoids, with some leading to production 
of series 3 prostanoids and consequently weaker agonist, TxA3 [339].  
Apart from EPA and DHA Lyprinol also contains a very rare n -3 AA, which can be incorporated into 
platelet membrane and is capable of displacing the n -6 AA within 24 hours of incubation with the cells. 
Even though the displacement of n -3 AA by EPA occurs within 24 hours in vitro, the accumulation of n -3 
fatty acids in platelet phospholipids occurs after 14 day supplementation [503]. In the study of Singh 
et.al. the extract was not able to inhibit adjuvant-induced arthritis swelling in Long Evans rats at 50 and 
100 mg/kg BW/day after 5 days, however the inhibition was achieved after 15 days supplementation 
[348]. Based on those studies the 7 day supplementation with Lyprinol may not be adequate and longer 
supplementation may be needed to achieve more prominent inhibition of platelet function, since longer 
supplementation will allow greater incorporation of n-3 PUFAs into cell membranes.  
Once Lyprinol PUFA were absorbed, some may have been incorporated into cell membranes while some 
may have remained free in plasma, based on already mentioned study [501]. Therefore the inhibitory 
effect of Lyprinol seen in pharmacodynamic studies could have been at least partially achieved by 
competition of free n-3 PUFAs, including n-3 AA, with n-6 AA present in the plasma.  This suggests that 
the differences in volunteer responses observed with AA induced LTA in the pharmacodynamic study 
could relate to the amount of free n-6 AA present. Under normal conditions, AA is always bound to 
phospholipids or proteins and the free AA levels are minimal. Free AA levels may be present in people 
with high dietary intake or in disease states, and such will lead to increased risk of CVD due to an 
imbalance between TXA2 and PGI2.  Higher n-6 AA intake is known to reduce the n-3 levels after dietary 
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intake [503], and the inhibition of eicosanoid synthesis is not determined by the quantity of n-3 present, 
but by the n -3 PUFA to n -6 PUFA ratio [504, 505], with lower ratios predisposing to CVD complications 
[506]. The typical Western diet gives n-3 to n-6 ratio in phospholipids of 0.1, which can be increased to 4 
in humans [507].  While membrane incorporated n-6 and n-3 PUFA can equivalently compete for COX 
metabolism since cPLA2α does not discriminate between them [507] higher free n-6 AA levels in some 
volunteers could more efficiently compete with n-3 PUFAs obtained from Lyprinol supplementation 
reducing the inhibitory effect of Lyprinol.  
Omega-3 PUFAs increase the platelet net negative surface charge dose dependently which can decrease 
platelets response to agonists [508]. Cohen et al. showed that increasing n-3 PUFA dose increased the 
negativity of the baseline platelet surface charge and consequently raised the concentration of AA 
required to activate the platelet above the threshold normally required for activation [508]. Higher 
doses of AA overcame the inhibition created by n-3 PUFAs [508] . 
Omega- 3 AA significantly inhibits PGHS activity and unlike EPA, forces n -6 AA to be metabolised by the 
12-LOX pathway therefore reducing overall platelet activity. Lipoxygenase products are produced from 
all PUFAs. They form mono-, di- or tri - hydroxyl derivatives. Platelet 12-LOX pathway represents 
approximately one third of AA metabolism, and even though 12-HPETE is shown to activate COX, LOX 
and PLA2 and is implicated in essential hypertension [342, 343, 509], the end products, particularly 
mono-hydroxy derivatives of 12-LOX are shown to have inhibitory platelet effects by possibly interfering 
with TP receptor [343, 344]. Some of the products are capable of inhibiting COX-1 directly [343]. The 
pronounced effect of EPA and DHA in the study of Phang et.al. [502] observed at 24 hours may be due 
to the higher activation of 12-LOX pathway which can be active hours after collagen stimulation, and 
therefore the mono-hydroxy derivatives and products showed more antiaggregatory effect after 24 
hours. Even though cPLA2α has no preference over EPA or AA, PGHS-1 oxygenates EPA at 5–10% of the 
rate at which it oxygenates AA, but both require the presence of alkyl hydroperoxide such as 12- or 15-
HPETE [507]. Therefore higher 12-HPETE produced by platelets’ 12-LOX due to higher n-3 PUFA intake 
allows formation of more series 3 prostanoids by PGHS from endogenous EPA [507]. Higher EPA intake 
(to a ratio of 1 compared to n-6 AA) inhibits AA oxygenation by 50%, giving rise to less series 2 
prostanoids [507]. 
The lipid profile of volunteers was not tested, however it is known that the metabolism of n-3 PUFA is 
different between normolipidemic and hyperlipidemic patients, with the latter showing their 
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accelerated clearance [310]. The differences in lipid profile amongst volunteers could also potentially 
explain the variability of response to agonist induced platelet activation amongst volunteers. 
This study underestimates the effect of Lyprinol supplementation on platelet function. The time-line 
trial that examined the effect of Lyprinol at 2, 6 and 24 hours after a single dose was mainly 
underpowered and the lack of significant inhibition could have been missed due to inadequate number 
of volunteers. One week supplementation may be long enough to influence already produced platelet 
and plasma n-3 levels, but may not have been sufficient to affect the production of new cells. Therefore 
the overall decrease and trend seen with AA and U-46619 induced platelet activation shows that the 
combination of PUFAs from Lyprinol has tendency to inhibit platelet activation, by mainly influencing AA 
pathway. This is again in agreement with our in vitro data.  Longer supplementation may be needed to 
produce more pronounced effects such as decrease of inflammation, strengthening of the anti-oxidative 
properties and enhancing endothelial NO release [338], which all together contribute to decreasing CVD 
risk factors. The 7-day supplementation trial included volunteers taking 1000 mg of Olive Oil capsules 
per day as control group. This is slightly less than what has been administered by volunteers taking 
Lyprinol supplements which contained 1200 g of Olive oil per day. It is unlikely that the inhibitory effects 
seen in these volunteers are due to additional 200 g of Olive Oil taken per day, but the results need to 
be interpreted with caution. Our pharmacokinetic study only assessed the acute effects of Lyprinol 
supplementation over the 24 hour period. It did not include the Olive Oil supplementation group of 
volunteers. Future, larger scale studies could be conducted to explore if the results obtained are due to 
ingestion of oil the n-3 PUFAs. 
As previously mentioned, recent study reported a difference between males and females in response to 
EPA/DHA supplementation [476]. This factor was not consider in our in-vivo trial as it was performed 
before the study was published. Sub-analysis of data would produce smaller and unequal groups and is 
not possible. Future studies should be conducted to explore this possibility further. The compliance in 
this study was measured by the left over capsules. We did not measure the major Lyprinol components 
in platelets or in plasma. Such measurement would not only test volunteer compliance but would give 
an insight into the incorporation and composition of n-3 PUFA from Lyprinol in platelet membrane and 
n-3 PUFAs in plasma.  
Considering that Lyprinol contains high EPA and DHA and other rare n-3 PUFAs, there may be a potential 
benefit of Lyprinol supplementation for decreasing CVD risk factors, by inhibiting platelet function which 
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is dependent on the AA metabolism and TxA2 synthesis. Inhibition of platelet activation may be 
beneficial to patients at high risk of CVD, but additional clinical trials adequately powered to show 
statistical benefit are required.  
Despite the high incidence of clinical and chemical resistance reported, aspirin is still most commonly 
used cardioprotective drug. Lyprinol shows similarity to aspirin but is much safer, as no literature 
reported any side-effects. The mechanism of action demonstrated by active ingredients of Lyprinol 
(described in the in vitro study) could potentially serve as new therapeutic targets for development of 
safer anti-platelet agents.  
4.5 Conclusion 
This study demonstrates that Lyprinol is acute and short-acting inhibitor of platelet aggregation and 
activation. It interferes with AA metabolism and TxA2 induced platelet activation. It would be beneficial 
to conduct longer and larger clinical trial in healthy population to assess the benefits of 
supplementation.   
It is also not known whether the inhibitory effect of Lyprinol, which is different to fish oil, is caused 
mainly by n-3 AA, or the combination of other PUFAs. Future studies need to be performed where 
different n-3 PUFAs found in CO2-SFE, including rare n-3 AA, are isolated and their action on platelets 
tested alone and in combination.  
  
192 
 
5 CHAPTER 5: ASSESSMENT OF PLATELET FUNCTION BY WHOLE 
BLOOD FLOW CYTOMETRY USING FINGERSTICK BLOOD  
5.1 Introduction 
Platelet function testing is, as described in Chapter 1, highly variable and irreproducible with poor 
correlation between methodologies and with clinical outcomes. Platelet function testing is 
prognostically significant in patients on antiplatelet therapies, since patients with high residual platelet 
reactivity whilst on treatment have increased risk of complications compared to those with low residual 
platelet reactivity on treatment [510]. The cut-off values for determining the high and low responders is 
variable in the literature and  depends on many factors  including  the platelet function test of choice as 
well as the timing and number of measurements [510].  There is a great need to develop a simple, quick 
and easy to perform test for platelet function activity that is reproducible. Several point of care 
analysers in use demonstrate, despite their poor correlation and reproducibility, that they could 
improve the management of antiplatelet therapy [511]. 
Most of the currently used routine methods assess only limited number of platelet activation pathways 
and may therefore fail to identify overall platelet activation. Flow cytometry can overcome the problems 
associated with this limitation as simultaneous pathways can be accurately assessed in one sample, with 
analysis being fast while thousands of cells can be examined. In addition to the ability to measure the 
platelets’ responses to various agonists, flow cytometry can determine the basal activation state of 
platelets without exposure to agonists in vitro [431]. However, there are many limitations of flow 
cytometry which prevent it from being used in routine diagnostic laboratories. Apart from the need for 
complex sample preparation and an experienced user, the need for immediate sample processing 
(within 15-45 minutes of specimen collection) places the use of this methodology in a research rather 
than a clinical setting [431].  Feasible method for analysis of platelets and platelet-leukocyte interactions 
using flow cytometry opens up opportunities for better diagnosis of platelet function disorders and 
monitoring of antiplatelet therapies, as it may allow rapid and complete assessment of multiple platelet 
activating pathways without the need for high degree of sample manipulation. 
This study consisted of two parts. The pilot study aimed to test if it is possible to obtain a clean, non –
activated capillary sample using a novel incision device (Fingerstick Lancet), and perform the assessment 
of platelet function using flow cytometry. We employed labeling of platelets after fixation, which 
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prolongs time for sample processing and analysis. The need for immediate sample preparation is 
currently one of the main reasons for impracticability of this assay in routine diagnostic laboratories. 
The pilot study served as a basis for creating and evaluating a point of care test for assessment of 
platelet activation. 
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5.2 Materials and Methods 
5.2.1 Materials 
Whole blood was collected into 3.2% (w/v) sodium citrate in 9:1 ratio (VACUETTE®, Greiner Bio-One 
GmbH, Austria). Sodium citrate from those tubes was added to reagent tubes for capillary blood 
processing (5.5 µL). Arachidonic acid and ADP were purchased from CHRONO-PAR ® (Chrono-Log 
Corporation, Havertown, PA) and were reconstituted and stored as per manufacturer’s instructions. AA 
was stored in 50 mM aliquots at -80°C for up to 3 months. ADP aliquots were 1 mM concentration, also 
stored at -80°C. U-46619 was  purchased from Cayman Chemical (Cayman Chemical Company, Ann 
Arbour, Michigan) and reconstituted in DMSO as per manufacturer’s instructions. 10mM aliquots were 
stored at -80°C. Working solution were made with HEPES buffered saline (pH 7.4), and 100 µM aliquots 
were stored at -20°C.  TRAP was purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO), 
reconstituted in 2 mM aliquots and stored as per manufacturer’s instruction until use at -80°C. 
FACS lyse, CD62p-PE (P-selectin), CD42a-PE (GPIX) and IgG-PE were purchased from BD Pharmingen TM 
(Becton, Dickinson and Company, Franklin Lakes, New Jersey) while CD14-PE Cy5.5 (glycosyl-
phosphatidylinositol-linked single-chain surface membrane glycoprotein, RMO52) from Beckman Coulter 
(Coulter Corporation, Miami, FL) and CD61-FITC (GPIIIa) from DAKO (Dako Denmark A/S, Glostrup, 
Denmark). These were all stored at 4°C as per manufacturer’s instructions until the date of expiry. FACS 
lyse was diluted 1:10 with distilled water. 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid N-(2-Hydroxyethyl)piperazine-N′-(2-ethanesulfonic 
acid) (HEPES) and Bovine serum albumin were purchased from Sigma Aldrich (St. Louis, MO, USA) and  
HEPES buffered saline (10 mM HEPES and 0.15 M NaCl) used was pH 7.4. BSA was used at 1% (w/v). 
Polypropylene tubes were used for all sample preparation. 
5.2.2 Statistical analysis 
Results are expressed as mean ± standard error of mean. All statistical analysis was performed using 
Graph Pad Prism 5 software for Windows.  Two sets of data were compared using Student’s paired t-
test. More than 2 sets of data were compared using repeated measures ANOVA.  Bonferroni multiple 
comparison test was used to compare all sets of results, while Dunnett’s multiple comparison test was 
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used to compare results to baseline values.  Correlation of venous and capillary blood was evaluated 
using the coefficient of correlation as well as Bland and Altman analysis [512]. 
5.2.3 Pilot study protocol 
5.2.3.1 Participants and Study Protocol 
A pilot study was performed to see if there is correlation between venous and capillary blood for P-
selectin expression (percentage positive population) and MPA formation in healthy volunteers.  After 
obtaining RMIT HREC approval (approval number 28/08/), 10 healthy volunteers aged 18-60 were 
recruited for the study. Medical history was obtained using a questionnaire. Exclusion criteria included 
use of any medication known to affect platelet function in the previous 14 days, any health conditions or 
known problems with venipuncture. 
A total of 4 mL of venous blood was collected using standard venipuncture and a total of 13 drops of 
capillary blood, with the first drop always discarded. Both capillary and venous samples were prepared 
for analysis of P-selectin expression and MPA formation. Resting and activated platelets were analysed. 
5.2.3.2 Determination of P-selectin expression 
For both venous and capillary protocols, ADP and TRAP were used as agonists. Final ADP concentrations 
were 1 µM and 5 µM, while TRAP was used at 2 µM, 4 µM and 20 µM. Antibodies used for this protocol 
were CD61-FITC and CD62p-PE or IgG-PE, all at 0.5 µg/mL final concentration. CD61-FITC  was used to 
identify platelets by integrin β3 expression, while CD62P-PE was used to determine the level of P-
selectin expression. 
5.2.3.2.1 Protocol for venous blood processing 
Venous blood was processed within 15 minutes of collection  to reduce spontaneous platelet activation 
[513]. 20 µl of blood (final dilution 1:10) was added to tubes already containing 0.5 µg/mL antibody mix 
or appropriate isotype control, and agonist or HEPES-buffered saline (HBS). Samples were then 
incubated at room temperature for 15 minutes and fixed using 800 µl of 1% (v/v) Formaldehyde 
dissolved in HEPES buffered saline (1% HSF (v/v)). 
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5.2.3.2.2 Protocol for capillary blood processing 
Tenderlett® (Edison, NJ) finger incision devices were used to obtain capillary blood. One drop of blood, 
approximating 50 µl, was added to pre-prepared reagents containing agonists, HEPES-buffered saline 
and sodium citrate. Pre-prepared reagents were frozen at -20°C until use for maximum of 1 month. 
Reagents were defrosted at room temperature. Samples used for determination of the P-selectin 
expression contained 450 µl of HEPES buffered saline or agonist (ADP or TRAP) resuspended in HEPES 
buffered saline and 5.5 µl of sodium citrate. After addition of 1 drop of capillary blood (final blood 
dilution 1:10) to each tube, samples were incubated for 15 minutes at room temperature. After 15 
minutes, samples were fixed with 1 mL of 1% HSF (v/v). They were left at room temperature for 15 
minutes and then refrigerated until labeling with antibodies. Capillary protocol for analysis of both P-
selectin and MPAs involved a post-fixation labeling of samples and was adapted from previously 
described protocols [432, 514]. Briefly, for determination of the P-selectin expression, 50 µl of fixed 
blood sample was incubated with antibody mix (final concentration 0.5 µg/mL) for 40 minutes at room 
temperature in the dark. After 40 minutes incubation, 500 µl of 1% HSF (v/v) was added. Samples were 
left at room temperature for 15 minutes and then refrigerated until analysis. 
5.2.3.3 Determination of MPA formation 
For both venous and capillary protocols, ADP and TRAP were used as agonists. Final ADP concentrations 
were 1 µM and 5 µM, while TRAP was used at 2 µM, 4 µM and 20 µM. CD14-PE Cy5.5 was used to 
identify monocytes while CD42a-PE was used to identify platelets. Final antibody concentration was 0.5 
µg/mL. 
5.2.3.3.1 Protocol for venous blood processing 
Venous blood was processed within 15 minutes of venipuncture for the determination of MPA 
formation. Briefly, 40 µl of blood was incubated with 20 µl of antibody mix (or isotype control) and 20 µl 
of agonist or HEPES buffered saline for 15 minutes at room temperature. 800 µl of FACS Lyse solution 
diluted 1: 10 with distilled water was added. Samples were analysed after 15 minutes on flow 
cytometer. 
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5.2.3.3.2 Protocol for capillary blood processing 
Pre-prepared reagents for determination of MPA formation contained 50 µl of HEPES buffered saline or 
agonist and 5.5 µl sodium citrate. They were kept frozen at -20°C and defrosted at room temperature 
before use. After addition 1 drop of capillary blood to each tube, samples were incubated for 15 minutes 
at room temperature. After 15 minutes incubation, samples were fixed using 1 mL of FACS Lyse solution 
diluted 1:10 with distilled water. Samples rested at room temperature for 15 minutes, and were then 
refrigerated until labeling with antibodies. 
Prior to labeling, samples were centrifuged at 1700g for 10 minutes and the supernatant was discarded. 
The cell pellet was resuspended in 60 µl HEPES buffered saline containing 1% BSA (w/v). Antibody mix 
(or isotype control), with final concentration of 0.5 µg/mL was then incubated with 60 µl of sample at 
room temperature for 40 minutes. 800 µl of 1% HSF (v/v) was added to samples, which were then 
refrigerated until analysis on flow cytometer. 
5.2.3.4 Analysis 
A pilot study was performed to see if there is correlation between venous and capillary blood for P-
selectin expression (percentage positive population) and LPA formation using Beckman Coulter Epics XL 
Flow Cytometer. The Beckman Coulter Epics XL Flow Cytometer was equipped with air-cooled 488 nm 
15 mw laser and connected to EXPO32 ADC acquisition and analysis software. 
For determination of P-selectin expression, platelets were identified based on characteristic forward and 
side scatter and CD61-FITC (integrin β3) expression (all on a logarithmic scale)[515].  The CD62P 
expression was determined on this cell population. The percentage of platelets expressing CD62P was 
recorded. A total of 10 000 platelets was counted using low acquisition speed. 
Monocytes were identified on the linear forward and side scatter plot as well as the strong expression of 
CD14 [515]. Histogram plot was drawn for CD42a positivity of the monocytic population. The percentage 
of monocytes with platelets attached (expressing CD42) was recorded. 1000 monocytes was recorded 
using medium acquisition speed. 
Appropriate isotype control was used to set up the gate at approximately 1% MPA or 1% P-selectin and 
to check the non-specific binding. Results were analysed using EXPO32 ADC or BD-Diva software. 
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5.2.4 Point of care test for evaluation of platelet function using flow cytometry 
5.2.4.1 Participants and Study Protocol 
This study consisted of two parts. In the first part of the study, methods for measuring P-selectin and 
LPA formation on capillary blood was improved, evaluated and compared to standard venous protocol. 
Apart from correlation studies, reproducibility and stability of the methods were assessed.  This part of 
the study was performed on healthy volunteers after obtaining RMIT HREC approval (approval number 
53/11). Both venous (4 mL) and capillary (up to 20 drops) blood was collected from healthy volunteers 
not on medication known to affect platelet function in the previous 14 days,  as determined by a 
questionnaire. 
The newly developed fingerstick method for platelet function testing were then evaluated for their 
ability to detect the anti-platelet effect of a single 100 mg dose of aspirin 2.5 hours after ingestion. 
Sensitivity of methods to in vivo aspirin were compared to standard LTA. For this part of the study, 8 mL 
of venous blood and 7 drops of capillary blood were collected before and 2.5 hours after ingestion of 
100 mg of Aspirin (Disprin Max, Reckitt Benckiser Group, Berkshire, UK). All volunteers were healthy and 
not on any medication known to affect platelet function in the previous 14 days. Volunteers were also 
excluded if they planned to have surgery or dental appointments in the following 14 days. 
Volunteers aged 18-60 were allowed to participate in the study. No side effects were reported and all 
participants completed the trial. 
5.2.4.2 Evaluation of protocol for determination of P-selectin expression 
Processing of blood for venous and capillary samples was similar to the protocol already described 
previously. Introduced changes included incubation temperature, blood dilution, antibody concentration 
and choice of agonists. Samples were incubated at 37°C instead of room temperature, blood was diluted 
1:4 with HEPES buffered saline and AA (0.2 mM), U-46619 (0.6 µM) and ADP (20 µM) were used as 
agonists.  Antibodies used for this protocol were CD61-FITC and CD62p-PE or IgG-PE, all at 1 µg/mL final 
concentration. 
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5.2.4.2.1 Venous Protocol 
Blood was diluted 1 in 2 with HEPES buffered saline and incubated with a mix of antibodies and agonist 
or HEPES buffered saline to yield a final 1 in 4 dilution. Samples were incubated at 37°C for 15 minutes, 
fixed with 1ml of 1% HSF (v/v) and immediately analysed for determination of P-selectin expression. P-
selectin was expressed as both, percentage positive population and mean fluorescence intensity. 
5.2.4.2.2 Capillary protocol 
For capillary protocol 150 µl of HEPES-saline or agonist was mixed with 5.5 µl of sodium citrate and 
frozen at -20
o
C until use for a maximum of 1 month. Pre-prepared reagents were defrosted at 37°C for 4 
minutes. One drop of blood was added to each tube. The first drop of blood was always discarded and 
consecutive drops collected. Samples were gently mixed and incubated at 37
o
C for 15 minutes. After 
incubation samples were fixed with 800 µl of 1% HSF (v/v) and left at room temperature for additional 
15 minutes. Samples were refrigerated until labeling with antibodies. Process of labeling samples with 
antibodies was the same as already described. Final antibody concentration was 1 µg/mL. 
5.2.4.2.3 Testing performed 
Agonists dose response curves were obtained by incubating both capillary and venous blood samples 
with increasing concentrations of agonists. Concentration selected were those that yielded adequate 
platelet activation in both protocols with the least amount of variability. 
The effect of fixative concentration was evaluated. Due to higher than standard blood concentration, 1% 
(v/v) HSF may not have been adequate for fixing the cells, and therefore samples were fixed with 2% 
(v/v) and 3%  (v/v) HSF simultaneously and analysed. 
Stability of capillary samples was evaluated by storing activated and fixed capillary samples for up to 48 
hours. Samples were labeled and analysed immediately (0 hours), 24 and 48 hours later. 
Due to a possibility that later drops of blood may be more activated than the previous, 6 consecutive 
drops of blood from 6 volunteers were analysed for resting platelet P-selectin expression. 
Reproducibility of both venous and capillary samples was evaluated. For venous samples, 1 tube of 
blood was collected and diluted blood was added to 10 consecutive tubes containing the same agonist 
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or HEPES buffered saline. As for capillary protocol, 10 tubes of pre-prepared reagents (all containing the 
same agonist) were defrosted and 10 consecutive drops of blood collected and added to each tube. A 
maximum of 20 drops was collected from one fingerprick. All samples were labeled and analysed. 
Coefficient of variation was then calculated for each set of data. 
Both venous and capillary blood was collected from 10 volunteers and activated with 0.2 mM AA, 0.4 
µM U-46619 and 20 µM ADP to determine the correlation of venous and capillary P-selectin expression 
under those processing conditions. 
5.2.4.3 Evaluation of protocol for LPA formation 
Both capillary and venous samples were processed similarly to already described method. Adjustments 
made were the choice of agonists and incubation temperature. Final agonist concentrations used in this 
part were 0.4 mM of AA, 0.4 µM and 10 µM U-46619 and 20 µM ADP. 
5.2.4.3.1 Venous blood protocol 
For the venous protocol, 40 µl of blood was incubated with 20 µl of antibody mix (or isotype control) 
and 20 µl of agonist or HEPES buffered saline for 15 minutes at 37°C within 15 minutes of blood 
collection. 800 µL of FACS Lyse diluted 1:10 in distilled water was used to fix the samples which were 
analysed immediately. 
5.2.4.3.2 Capillary blood protocol 
For the capillary protocol, a mix of 50 µl of HEPES buffered saline or agonist and 5.5 µl of sodium citrate 
was frozen. Pre-prepared reagents were thawed at 37°C for 4 minutes. 1 drop of blood was added to 
each tube and incubated for 15 minutes at 37°C. 800 µL of FACS Lyse was added to fix the samples, 
which were then refrigerated until labeling. Choice of antibodies, their final concentration and labeling 
procedure is the same as already described in the pilot study. No changes were made. 
5.2.4.3.3 Testing performed 
Both capillary and venous samples were incubated with increasing concentrations of selected agonists 
to obtain agonist dose-response curves. Final agonist concentrations selected were those that gave 
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sufficient MPA formation in both capillary and venous blood, with the least variability amongst 
volunteers. 
Due to the possibility that consecutive drops of blood may yield higher platelet activation and 
consequent MPA formation, 6 drops of blood from 5 volunteers was collected and analysed for resting 
LPA formation. Samples were processed as per capillary protocol and analysed for MPA formation. 
Capillary samples were collected from 4 volunteers and activated with a range of concentrations of AA, 
U-46619 and ADP. Samples were then labeled and analysed immediately (0 hours), 24 and 48 hours 
after fixation in order to test the stability of both MPAs and NPAs formed. 
The reproducibility of both venous and capillary blood was evaluated. For venous blood, 1 sodium 
citrate tube was collected and blood added to 10 tubes containing the same agonist or HEPES buffered 
saline. All 10 samples were analysed immediately and the coefficient of variation of MPA formation 
calculated. For capillary protocol, 10 consecutive drops of blood were added to 10 pre-prepared reagent 
tubes containing the same agonist or HEPES buffered saline. Blood was fixed and lysed using FACS Lyse, 
labeled and analysed for MPA formation. Similarly to venous protocol, coefficient of variation was 
calculated. 
This processing of capillary samples was compared to standard venous protocol.  Capillary and venous 
blood from 10 volunteers was collected and analysed for MPA formation as per above described 
protocols. Coefficient of correlation was calculated and Bland-Altman analysis was performed using 
Graph Pad Prism software. 
5.2.4.4 Sensitivity of P-selectin and LPA protocols to in vivo aspirin ingestion 
8 mL of venous and 7 drops of capillary blood were taken from 10 healthy volunteers before and 2.5 
hours after ingestion of a 100 mg of aspirin. Aspirin was taken immediately after the first venipuncture 
and fingerstick, which allowed monitoring of compliance. 
Samples for measurement of the P-selectin expression were activated with 0.2 mM AA and 10 µM TRAP, 
while samples for measurement of MPA formation were activated with 0.4 µM U-46619 and 0.4 mM AA.  
All capillary samples were processed using newly developed protocols, described above. 
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5.2.4.4.1 Light transmission aggregometry 
Optical aggregometry was used to determine platelet aggregation in platelet rich plasma. Platelet rich 
plasma was obtained by centrifuging whole blood collected into sodium citrate anticoagulant for 10 
minutes at 250g without brake and the supernatant platelet-rich plasma was removed. Remaining blood 
was then centrifuged at 2000g for 10 minutes to obtain platelet poor plasma. Platelet aggregation was 
performed on Chronolog aggregometer (Chrono-Log Corporation, Havertown, PA).  Briefly, the 
instrument was calibrated with PPP and PRP for 100% and 0% transmission. 300µl of PRP was incubated 
at 37°C for 2 minutes. Agonists were added (0.5 mM AA, 10 µM U-46619 and 10 µM TRAP final 
concentration) to constantly stirred samples. Maximal aggregation was recorded in samples collected 
before and after aspirin ingestion. 
5.2.4.5 Flow cytometric analysis 
The BD FACSCanto II flow cytometer was used in this study BD FACSCanto II is equipped with a solid 
state blue laser operating at 488nm connected to a FACS Diva acquisition and analysis software. 
P-selectin expression was measured using protocol already described. 
Analysis of NPA formation has been included in this study. Identification of monocytes and neutrophils 
was based on the characteristic forward and side scatter for both cell populations. Further 
differentiation was made using CD14 expression with monocytes having strong and neutrophils dim 
expression.  1000 monocytes was recorded using medium acquisition speed. Appropriate isotype control 
was used to set up the gate at approximately 1% LPAs and to check for the non-specific binding. 
Before analysis optimal voltages were determined as per instructions of the BD Biosciences in order to 
get the best signal to noise separation. PMT voltages for each channel were increased in 25V intervals 
from 250-600V. The coefficient of variation obtained by analysing dim particle at each voltage point was 
recorded. Values were plotted on the graph (voltage versus CV).  Voltages selected for further 
experiments were the lowest that produced the lowest CV.  Instrument was compensated for selected 
voltages. 
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5.3 Results 
5.3.1 Pilot study 
 This study was performed to test the possibility of obtaining clean, non-activated blood from finger stick 
suitable for analysis of resting and agonist induced platelet activation and MPA formation. Venous and 
capillary P-selectin expression and MPA formation in activated and resting samples were compared 
using correlation coefficient and  Bland-Altman analysis of ratio (venous versus capillary) versus average 
value [512].  
5.3.1.1 Correlation of venous and capillary blood for evaluation of P-selectin expression 
A pilot study was performed to determine the extent of correlation between the venous and capillary 
protocols using 1 and 5 µM ADP and 2, 4 and 20 µM TRAP.  The methodology used 1:10 dilution of 
whole blood for both capillary and venous samples and incubation with agonists at room temperature. 
The pilot study showed strong correlation between venous and capillary protocols when P-selectin was 
expressed as mean fluorescence intensity (Figure 5.1 A) or percentage positive population (Figure 5.2 B) 
(r=0.9.323; p<0.0001 and 9.246; p<0.0001 respectively). Bland-Altman analysis showed that some 
capillary samples (Figure 5.2) showed slightly higher activation in venous samples, although when MFI 
was used to express P-selectin the ratio of venous to capillary samples was between 0.5 to 1 for majority 
of samples. The greatest variability was observed in low activated samples when P-selectin was 
expressed as percentage positive population. 
5.3.1.2 Correlation of venous and capillary blood for evaluation of MPA formation 
Similarly to P-selectin, there was a strong correlation between venous and capillary samples for 
determination of MPA formation in resting and activated samples. Figure 5.3A shows correlation 
coefficient of 0.8476, while Figure 5.3B shows Bland-Altman plot of data. When ratio of venous versus 
capillary MPA percentage was plotted against average values, it was noted that ratio for most samples 
was between 0.5 and 1.5. 
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Figure 5-1: Correlation of venous and capillary blood for evaluation of P-selectin expression. 
  
F
ig
u
re
 5
.1
: 
C
o
rr
e
la
ti
o
n
 o
f 
v
e
n
o
u
s 
a
n
d
 c
a
p
il
la
ry
 b
lo
o
d
 f
o
r 
e
v
a
lu
a
ti
o
n
 o
f 
P
-s
e
le
ct
in
 e
xp
re
ss
io
n
. 
 
V
e
n
o
u
s 
a
n
d
 c
a
p
il
la
ry
 b
lo
o
d
 w
a
s 
co
ll
e
ct
e
d
 f
ro
m
 1
0
 r
a
n
d
o
m
 v
o
lu
n
te
e
rs
 a
n
d
 a
ct
iv
a
te
d
 w
it
h
 1
 a
n
d
 5
 µ
M
 A
D
P
 a
n
d
 2
, 
4
 a
n
d
 2
0
 µ
M
 T
R
A
P
. 
R
e
st
in
g
 p
la
te
le
t 
P
-s
e
le
ct
in
 e
xp
re
ss
io
n
 w
a
s 
a
ls
o
 r
e
co
rd
e
d
. 
 W
h
e
n
 P
-s
e
le
ct
in
 w
a
s 
e
xp
re
ss
e
d
 a
s 
m
e
a
n
 f
lu
o
re
sc
e
n
ce
 i
n
te
n
si
ty
 (
A
) 
 o
r 
 p
e
rc
e
n
ta
g
e
 p
o
si
ti
v
e
 p
o
p
u
la
ti
o
n
 (
B
) 
co
rr
e
la
ti
o
n
 w
a
s 
st
ro
n
g
 (
r 
=
 0
.9
3
2
3
; 
p
<
0
.0
0
0
1
 a
n
d
 r
=
 0
.9
2
4
6
, 
p
<
0
.0
0
0
1
 r
e
sp
e
ct
iv
e
ly
).
 
 
 Figure 5-2: Bland-Altman analysis of venous and capillary blood for evaluation of P
 
  
-selectin expression. 
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Figure 5-3:  Correlation of venous and capillary blood for evaluation of monocyte-platelet aggregate formation. 
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5.3.2 Point of care test - Evaluation of fingerstick protocol 
5.3.2.1 P-selectin expression 
5.3.2.1.1 Dose response curves 
Dose response curves for AA, ADP and U-46619 were obtained for both venous and capillary protocols 
and both percentages of platelets expressing P-selectin and the MFI were recorded (Figure 5.4). Based 
on the results obtained 0.2 mM AA, 0.6 µM U-46619 and 20 µM ADP were selected for further studies as 
those concentrations gave sufficient sample activation and least variability (n=3). 
5.3.2.1.2 The effect of Formaldehyde concentration on P-selectin Expression 
The samples were to be fixed at point of collection and thus the effect of various concentrations (1% 
(v/v), 2% (v/v) and 3% (v/v)) of formaldehyde for fixation was determined.  Both non - activated and 
activated (0.2 mM AA, 0.6 µM U-46619 and 20 µM ADP) samples were examined in 3 volunteers and the 
data are presented in Figure 5.5. The percentage of platelets expressing P-selectin is not different 
between samples fixed with 1% and 2% HSF (p>0.05; 50.60% ±11.34% and 43.82% ± 9.524%; n=3 
respectively). The MFI was significantly lower in samples fixed with 2% HSF (p<0.05; 3533 ± 825.2 versus 
2353 ± 532) with the decrease being more prominent in more activated samples. Sample fixed with 3% 
(v/v) HSF had average MFI of 1397 (data not shown) and 3% (v/v) HSF was excluded from further 
analysis. 
5.3.2.1.3 Drop selection for testing P-selectin expression 
It was postulated that the fingerstick procedure may induce platelet activation thus resting P-selectin 
expression was assessed in 5 consecutive drops (drops 2-6, first drop always discarded) collected from 6 
volunteers (Figure 5.6). The P-selectin expression of resting samples was expressed as the percent 
positive population and the MFI which were then, compared using a repeated measures ANOVA with 
Bonferroni multiple comparison test. The MFIs were 509.3 ± 17.7, 505.8 ± 17.63, 510.0 ± 22.77, 508.2 ± 
22.13, 515.7 ± 24.03 for drops 2-6 respectively showing no difference in resting platelet activation 
(p>0.05; n=6). 
  
 Figure 5-4: Arachidonic acid, U-46619 and ADP 
Figure 5.4: Arachidonic acid, U-46619 and ADP dose response curves.
Blue line indicates venous , while red line indicates capillary blood. 
Based on P-selectin MFI and % positive  population for both venous and capillary samples the concentration of agonists chosen 
was: AA – 0.2 mM; U-46619 – 0.6 µM; ADP 
  
dose response curves. 
 
 
– 20 µM. All results are expressed as mean ± SEM.  
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Figure 5-5: P-selectin expression on paired samples fixed with 1% (v/v) and 2% (v/v) HSF. 
 
Figure 5.5: P-selectin expression on paired samples fixed with 1% (v/v) and 2%  (v/v) HSF. 
1 and 2% formaldehyde (v/v) was used to fix the samples from 3 volunteers (resting and activated with 0.2 mM AA, 0.6 µM U-
46619 and 20 µM ADP) for P-selectin expression , both MFI  (B) and % positive population (A). Results  were compared using 
Students Paired t-test. There was no significant difference in the percentage positive population, however the MFI was 
significantly lower in samples fixed with 2% HSF (* indicates p=0.05).  
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Figure 5-6:  The effect of consecutive drops collection on P-selectin expression.   
 
Figure 5.6: The effect of consecutive drops collection on P-selectin expression.  
In order to test if consecutive drops during fingerstick produce more activated platelets, 6 consecutive drops of blood were 
collected from 6 volunteers. The first drop was always discarded and the remaining 5 drops analysed for resting platelet P-
selectin level, expressed as  MFI (A) and % positive  population (B). Results were expressed as mean ± SEM and analysed using 
repeated measures ANOVA  with Bonferroni multiple comparison post test. There was no significant difference between drops 
when activation status was measured by P-selectin (p>0.05, n=6).  
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5.3.2.1.4 Stability of samples fixed with 1% (v/v) HSF for P-selectin analysis 
The stability of P-selectin expression over 48 hours is shown in Figure 5.7. Blood was collected from 3 
volunteers and both resting and activated (0.2 mM AA, 0.6 µM U-46619 and 20 µM ADP) P-selectin 
expression was recorded. Figure 5.7A shows the change in individual results over time, while Figure 5.7B 
shows the average results over 48 hours for each agonist. Average P-selectin expression decreased from 
50.6 ± 11.3 to 45.5 ± 10.7 and 39.6 ± 9.4. The P-selectin expression was significantly lower in samples 
that were 48 hours old (p<0.05).  When P-selectin expression was recorded as MFI (Figure 5.8) it showed 
less stability over 48 hours than when expressed as the percentage positive population. A significant 
decrease in MFI (Figure 5.8A) was noted at 24 hours (from 3533 ± 825.2 to 2106 ± 511.9, p<0.01 in 
comparison to 0 hours) which continued to decrease further over 48 hours (1263 ± 276.0, p<0.001). The 
samples that were more activated and showed higher P selectin expression, showed a greater tendency 
to decrease (Figure 5.8B). 
Figure 5.9 however shows that the decrease in MFI over 48 hours was steady and proportional and still 
correlated well with baseline activation (r=0.9928 for 0 and 24 hours and r = 0.9747 for 0 and 48 hours). 
Bland-Altman plots (Figures C and D) of average MFI versus ratio shows that after 24 hours the ratio of 
MFI for all samples was between 1.5 and 2 (Bias 1.680 and SD of bias 0.132; 95% limits of Agreement 
from 1.421 to 1.939) regardless of the original sample activation.  More variable decrease in MFI was 
observed after 48 hours (Bias 0.2.635 and SD of bias 0.4668 with 95% limits of agreement from 1.721 to 
3.550). 
Due to the decrease in MFI over the 48 hour period, P-selectin levels in activated samples were 
expressed as a ratio of MFI (activated versus resting)(Figure 5.10). Figure 5.9A shows that MFI ratios 
remain stable for at least 24 hours (8.4 ± 1.5 and 7.9 ± 1.6 at 0 and 24 hours respectively) and mildly 
decrease to 6.8 ± 1.2 at 48 hours (p<0.05; n=3). Figure 5.10B shows the mean MFI ratio for each agonist 
and shows that the biggest decrease was seen in more activated samples. In samples activated with 0.6 
µM U-46619, MFI ratio decreased from 13.3 at 0 hours to 11.1 at 48 hours and in samples activated with 
0.2 mM AA it decreased  from 7.4 at 0 hours to 5.3 at 48 hours while samples activated with 20 µM ADP 
remained stable (4.5 to 3.9 at 0 and 48 hours respectively). 
 
  
212 
 
Figure 5-7: Stability of P-selectin expression (% positive) over 48 hours. 
 
 
 Figure  5.7: Stability of P-selectin expression (% positive) over 48 hours. 
A) The data represents P-selectin expression (% positive population ) of samples fixed with 1% (v/v) HSF over a 48 hour period 
(n=3) prior to analysis.  Resting and agonist-induced  expression  of P-selectin was recorded. Samples were activated with  0.2 
mM AA, 0.6 µM U-46619 and  20 µM ADP. This graph shows changes in individual results over a 48 hour period. Results are 
analysed using repeated measures ANOVA with Dunnett's multiple comparison test. A significant decrease in the percentage of 
the platelets expressing P-selectin was noted at 48 hours (* indicates P<0.001). 
B) The graph shows the variability for the mean P-selectin expression (n=3) for each agonist over a 48 hour period.  A significant 
decrease in the expression of P-selectin was observed after 48 hours in AA and ADP  activated samples (p<0.05). There was no  
significant difference in the P-selectin expression at 24 hours.  
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Figure 5-8: Stability of P-selectin expression (MFI) over 48 hours. 
 
 
Figure  5.8: Stability of P-selectin expression (MFI) over 48 hours. 
A) This figure shows individual changes in the P-selectin expression (MFI) in resting and activated samples  fixed for up to 48 
hours (n=3) prior to analysis.  Samples were activated with  0.2 mM AA, 0.6 µM U-46619 and 20 µM ADP. 
There was a significant decrease in the MFI of the CD62P stained population over time. Results were  analysed  using  repeated 
measures ANOVA with  Dunnett's multiple comparison test. ** represents p<0.01; *** represents p<0.001.  
B) The graph shows the variability for the mean P-selectin expression (MFI) for each agonist over 48 hour period. A significant 
decrease in P-selectin expression was observed in U-46619 and AA activated samples  within 24 and 48 hours. Results are 
analysed using  1-way ANOVA with Dunnett's post test.   
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Figure 5-9: Correlation and Bland-Altman plots of P-selectin expression (MFI) over 48 hours.  
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Figure 5-10: Stability of P-selectin over 48 hours when activation was expressed as MFI Ratios. 
 
 
Figure  5.10: Stability of P-selectin over 48 hours when activation was expressed as MFI Ratios. 
A) When P-selectin was expressed as a ratio of MFI in activated versus non-activated samples, it remained stable for up to 48 
hours.  Individual changes are  presented  (n=3).  Results were analysed using  repeated measures ANOVA with  Dunnett's  post 
test. Mild decrease in MFI Ratio was observed after 48 hours. * indicates p<0.05; n=3. 
B) The graph shows the variability  of the mean P-selectin expression (MFI ratios ) for each agonist over 48 hour period (n=3).   
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5.3.2.1.5 Stability of samples fixed with 2% HSF for P-selectin analysis 
Higher formaldehyde concentrations produced less P-selectin expression (MFI) but it may be more 
stable fixative than 1% (v/v) HSF over 48 hour period. In order to see if higher concentrations were 
capable of preventing a decrease in the P-selectin expression, capillary blood from 3 donors was fixed 
with 2% (v/v) formaldehyde buffer and tested over 48 hour period. 
Figure 5.11A shows individual variability in P-selectin expression (% positive population) in samples fixed 
with 2% (v/v) HSF and shows that the number of platelets expressing P-selectin decreased over 24 hour 
period (from 43.8 ± 9.5 at 0 hours to 29.6 ± 7.5 at 24 hours to 29.8 ± 8.5 after 48 hours). Samples were 
analysed using 1-way ANOVA with Dunnett’s multiple comparison tests that compared 24 and 48 hours 
results to baseline. 
Samples fixed with 2% (v/v) HSF demonstrate a larger decrease in MFI over 24 and 48 hours (Figure 
5.11B) compared to samples fixed with 1% HSF. However, if P-selectin expression is expressed as the 
MFI ratio, samples fixed with 2% (v/v) HSF demonstrate stability over 48 hours (Figure 5.11C) even 
though non-significant variability occurs between 24 and 48 hours.  Since use of 2% (v/v) HSF did not 
prevent a decrease in the P-selectin expression (despite the stability of the MFI Ratios) and since it 
caused less original activation than samples fixed with 1% (v/v) HSF, 1% (v/v) HSF was used for the rest 
of the study. 
5.3.2.1.6 Reproducibility of venous and fingerstick protocol for determination of P-selectin 
expression 
The reproducibility of the capillary and venous protocols for P-selectin expression (Tables 5.1 and 5.2) 
was estimated on activated and resting blood samples. While one venous sample was collected and 
prepared in 10 consecutive tubes, 10 consecutive drops of blood were collected to test reproducibility of 
capillary protocol for each agonist. Ten samples were activated by either 0.2 mM AA, 0.6 µM U-46619, 
20 µM ADP or no agonist. 
Analysis of data showed that the highest variability was observed in resting platelet activation when P-
selectin was expressed as a percentage positive population (26.57 and 59.46% for capillary and 16.20 
and 15.27% for venous blood samples). When minimum and maximum values were observed, there was 
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no clinical difference in the amount of P-selectin expression (0.6% was minimum and 3.1% maximum in 
capillary protocol with the highest CV). 
However when P-selectin was expressed as mean fluorescence intensity, the CV decreased to 3.33 and 
6.37% for capillary and 5.11 and 5.73% for venous protocols. The CV was much lower in activated 
samples for both protocols, and the use of MFI gave more reproducible results. 
5.3.2.1.7 Correlation of venous and capillary protocols for P-selectin expression 
Figure 5.12A shows the correlation of venous and capillary protocols for P-selectin expression when 0.2 
mM AA, 0.6 µM U-46619 and 20 µM ADP were used as agonists and the sample was incubated at 37°C. 
Overall, weaker correlation was observed than in the pilot study (r=0.6337, p<0.001). When data was 
analysed separately for each agonist, it was noted that while samples activated with 0.2 mM AA showed 
strong correlation (Figure 5.12B; r=0.6243; p=0.01), samples activated with 20 µM ADP (Figure 5.12C) 
showed no correlation (r=0.3251; p>0.05). Sub-analysis of the pilot study showed that when capillary 
samples were activated with 1 and 5 µM ADP (n=9) and incubated at room temperature, they showed 
strong correlation (r=0.6952; p=0.001). 
The correlation of MFI between venous and capillary (Figure 5.13) showed negative bias in capillary 
samples (Bias 2.408 and SD of bias 2.667) due to labeling of platelets after fixation and the correlation 
was weaker than in the pilot study (r=0.5345; p<0.0001). 
  
 Figure 5-11:  Stability of P-selectin expression (% positive) in samples fixed with 2% (v/v) HSF. 
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 Table 5-1: Reproducibility of venous and capillary methods for estimation of P-selectin expression (% positive). 
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 Table 5-2: Reproducibility of venous and capillary methods for estimation of P-selectin expression (MFI). 
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Figure 5-12: Correlation of venous and capillary protocols for P-selectin expression (% positive). 
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Figure 5-13: Correlation of venous and capillary protocols for P-selectin expression (MFI). 
 
 
 
Figure  5.13: Correlation of venous and capillary protocols for P-selectin expression (MFI). 
 
Venous and capillary blood was collected from 10 random volunteers and activated with 0.2 mM AA, 0.6 µM U-46619 and 20 
µM ADP. Resting platelet P-selectin expression was also recorder.  Correlation  (A) was  weak (r=0.5345; p<0.0001). Bland-
Altman plot (B) showed that P-selectin expression (MFI) was higher in venous than in capillary blood and ratio of capillary and 
venous P-selectin expression had bias 2.408 (SD of bias  2.667).  
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5.3.2.2 Evaluation of  leukocyte-platelet aggregate formation 
5.3.2.2.1 Dose response curves 
The effect of agonist concentration on the generation of monocyte-platelet aggregates is shown in 
Figure 5.14. The concentrations that gave sufficient sample activation and the least variability were 
selected for further studies (0.4 mM AA, 0.4 µM U-46619 and 20 µM ADP). 
5.3.2.2.2 Drop selection for testing LPA formation 
It was postulated that the fingerstick procedure may lead to platelet activation and subsequent 
leukocyte-platelet interaction, thus, the resting LPA expression was assessed in 5 consecutive drops 
collected from 6 volunteers (Figure 5.15). MPA and NPA were compared using repeated measures 
ANOVA with Bonferroni multiple comparison test comparing all sets of results. The mean percentage of 
MPA formation in consecutive drops was 8.8 ± 1.3, 8.4 ± 1.0, 9.5 ± 1.1, 8.9 ± 0.3 and 9.6 ± 0.7, while the 
mean of NPAs was 7.6 ± 1.1, 7.6 ±0.5, 7.5± 0.2, 7.1 ± 0.2 and 7.5 ± 0.2. There was no significant 
difference in LPA formation between any samples (p>0.05; n=5). 
5.3.2.2.3 The effect of storage on monocyte-platelet aggregate formation in fixed samples 
The purpose of this method is to enable remote testing of LPA formation and it was therefore important 
to demonstrate that results are stable for at least 24 hours after collection and fixation of resting and 
activated samples. Formation of MPAs appears to be stable over 48 hours (except one outlier), as shown 
on Figure 5.16. There was no significant difference in the MPA formation at 24 and 48 hours in 
comparison to 0 hours when results were analysed using repeated measures ANOVA with Dunnett’s 
comparison test (p>0.05; n=4). 
One capillary blood sample (shown on Figure 5.16) activated with 0.4 mM AA showed 72.8% MPA 
formation, which decreased to 33.5% at 24 hours and then increased back to 77.0% at 72 hours.  
Considering that labeling procedure involves sample centrifugation and isolation of cell pellet, different 
drops of blood were collected at 0 hours (3 drops in 3 separate pre-prepared reagent tubes containing 
0.4 mM AA) for processing at 0, 24 and 48 hours interval. It is possible that the drop of blood or more 
likely the pre-prepared reagent in the tube prepared for processing at 24 hours after fixation was faulty.   
The average percent of MPA was 49% at 0 hours, 47% at 24 and 55% at 48 hours. The difference seen in 
the results was not clinically significant (p>0.05; n=4). 
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Overall, MPA values at 0 hours correlated well with values obtained at 24 (Figure 5.17A, r= 0.8839) and 
48 (Figure 5.17B, r=0.9130) hours later. Bland-Altman plots (5.17CB) show that after 24 hours the ratio 
of most samples is 1, showing bias of 1.070 (SD of bias 0.45) and after 48 hours (Figure 5.17D) there was 
a tendency for increased MPA formation (Bias 1.25; SD of bias 0.4909). 
When MPAs were expressed as a ratio of activated versus non activated samples, they remained stable 
over 48 hour period (Figure 5.18). The greatest decrease in the MPA ratio was seen in the same sample 
activated with 0.4 mM AA described above, with ratio decreasing from 16.2 at 0 hours to 3.2 at 24 
hours. Arachidonic acid activated samples hence showed the greatest change over time as shown on 
Figure 5.18B. On average ratios changed from 9.0 ± 1.1 at 0 hours to 8.1 ± 1.4 at 24 and 7.3 ±0.9 at 48 
hours, demonstrating overall stability of the protocol. 
NPA analysis was not stable over time and a tendency to increase was noted at 24 hours, and they 
continued to increase at 48 hours (p<0.01 in comparison to baseline) also showing increased variability 
of results (Figure 5.19A). Average NPA at 0 hours were 20.1 ± 3.4 which increased to 27.0 ± 4.8 within 24 
hours up to 33.7 ± 6.2 within 48 hours. Sub-analysis of results (not shown) revealed that the increase 
was not observed with one agonist, but occurred randomly across the range of samples. Due to stability 
of MPA formation in those samples, it was unlikely that sample processing or poor blood collection 
caused this variability. NPA Ratios (Figure 5.19B) were also unstable over time, even though the increase 
did not reach statistical significance. Analysis of NPA formation was therefore excluded from further 
analysis. 
  
 Figure 5-14: Agonist dose response curves for AA, U-46619 and ADP. 
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Figure 5-15: The effect of consecutive drops collection on leukocyte-platelet aggregate formation.  
 
  
Figure  5.15: The effect of consecutive drops collection on leukocyte-platelet aggregate formation.  
In order to test if  the sample collection would affect the measurement of LPA formation, 6 consecutive drops of blood were 
collected from 5 volunteers. The first drop was always discarded and the remaining 5 analysed for resting LPA formation. Results 
were expressed as mean ± SEM and analysed using repeated measures ANOVA  with Bonferroni multiple comparison test. There 
was no significant difference between any drops when activation status was measured by MPA  (A) or NPA (B); p>0.05; n=5.  
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Figure 5-16: The effect of storage on monocyte-platelet aggregate formation. 
 
 
Figure 5.16: The effect of storage on monocyte-platelet aggregate formation.  
A) MPAs from 4 volunteers were analysed over 48 hour period. MPA formation  was  analysed in  resting samples  and those  
activated with  0.4 mM AA, 0.4 µM U-46619 and 20 µM ADP.  Changes in individual results are presented (n=4). Results  were 
analysed using repeated measures ANOVA with Dunnett's post test. There was no significant change in the  percentage of MPAs 
over 48 hour period (p>0.05; n=4). 
B) The graph shows the variability for the mean MPA formation  for each agonist over 48 hour period.   
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Figure 5-17: Correlation and Bland-Altman plots of monocyte-platelet aggregate formation over 48 hours. 
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Figure 5-18: The effet of storage on monocyte-platelet aggregate ratios. 
 
Figure  5.18: The effect of storage on monocyte-platelet aggregate ratios.  
A) MPA ratios  were calculated (data from Figure  5.16) and analysed over 48 hour period. Individual results  are presented. 
Data was analysed using  repeated measures ANOVA with Dunnett's post test. MPA Ratios remained stable over 48 hour 
period. 
B) The graph shows the variability for the mean MPA ratios for each agonist over 48 hour period. Even though there were no 
significant differences  when results for each agonist were compared using repeated measures ANOVA with Dunnett’s multiple 
comparison test (p>0.05; n=4), AA activated samples showed a tendency for decreased MPA formation over time (outlier has 
been included in the  analysis).  
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Figure 5-19: The effect of storage on neutrophil-platelet aggregate formation. 
  
Figure  5.19: The effect of storage on neutrophil-platelet aggregate formation.A) NPA formation was recorded in samples described  
on Figure 5.16. Individual changer are presented. NPAs  showed tendency  for significant increase over 24 hours and continued to 
increase over 48 hour period since the blood collection. 
B) NPA ratios  were calculated on previous samples and  individual results are  presented. There was a tendency for increase of 
NPA ratios over 48 hour period although the increase did not reach statistical significance (p>0.05; n=4). 
Results were analysed using  repeated measures ANOVA with Dunnett's post test. ** indicates p<0.01.  
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5.3.2.2.4 Reproducibility of capillary protocol for MPA formation 
Reproducibility of the capillary protocols for MPA formation was evaluated by collecting 10 consecutive 
drops of blood in 10 pre-prepared reagent tubes containing the same agonist or HEPES buffered saline.  
For the venous protocol, 4 mL of blood was collected from 2 volunteers and aliquoted into 10 tubes 
containing antibodies and the same agonist. 
On average, as shown in Table 5.3, venous and capillary methods showed similar reproducibility. The 
highest variability was observed in resting platelet MPA formation for capillary protocol. The percentage 
of MPAs ranged from 5.6 to 14% which is unlikely to have clinical significance. 
U-46619 induced samples showed the lowest variability (CV was 3.42% and 8.63%) in capillary method, 
although the variability did not seem to be agonist induced as the same concentration of AA had CV of 
9.44% in one volunteer and 17.37% in the second one. Overall, the CVs for all samples except 1 was 
below 20%. 
5.3.2.2.5 Correlation of venous and capillary protocols 
Figure 5.20 shows the correlation of venous and capillary protocols for MPA formation when 0.4 mM 
AA, 0.4 µM U-46619 and 20 µM ADP were used as agonists. Correlation (Figure 5.20A) was weaker than 
in the pilot study (r=0.734, p<0.0001; n=10) and Bland-Altman plot (Figure 5.20B) showed that capillary 
samples had less MPA formation than venous samples, showing a small negative bias (0.8550 and SD of 
bias 0.360). 
5.3.2.3 Using MFI and MPA ratios of activated and resting platelets to express P-selectin and 
MPA formation 
The P-selectin expression in samples activated with 0.2 mM AA, 0.4 µM U-46619 and 20 µM ADP and 
MPA formation in samples activated with 0.4 mM AA, 0.4 µM U-46619 and 20 µM ADP were determined 
using both the capillary and venous protocols. 
The ratio of the P-selectin expression recorded as MFI of the activated to the non-activated samples was 
consistently higher than 2 for all agonists used as shown on Figure 5.21. 
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Figure 5.22 shows the percentage of MPA in activated samples expressed as ratio of activated versus 
resting samples. Similarly to the P-selectin MFI ratios, the MPA ratios were above 2. 
Since we tested healthy volunteers not currently on any medication, we propose the use of ratios 
instead of MFI and percentage for expression of the P-selectin and MPAs as a more stable measure. 
Ratio of 2 may be a cut-off point for differentiation of normal versus abnormal. 
5.3.3 Ability of fingerstick protocol to detect aspirin 
One of the aims of this project was to design a protocol for platelet function testing using flow 
cytometry in order to enable better monitoring of anti-platelet therapies. We therefore performed a 
small trial in which we tested the ability of the designed methods to detect the presence of a single 100 
mg dose of aspirin. 
Figure 5.23 shows that aspirin inhibited 0.2 mM AA activated P-selectin expression (MFI) 2.5 hours after 
ingestion of a 100 mg dose (n=10). The MFI decreased from 2232 ± 265.8 to 858 ± 86.2. Results were 
compared using Students paired t-test and p<0.01; n=10. 10 µM TRAP was used as a positive control, 
and neither TRAP activated or resting platelet P-selectin expression changed after aspirin (5724 ± 664.3 
to 4652 ± 705.7 for TRAP and 773.4 ± 55.17 to 875.9 ± 86.08 for resting P-selectin expression; p>0.05; 
n=10). 
The MFI in pre-aspirinated samples (Figure 5.24A) was significantly lower in resting than in 0.2 mM AA 
induced samples, 773.4 ± 55.2 and 2232 ± 265.8 respectively, p<0.001; n=10, while after aspirin 
ingestion (Figure 5.24B) the MFI changed to 875.9 ± 86.1 in resting and 898.0 ± 86.3 in AA induced 
samples, p>0.05; n=10. 
Figure 5.25 shows the change in MFI ratios in 0.2 mM AA (A) and 10 µM TRAP (B) induced samples after 
aspirin (100 mg) ingestion. In AA induced samples the MFI ratios changed from 2.94 ± 0.30 to 1.03 ± 
0.02, p<0.001; n=10, when results were compared using Student's paired t-test. The MFI in aspirinated 
samples was in all cases almost the same as the MFI of the resting platelet activation with ratio ranging 
from 0.89 to 1.16, while in pre-aspirinated sample minimum ratio was 2.005 and maximum 5.25. 
As shown in Figure 5.26, apart from MFI and MFI ratios, 100 mg of aspirin also decreased percentage of 
platelets expressing P-selectin from 24.97% ± 3.78 to 1.51% ± 0.45 (p<0.001; n=10). Resting platelet P-
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selectin expression was 1.59% ± 0.56 and AA induced 1.51% ± 0.46 after aspirin (data not shown), which 
was not significantly different when compared using Student’s paired t-test (p>0.05; n=10). 
Similarly to the P-selectin expression, a 100 mg of aspirin showed a 10-fold decrease of 0.4 mM AA 
induced MPA formation (Figure 5.27), which decreased from 52.96% ± 9.55 before aspirin to 6.73% ± 
1.03 after aspirin ingestion with p<0.001; n=10, when data was compared using Student’s paired t-test. 
Resting (Figure 5.27A) and 0.4 µM U-46619 (Figure 5.27B) induced MPA formation was not statistically 
different, p>0.05; n=10. 
When MPA was expressed as a ratio of activated versus resting samples, AA induced samples (Figure 
5.28) showed the decrease in ratios from 8.46 ± 1.73 to 1.21 ± 0.11, p<0.001, n=10. The minimum ratio 
before aspirin in AA induced samples was 2.82 and maximum 20.18, while after aspirin ingestion, the 
minimal ratio was 0.35 and maximum 1.65. The MPA ratios in 0.4 µM U-46619 activated samples did not 
change significantly (12.75 ± 2.55 before aspirin to 10.88 ± 1.52 after aspirin, p>0.05; n=10). 
Light transmittance aggregometry (Figure 5.29) was performed in parallel to flow cytometric fingerstick 
protocol and samples were activated with 0.5mM AA, 10µM U-46619 and 10µM TRAP before and after 
aspirin ingestion. Maximal AA induced aggregation decreased from 89.10% ± 2.536 to 0 (p<0.0001), 
while TRAP induced maximal aggregation decreased from 90.80% ± 2.01 to 77.9% ± 2.63, p=0.0129. 
Maximal U-46619 platelet aggregation did not change (85.60%± 1.73 80.30± 2.61, p=NS). 
Figure 5.30 shows that in all the methods used aspirin inhibited AA induced platelet activation by at 
least 50%. The smallest inhibition was observed when P-selectin was expressed as MFI, while MPA and 
MPA ratios showed inhibition of 83.16% ± 3.65 and 80.24% ± 4.28 respectively. When P-selectin was 
expressed as percentage positive population, the inhibition was 90.95% ± 3.96 and was not statistically 
different from LTA, while other methods were when compared using 1-way ANOVA with Dunnett’s 
multiple comparison test. 
 
  
 Table 5-3: Reproducibility of capillary and venous protocols for determination of monocyte-platelet aggregate formation. 
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Figure 5-20: Correlation of venous and capillary protocols for determination of monocyte-platelet aggregate formation. 
 
 
  
Figure 5.20: Correlation of venous and capillary protocols for determination of monocyte-platelet aggregate formation.  
A) Blood was  collected from 10 volunteers. Resting and agonist induced activation was analysed for MPA formation. Agonists used 
were 0.4 mM AA, 0.4 µM and 10 µM U-46619 and 20 µM ADP.  Protocols showed strong correlation (r=0.734; p<0.0001; n=10). 
B) Bland-Altman plot showed overall small  negative bias in capillary samples  (bias 0.8550 and SD of bias 0.357).  
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Figure 5-21: Mean fluorescence intensity ratios of activated versus resting samples to determine P-selectin expression. 
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Figure 5-22: Monocyte-platelet aggregate ratios of activated versus resting samples to determine monocyte-platelet aggregate formation. 
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Figure 5-23: P-selectin expression (MFI) before and 2.5 hours after ingestion of 100mg of aspirin. 
 
 
 
Figure  5.23: P-selectin expression (MFI) before and 2.5 hours after ingestion of 100 mg of aspirin.  
Results are expressed as mean ± SEM. Resting  (A) and 10 µM TRAP (C) induced P-selectin expression  did  not change, while  0.2 
mM AA  (B) induced P-selectin expression significantly decreased  2.5 hours after a single 100 mg dose of aspirin. Results were 
compared using Students paired t-test.  
** indicates p<0.01; n=10.  
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Figure 5-24: Comparison of resting and 0.2mM AA induced P-selectin expression (MFI) before and after aspirin (100 mg) 
ingestion. 
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Figure 5-25:  The effect of aspirin ingestion on 0.2 mM AA and 10 µM TRAP induced P-selectin expression (MFI Ratios). 
 
  
Figure  5.25: The effect of aspirin ingestion on 0.2 mM AA and 10 µM TRAP induced P-selectin expression (MFI Ratios).  
Aspirin ingestion significantly decreased P-selectin level expressed as the MFI ratio in 0.2 mM AA induced samples (A) in 
comparison to pre-aspirin level, while  the  MFI ratios in 10 µM TRAP  (B) induced samples  remained unchanged. Data 
was analysed using Students paired t-test. *** indicates p<0.001; n=10. 
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Figure 5-26: Comparison of resting and activated P-selectin expression (% positive) before and after aspirin (100 mg) ingestion. 
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Figure 5-27: Monocyte-platelet aggregate formation before and 2.5 hours after ingestion of 100 mg of aspirin. 
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Figure 5-28: Monocyte-platelet aggregate formation (MPA ratios) before and 2.5 hours after ingestion of 100 mg of aspirin. 
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Figure 5-29: Light transmittance aggregometry  before and 2.5 hours after ingestion of 100 mg of aspirin. 
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Figure 5-30: Platelet aggregation and activation expressed as percentage of inhibition in arachidonic acid activated samples after 100 mg of aspirin. 
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5.4 Discussion and Conclusion 
We developed a simple and reproducible method for measuring platelet activation using quantitative 
flow cytometry. Collection, labeling and stabilisation of blood collected from a minimally invasive finger-
prick procedure was optimised for immunophenotyping of platelets and platelet-leukocyte interactions. 
The method overcomes one of the most important limitations of flow cytometry and does not require 
an immediate processing. It is also sensitive to aspirin ingestion and comparable to LTA in its ability to 
detect aspirin in AA induced samples. The results showed that a variety of agonists may be used to 
assess platelets P-selectin expression and MPA formation. We also propose that the MFI and MPA ratios 
of activated versus resting samples could be used to express P-selectin and MPA as they appear to be 
stable and may decrease the variability of samples due to poor collection or artifactual platelet 
activation. We propose that the agonist concentrations used, must be high enough to give ratio of at 
least 2. 
Some may claim that fingerstick blood should not be used for platelet function testing since the blood 
sample should always be free flowing to minimise the artifactual platelet activation [515]. The pilot 
study showed that resting P-selectin expression and MPA formation was within the acceptable range if 
minimally invasive Fingerstick Lancets (Tenderlett ®) were used and free flowing drops of blood 
collected, with first drop always being discarded. In this experiment we estimated that one free flowing 
drop of blood is approximately 50 µL, however, there may be some small variability in the drop volume 
obtained from different volunteers, depending on the size and position of a fingerstick. Capillary blood 
samples are frequently used for patients requiring frequent blood testing, blood donors, bed-side point 
of care analysers in hospitalised patients, neonates or in patients unable to have classic phlebotomy. It 
has been shown that the capillary blood has significantly higher hemoglobin, haematocrit, erythrocytes 
(p<0.0001)  and leukocytes (p<0.002) while platelet count is has tendency to be lower in capillary than in 
venous samples (p=0.08) [516]. As much as the difference in most parameters measured reached 
statistical significance, the difference is unlikely to be of clinical importance; for example the leukocyte 
count in venous blood was 8.9 ± 17.7 x10
9
/L, while in capillary blood it was 9.1 ± 18.3 x 10
9
/L.  This study 
enrolled the healthy as well as haematological patients, including patients with lymphomas, leukemias 
and myeloproliferative disorders, hence greater variability in the white cell count.  In fact, leukocyte 
count was increased on average for only 0.2 x 10
9
/L except in patients with leukocyte count greater than 
11.5 x 10
9
/L, where capillary blood showed on average 1.4 x 10
9
/L (p<0.05), again posing no real clinical 
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difference. Similarly the haematocrit was 0.38 ±0.07 L/L in venous and 0.40 ±0.07 L/L in capillary blood 
[516], therefore the hypothesis of our study was that the different blood composition is unlikely to 
cause great variability between the methods. The study showed slightly different level of activation of 
platelet in capillary and venous samples which could relate to the different composition of blood that 
could have produced different agonist concentration per cell. Capillary blood also showed tendency for 
higher inter-individual variability than venous samples. Even though it was ensured that drops of 
capillary blood are large enough (approximating 50 µL), are free flowing and up to 20 drops of blood 
could be collected from the same finger prick with minimal variability, the variability in the blood drop 
size has probably occurred between volunteers. 
The aim of the pilot study was to see if fingerstick blood collected with Tenderlett Lancet device was 
suitable for analysis of platelet activation and if there was correlation with blood collected by standard 
venipuncture. As a result, only limited agonists were used in the initial evaluation. We used submaximal 
doses of ADP and TRAP, with only one high TRAP concentration. The reason behind the use of mainly 
submaximal agonist concentration was the hypothesis that obtaining fingerstick blood samples may lead 
to artifactual platelet activation, hence only the use of low agonist concentration would enable us to 
assess higher level of platelet activation, if present. These agonists were also chosen as they are both 
stable upon defrosting.  ADP and TRAP however may not be adequate for certain investigations, like 
monitoring of antiplatelet therapies. Further studies require evaluating stability of other agonists like AA 
and TxA2 analogue, U-46619,in this setting. 
Whilst blood for analysis of MPA formation was diluted 1 in 2 with HEPES saline, blood used for P-
selectin analysis was diluted 1:10 with HEPES saline, as it is commonly used dilution for samples that are 
labeled immediately [515]. Lower blood dilutions may be required in order to label platelets post 
fixation [432]. However, higher blood concentration may lead to spontaneous platelet-platelet and 
platelet-red cell aggregation, obscuring the analysis [431, 432].  Both set of samples were incubated at 
room temperature with agonists, however, a 37°C incubation may be required to investigate resistance 
to antiplatelet therapies as many assays employing activation of platelets with AA use this incubation 
temperature [243, 517]. This incubation temperature may also be required to upgrade methods for 
estimation of pro-coagulant activity and estimation of FX/Xa and TF on monocytes with or without 
platelets [432, 518]. 
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P-selectin expression was also assessed as percentage positive population, although many authors 
report mean fluorescence intensity of entire platelet population as it represents the least variable 
measure. We expected lower mean fluorescence intensity of capillary samples as the labeling was done 
after fixation, and therefore used percentage positive population [432]. We found that the use of MFI 
only in this setting would be inappropriate as the aim was to see the extent of platelet activation, which 
could be obscured in capillary samples if MFI was used, due to potentially lower increase in the values 
after activation. Due to hypothesis of lower MFI in capillary samples, we chose to analyse all data using 
ratios of venous and capillary blood activation versus average (Bland-Altman) rather than difference of 
the two versus average [512]. 
The pilot study showed that capillary blood may be used for assessment of platelet activation. Good 
correlation of this method with already established venous protocols raised a possibility of creating a 
point-of care test for platelet function testing using whole blood flow cytometry suitable for routine 
diagnostic laboratories. Simplicity of the method would allow its use in remote sites as well as hospitals, 
for not only estimation of platelet activation, but a possible diagnosis of myocardial infarction. 
The point of care test evaluated showed that resting P-selectin expression and MPA formation were 
within the acceptable range if minimally invasive Fingerstick Lancets were used and free flowing drops 
of blood collected. Volunteers had 6.66% ± 0.71 resting MPAs and 0.59% ± 0.37 resting P-selectin 
expressing platelets. Fingerstick reference ranges would however need to be established on larger group 
size. Using MFI ratios in activated samples could also minimise the variability introduced by poor blood 
collection. 
We found that it was important to perform the test 4 minutes after incubating the pre-prepared 
reagents at 37°C and 10 minutes after incubating them at room temperature since the prolonged timing 
caused the lack of activation due to agonist inactivation. Fixing platelets with 1% (v/v) HSF and MPAs 
with diluted FACS Lyse was sufficient to stabilise the test for at least 24 hours and the use of ratios 
stabilised the samples even more. Since pilot study only included ADP and TRAP as agonists and both 
ADP concentrations used were low, in the second part of the study, AA, U-46619 and higher ADP 
concentrations (20 µM) were introduced to explore a range of agonists that could be used in the 
method and to obtain more sample activation.  Apart from strong correlation between the two 
protocols, the pilot study also showed that capillary method can be used at room temperature. Samples 
were, in the second part of the study, incubated at 37°C, for method to be sensitive for aspirin 
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detection.  If percentage positive population was used to express P-selectin levels, capillary protocol 
showed better correlation than MFI (r=0.5272). Binding of antibodies post fixation and longer incubation 
at room temperature (40 minutes) during the labeling step may have decreased the brightness of 
antibodies used. This may be overcome by the use of ratios rather than MFI only to examine the activity 
of platelets. Also in the pilot study all agonists except 20 µM TRAP were weak, while concentration of 
agonists in this part and consequent sample activation were higher, producing more variability between 
methods.  Even though the correlation was weak, and there was negative bias in capillary samples, it still 
existed. Neutrophil platelet aggregates were however unstable and showed significant tendency to 
increase over time, so they were excluded from further analysis. They could be analysed simultaneously 
with MPAs, but would be valid only if samples are processed on the same day.  Capillary protocol for 
MPA formation in resting and activated samples is reproducible and comparable to venous protocol. 
This method could potentially replace some of the currently used platelet function analysers for variety 
of conditions some of which are described below. 
Inherited platelet function disorders are the most common causes of bruising and bleeding, the 
diagnosis is clinical practice is still challenging due to lack of appropriate and reliable methodology [519].  
While LTA is still considered a gold standard for platelet function testing, it lacks standardisation world-
wide [520] as described in the literature review and it may also not be appropriate for paediatric 
patients since the volumes of blood required are 15-30 mL and it can lead to hypovolemic symptoms 
[519]. The British Society for Haematology BCH Haemostasis and Thrombosis Guidelines therefore 
recommend the use of flow cytometry or the PFA-100 for the diagnosis of bleeding disorders in infants 
[520]. In some situation platelet aggregometry may not be available for daily diagnostic use and requires 
a confirmatory test in case platelet defect is identified [519]. In some instances, flow cytometry is used 
to confirm platelet defects identified using LTA [520]. On the other hand, the PFA-100 in this population 
is not suitable since it fails to accurately detect milder platelet defects and normal closure time does not 
exclude platelet defect [519, 520]. The PFA-100 closure times are also affected by platelet counts, 
haematocrit and the amount of vWF [520]. While lumi-aggregometers may assess platelet release 
reaction, the reagent used to measure the release may modify aggregation for some platelet disorders 
[521]. Flow cytometry measurement may also be used to predict bleeding tendencies in some patients. 
Psaila and colleagues examined cancer patients (Acute Myeloid Leukemia and Myelodysplastic 
syndromes) with increased platelet reactivity and GPIb and GPIIb/IIIa expression  who were bleeding 
and the amount of GPIb and activated GPIIb/IIIa correlated with the immature platelet function 
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representing platelet regeneration [522].  Considering the range of agonists and antibodies that could be 
used with fingerstick protocol, it could be utilised for the diagnosis of some bleeding disorders. Further 
studies are needed to test the hypothesis and establish correlation with other analysers. Normal adult 
and paediatric reference ranges need to be created on a larger sample size. 
There is also the need to monitor the antiplatelet therapy and replace monotherapy with dual and triple 
therapy in resistant patients [523]. It is estimated that the prevalence of aspirin resistance varies 
between 0 to 60% with claims that the resistance in some situation is purely due to non-compliance 
[523].  Apart from poor correlation of methodology used to identify the resistance to antiplatelet 
agents, the authors do not necessarily use the correct terminology. The term ‘resistance’ should only be 
used when aspirin is unable to inhibit COX-1 in platelets, while treatment failure or clinical resistance 
should be used when adverse events occur despite the use of drugs [63]. Antithrombotic effect of 
aspirin may be diminished in conditions that increase platelet turnover and oxidative stress, some of 
which are diabetes and arthritis, but it may still be able to sufficiently inhibit COX-1 [523]. In order to 
identify broadly defined aspirin resistance, researchers have used a variety of tests and agonists, some 
of which are not specific to TxA2 production and were therefore unable to identify if the patient is likely 
to have poor clinical outcome due to chemical resistance to aspirin or other causes [63]. Such patients 
with clinical rather than chemical aspirin resistance may still benefit from aspirin therapy in conjunction 
with another agent and replacement of aspirin would not always be beneficial. In this method we only 
used AA as an agonist to assess inhibition of platelets with aspirin. Only 10 volunteers were tested and 
all of them showed lack of AA induced platelet activation and aggregation as well as MPA formation. In 
all cases the activation of AA activated samples was equivalent to resting sample activation, which 
would therefore enable identification of chemical aspirin resistance as well as high residual platelet 
reactivity, which has been linked to poor chemical outcomes [63]. 
The MPA protocol may potentially be used to diagnose AMI. The European Society of 
Cardiology/American College of Cardiology Joint Committee states that AMI shows elevation of 
Troponin above the 99
th
 percentile of the healthy reference population in the presence of ischaemic 
signs and symptoms [524]. However the major issue with cardiac Troponins is the time taken for their 
increase, which can take between 4-12 hours and requires several blood samplings from patients [524]. 
Cardiac Troponins may also be elevated in conditions other than ACS, usually those that increase 
myocardial oxygen demand,  including strenuous exercise, therefore decreasing the specificity of 
Troponins  [524]. Even though false positive elevation of Troponins is uncommon, it can occur in 
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patients with frequent animal contacts, rheumatoid factors, heterophilic antibodies or blood transfusion 
[524]. Furman and colleges [172] however showed that MPA of patients who presented to Emergency 
Department with chest pain are higher in AMI than in those without AMI or with unstable angina [172]. 
The increased number of circulating MPAs was significantly higher within the first 4 hours of the 
symptom onset, which preceded the increase of other cardiac markers [172]. The fingerstick protocol 
could therefore be used for earlier diagnosis of AMI since the preparation of samples and analysis takes 
approximately 1 hour with flow cytometer on-site. 
The limitation of this study was the small group sizes which prevented establishment of reference 
ranges and correlation for each agonist separately.  The method should also be evaluated for its ability 
to detect thienopyridines or dual antiplatelet therapy. Study also included only healthy volunteers, none 
of which showed chemical aspirin resistance. However more volunteers would be needed to test if the 
method is capable of identifying aspirin semi- and non- responders and CVD patients should also be 
tested to evaluate ability of method to detect high residual platelet reactivity. 
We demonstrated that this method is sensitive to inhibition of platelet function by aspirin and correlates 
well with standard laboratory techniques for the assessment of platelet function.  The development of 
this novel technique allows valid and accurate platelet function testing to take place without the need 
for venipuncture, and once stabilised the sample can be transported from the site of collection to the 
core facility for analysis up to 24 hours later, whereas standard diagnostic methods require almost 
immediate analysis. The method is simple as the pre-prepared kits would be supplied and after 
collecting blood, only fixative should be added after 15 minutes incubation. This new technique may be 
utilised by patients and their clinicians who do not have ready and immediate access to core scientific 
infrastructure required for diagnostic platelet function testing, such as in regional or rural areas. 
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6 Overall Discussion and Conclusion 
 
Cardiovascular disease is the main cause of morbidity and mortality. Platelets play a major role in its 
initiation, progression and complications in a complex and still not fully defined manner. Due to clear 
role of platelets in atherothrombosis, current therapies for primary and secondary prevention of 
cardiovascular disease focus exclusively on targeting platelet activation and aggregation. While 
beneficial in a portion of patient population, they inhibit both resting and activated platelets, disrupting 
normal process of haemostasis, hence increasing the risk of major and minor bleeding. Clinical and 
chemical resistance are also well recognised limitation of currently available therapeutics. This prompts 
the need for careful monitoring and suggests that personalised treatment approach would be beneficial. 
We currently do not have a readily available, reproducible and standardised methodology for 
assessment of platelet function in routine diagnostic laboratories.  No currently used routine diagnostic 
instrument is capable of examining a complete pathway of platelet activation.  This is partially caused 
due to complexity of platelet activation per se, and partially because platelets are not the sole mediators 
of poor cardiovascular outcomes. Factors such as inflammation, increased reactive oxygen species, 
dyslipidemia and sedentary lifestyle contribute to disease progression and complication. The complex 
relationship between these factors, particularly inflammation and platelet activation is being 
increasingly elucidated. Despite its complexity and related expense, flow cytometric analysis offers the 
most encompassing assessment of platelet function and the relationship between platelets and other 
blood elements, such as monocytes and neutrophils. However, for flow cytometric analysis to be 
introduced into the routine laboratory setting, the developments of methods that prolong the current 
processing time are necessary. 
To overcome the limitations of platelet function testing, I have developed a novel method for  
immunophenotyping of both resting and activated platelets and monocyte-platelet aggregates by 
quantitative flow cytometry. The method is simple and reproducible and overcomes the main limitation 
of flow cytometry - the need for immediate sample processing. Chapter 5 of this thesis demonstrates 
that capillary blood can be used for assessment of platelet function and does not lead to artifactual 
sample activation if minimally invasive fingerstick device is used to obtain a blood sample. Despite the 
small differences in the composition of venous and capillary blood, we found that there is a good 
correlation between venous and capillary methods for assessment of both, platelet P-selectin expression 
and monocyte-platelet aggregate formation. I have demonstrated that this method is sensitive to 
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inhibition of platelet function by the most commonly used antiplatelet agent, aspirin, and correlates well 
with standard laboratory technique, light transmittance aggregometry. The development of this novel 
technique allows valid and accurate platelet function testing to take place without the need for 
venepuncture, and once stabilised the sample can be transported from the site of collection to the core 
facility for analysis up to 24 hours later. This new technique not only facilitates some of the work 
performed in this thesis, but if adequately evaluated, may be applied to several areas.  It opens up 
opportunity for method to be utilised in regional and rural areas, for monitoring of antiplatelet therapy, 
possible diagnosis of myocardial infarction or some bleeding disorders. It also opens up opportunity to 
expand platelet function research to many research groups that do not readily have a scientist 
experienced in processing blood for platelet function studies. Specialised platelet research laboratories 
could potentially upgrade the method for examination of monocytic procoagulant function by 
estimating levels of tissue factor, activated coagulation factor X or fibrinogen on the surface of 
monocytes. 
Work presented in this thesis demonstrates strong basis for creating the most encompassing point of 
care test for the assessment of platelet function. Continuing method evaluations are necessary. Further 
studies should establish reference ranges for each parameter measured and for each agonist used. Once 
reference ranges are established, the method should be further evaluated by testing cardiovascular 
disease patients, or patients with increased risk for cardiovascular disease, such as diabetic population. 
Furman et.al. [172] already demonstrated that resting monocyte-platelet aggregates are sensitive and 
earliest marker for diagnosis of acute myocardial infarctions, hence the point of care test described here 
should be evaluated for its ability to detect increased circulating heterotypic aggregates following the 
adverse event. We have demonstrated the sensitivity of the method to Aspirin ingestion, however 
further studies should aim to demonstrate if method is sensitive for thienopyridines and other 
antiplatelet agents, including dual antiplatelet therapy.     
High incidence of resistance to current antiplatelet agents as well as high incidence of reported side 
effects, prompts for investigation of  different agents for targeting the interaction of platelets and 
inflammation, such as antioxidants and novel prostanoid modulating lipids. Such agents may provide a 
novel, alternative and safer approach to antiplatelet therapy. To achieve this I evaluated 
cardioprotective abilities of natural products, an antioxidant gamma tocopherol and novel marine lipids 
found in anti-inflammatory supplement Lyprinol.  Both compounds share similarity in their ability to 
inhibit arachidonic acid platelet activating pathway, as described in Chapter 3. While gamma tocopherol 
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is also antioxidant, marine oils are proven anti-inflammatory agents. Chapter 3 of this thesis 
demonstrates that while gamma tocopherol is likely to inhibit platelet COX-1, marine lipids have 
multiple inhibiting targets. I have demonstrated, for the first time, that the New Zealand Green Lipped 
mussel (Perna Canaliculus) extract, currently used as an anti-inflammatory agent, also inhibits platelet 
activation in dose dependent manner.  The magnitude of inhibition is greater than standard fish oil 
formulations and in case of arachidonic acid induced aggregation, comparable to aspirin. The work 
presented here demonstrates that 0.5 mg/mL of marine lipids modulate platelet function by novel and 
complex mechanisms, requiring both prostacyclin and TP receptors as well as COX-1 for its action. This 
potent and novel antiplatelet mechanism may represent therapeutic potential for the use of Lyprinol in 
cardiovascular disease, but also represent a novel therapeutic target for next generation antiplatelet 
therapeutics. While our 7-day clinical trial greatly underestimates cardioprotective potential of Lyprinol 
supplementation, our pharmacodynamic study demonstrates that supplements are capable of 
decreasing platelet activation and degranulation in a short-lasting and reversible manner. It also shows 
that 8 Lyprinol capsules per day are sufficient to induce changes and no side - effects were reported. 
Further studies should aim to evaluate if longer Lyprinol supplementation, required for anti-
inflammatory potential as described in Chapter 1, would demonstrate stronger and more lasting 
cardioprotective potential. Due to importance of platelet- monocyte cross-talk in development of 
atherosclerosis, heterotypic aggregates should be evaluated in volunteers after Lyprinol 
supplementation and compared to the effect on platelet P-selectin expression. While monocyte-
platelets aggregates require P-selectin for formation, they are better marker for platelet activation as 
platelets rapidly lose P-selectin, but still continue to function and circulate. While in vitro study provided 
a great insight into mode of action of complex marine oil, we have not investigated which of the rare 
Omega-3 fatty acids contained are the most bioactive. Testing them alone or in combination would 
provide a more in-depth understanding of their mechanism of action and may provide a basis for 
creation of new therapeutic agents. We proposed that marine oil inhibits cAMP increase in platelets due 
to occupancy and desensitisation of the thromboxane receptor. We have not measured cAMP levels in 
platelets and did not account the contribution of other platelet prostanoid receptors on the inhibition 
observed. Additional studies should explore this further.  
Gamma tocopherol at concentration of 300 µM inhibited arachidonic acid induced platelet activation 
and degranulation. Platelet COX-1 was required for the action of this antioxidant, as described in 
Chapter 3, and blockage of COX-1 ameliorated the inhibitory effect observed. This thesis provides the 
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proof that gamma tocopherol, apart from being a potent antioxidant, may inhibit platelet COX-1, 
however further studies need to fully elucidate the mechanism involved. The activity of COX-1 after 
treatment with gamma tocopherol needs to be measured to estimate the level and duration of 
inhibition. It is also not known if the inhibitory effect observed is result of tocopherol's antioxidative 
properties or direct inhibiton of the enzyme caused by unrelated mechanism. Chapter 2 of this thesis 
demonstrated that gamma tocopherol supplementation is cardioprotective, even in increased oxidative 
stress setting induced by strenous exercise. While there is substantial evidence that exercise improves 
cardiovascular health, platelet activation increases in the acute period following intensive exercise, 
potentially due to a reactive oxygen acute phase response to the strenuous exercise bout. This 
represents a period of acute risk for cardiovascular events. I have demonstrated that six weeks long 
vitamin E supplementation with high gamma and low alpha tocopherol decreases platelet aggregation 
better than alpha-tocopherol supplementation or placebo. Supplementation with high dose gamma 
tocopherol in combination with exercise significantly reduced collagen-induced platelet aggregation 
below pre-exercise levels.  Further studies need to elucidate if the inhibitory effect observed is due to 
decreased platelet activation, degranulation or platelet-fibrinogen binding. Flow cytometric markers 
including P-selectin and monocyte-platelet aggregates should be measured after gamma tocopherol 
supplementation in increased oxidative stress setting. 
In summary, the work presented in this thesis provides novel information on the cardioprotective effect 
achieved by supplementation with two safe natural products, both of which are targeting platelet 
arachidonic acid pathway, one antioxidant, one anti-inflammatory.  While we provide valuable 
information into their mode of action and effect in healthy population, their potential high risk 
population should also be  evaluated. Their mechanism of action may serve as a new therapeutic target. 
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